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ABSTRACT 
Interest in computer-aided methods for investigating the biological field has 
increased significantly. One method is Quantitative Structure-Activity 
Relationships (QSAR), a valuable technique for predicting the effects of a 
substance from its chemical structure. A challenging application of QSAR is in 
characterizing the (bio)activity profiles of chemicals. Endocrine disrupters (EDs) 
are exogenous substances interfering with the function of the endocrine system 
and represent an interesting field of application for in silico methods. EDs targets 
include nuclear receptors, particular1y effects mediated by the oestrogen 
receptor (ER). 
They are also mentioned as substances requiring a more detailed control and 
specific authorisation within REACH, the new European legislation on chemicals. 
QSAR represents a challenging method to approach data gap about EDs since 
REACH substantially boosted interest on computational chemistry to replace 
experimental testing. 
This work: aimed to explore the status, availability and reliability of non-testing 
methods applied to endocrine disruption via oestrogen receptors and eventually 
to propose new models easily exploitable in regulatory contexts. 
The work evaluated existing QSAR models present in literature to assess their 
validity on the basis of the OECD principles for QSAR validation. Different kinds of 
models have been analysed and they were externally validated with new data 
found in the literature. 
Furthermore, new QSAR binary classifiers have been developed using different 
data mining techniques (e.g.: classification trees, fuzzy logic, neural networks) 
based on a very large and heterogeneous dataset of chemical compounds. The 
focus was given to both binding (RBA) and transcriptional activity (RA) better to 
characterize the effects of EDs. A possible combination of the models was also 
explored. A very good accuracy was achieved for both RA and RBA (>85%). 
These models can be a valuable complement to in vivo and in vitro studies in the 
toxicological characterisation of chemical compounds. 
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PREFACE 
Interest in computer-aided methods for investigating biological events has 
increased significantly in recent years. Analogously to the expressions in vivo 
(referring to methods using animals) and in vitro (referring to methods using mainly 
cellular systems), the expression in silico has been introduced referring to silicon, as 
a metaphor for computers. In silico tools are becoming more accessible to 
researchers as their cost drops and the speed of computational calculation 
increases, so interest in their application can spread to a wide range of biological 
problems. Data mining techniques are frequently used to analyse biological data 
such as genomic or proteomic findings, for example. A challenging application of 
these methods is modelling and characterizing the (bio)activity profiles of 
chemicals. Many studies have addressed, for example, ecotoxicity or human 
health. These methods seek relations between chemical structures and the 
observed properties exhibited by the compounds under investigation. Among the 
properties that can be analysed in silico, endocrine disruption forms an emerging 
field that is attracting attention from scientists and political institutions. Endocrine 
disrupters (EDs) represent a number of exogenous substances interfering with the 
function of the endocrine system. producing consequences on the homeostasis 
of all the processes controlled by this system in humans and wildlife. The EDs issue 
is highly complex on account of the wide range of mechanisms of action they 
can interfere with. The targets include receptors belonging to the nuclear 
receptor superfamily. Among them the receptor more extensively investigated to 
account for endocrine disrupting effects is the oestrogen receptor (ER) mediating 
the effects of the steroid hormone 17~-estradiol. In this field in silico techniques 
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could be a valuable complement to in vivo and in vitro studies in assessing hazard 
of chemicals. 
Many computational methods can be used to analyse the toxicity or biological 
activity of chemicals. particularly as regards their interactions with biological 
macromolecules such as receptors. 
QSAR and other in silico tools are very suitable for addressing the direct 
interaction of chemicals with receptors. since both the ligands and the receptors 
can be characterised by their chemical structure. The ER was one of the first 
targets studied with computer-aided methods addressing specifically EOs 
especially because of the great number of data available to be modelled. 
One of the eligible methods is Quantitative Structure-Activity Relationships 
(QSAR). a widespread and valuable technique for predicting the risk of a 
substance from its chemical structure. It is based on the assumption that a 
relationship exists between molecular features encoded in chemical descriptors 
and the biological activity or biochemical property. 30-QSAR relies on field-based 
descriptors derived by mapping the environment surrounding the molecules in 
terms of energetic interactions of various natures once the molecules are properly 
aligned in the space. This is obtained by placing the molecule within a lattice and 
calculating the interaction energies of that molecule with a probe at each point 
of the grid. 
Virtual docking is a methodology to predict computationally the binding 
between two molecules. usually a protein and a small molecule (ligand). 
It is difficult to compare the results of different approaches since often these 
models rely on different datasets or at least on different validation procedures to 
assess their reliability. A further aspect to be considered is the intended use of the 
model. 
A very challenging field of application of these methods is predictive toxicology. 
particularly to satisfy regulatory requirements. The main obstacle to completing 
2 
Preface 
hazard assessment of chemicals is the lack of adequate experimental data. 
required to cover all the major effects relating to human health or ecological 
safety. 
In the near future this situation will change with REACH (Registration. Evaluation. 
Authorisation and restriction of Chemicals). the new European legislation on 
chemicals. REACH legislation has substantially boosted interest in computational 
chemistry to replace experimental testing since it provides some indications for 
the use of existing information. techniques such as QSARs. read-across and 
analogue identification. to avoid unnecessary testing. Some studies have 
estimated that these alternatives. including QSARs. will reduce the additional 
costs due to implementing REACH by about one billion Euros and these 
alternatives could potentially save more than a million animals. 
Some efforts are still needed to facilitate regulatory acceptance of QSAR as an 
alternative by increasing the transparency and reproducibility of the models 
generated with QSAR and by taking account of regulators' needs. The OECD has 
identified some principles of QSAR validation to satisfy these aspects. 
In particular EDs are mentioned as substances requiring more detailed control 
and specific authorisation within the REACH framework together with other 
groups of chemicals of particular concern. 
Overall on the one hand there is the need to cover data gaps. but on the other 
hand no technique is yet able to deal efficiently with this need; computational 
toxicology can be of help in this task but more efforts to gain a wider 
acceptance are still required. The main issue this work aims to contribute is to 
provide an insight about the use of in silico models to address EDs effects 
mediated through the oestrogen receptor. 
In particular this work aims to explore the status. availability and reliability of non-
testing methods applied to endocrine disruption mediated through the oestrogen 
3 
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receptor and eventually to propose new models easily exploitable in regulatory 
contexts. 
Therefore the project objectives and their implementation adopted during this 
work are: 
To analyse the existing information and models in order to: i) assess what 
level of accuracy was already obtained and ii) identify the most promising 
methods to be explored further. This was done by close investigation of 
the literature to identify existing in silico models developed for EDs with 
QSAR. 3D-QSAR or docking approaches. 
Secondly. the focus was given to QSAR only. the method more frequently 
used and better characterised for its use in regulatory assessment. in order 
to validate promising models. Complementarily. this process involved 
collecting experimental data. either to validate the models identified in 
literature. or to use them for developing new models. 
To validate existing models. This included both intemal and external 
validation. Internal validation aims to analyze model reproducibility and 
transparency of all steps including descriptor calculation and the 
application of the algOrithm suggested in the literature. External validation 
is focused on the assessment of performances in prediction by using newly 
identified compounds and on the assessment of applicability domain. 
To apply different modelling techniques. studying new models for 
oestrogenicity to be of practical use as fast and reliable screening 
method. by adopting the most promising approaches identified dUring 
the previous steps of the project. 
This thesis is divided in three conceptual Parts for a total of six Chapters. In the first 
introductory Part. the general issue of EDs and oestrogen-mediated effects. in 
particular. is presented {Chapter 1). This is followed by an introduction on in silico 
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methods to study the interaction of chemicals with receptors including a review 
of existing models for EDs effects mediated through the ER (Chapter 2). 
In the second Part the literature findings have been rationalised and key factors 
for the practical application of QSAR in the context of regulatory framework are 
discussed. This includes some theoretical considerations on desirable 
characteristics of QSAR and a detailed discussion on OECD principles for QSAR 
validation from a practical point of view (Chapter 3). Chapter 4 reports the 
validation exercise of the three most promising models identified in the literature. 
The third Part describes in Chapter 5 the development of new binary classification 
models for addressing oestrogenic effects (binding and transcriptional activity of 
ER). Finally the sixth Chapter draws the main conclusions on the overall themes 
developed in the thesis. 
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INTRODUCTION ON QSAR 
AND ENDOCRINE DISRUPTERS 
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CHAPTER 1 
THE ENDOCRINE DISRUPTERS ISSUE 
The issue of chemical compounds interfering with the endocrine system. 
commonly called endocrine disrupters (EDs). is an emerging field of high concern 
for scientists [1] and political institutions [2.3]. 
An endocrine disrupter is an exogenous substance or mixture that alters functions 
of the endocrine system and consequently causes adverse health effects in an 
intact organism. its progeny. or populations in both humans and wildlife. As a 
consequence effects on reproductive. developmental. immunological and 
neurological functions may occur such as cancer. behavioural changes and 
reproductive abnormalities [4]. 
A great number of targets can be affected by EDs and thus a wide range of 
substances are suspected to be endocrine disrupters [5]: they range from 
pesticides to plastics additives such as phthalates. from environmental pollutants 
(like PCBs. dioxins and furans) to flame retardants. from cosmetic ingredients to 
natural products. Many of these chemicals. such as plasticizers. are relevant in 
industrial processes and some of them are Persistent Organic Pollutants (POPs). 
Due to the key role of many of these substances in industrial processes. it is 
essential to fill the data gap also in view of new legislation requirements. 
The high complexity of the EDs issue is related to the wide range of mechanisms 
of action they can interfere with. since they can directly damage an endocrine 
organ. directly alter the function of an endocrine organ. interact with receptors or 
alter hormone metabolism. inhibiting steroidogenesis or increasing hepatic 
metabolism and clearance [61. 
7 
Chapter 1 - The EDs issue 
In particular. amongst the receptor targets a series of receptors belonging to the 
Nuclear Receptor INR) superfamily can be enumerated. This is a group of ligand-
inducible transcription factors that mediate the effects of hormones and other 
endogenous ligands to regulate the expression of speCific genes [7J. Among 
them are included receptors for various hormones lilce steroids. retinoic acid and 
thyroid hormones. This family also includes some "orphan" receptors whose 
natural substrates are still unknown [8J. 
QSAR and other in silico tools work very well in addressing the direct interaction of 
chemicals with receptors since either the ligands or the receptors can be 
characterised by their chemical structure. 
In this project attention has been focused on the study of chemicals interfering 
with the oestrogen receptor (ER) and more details about this specific system will 
be introduced in the next paragraph. 
1.1. THE OESTROGEN RECEPTOR (ER) 
The oestrogen receptor is a ligand-activated transcription factor that mediates 
the effects of the steroid hormone 17~-estradiol (E2) in both males and females 
[9J. It is involved in the development. growth and maintenance of reproductive 
tissues but it is also present in a number of non-reproductive tissues such as bone, 
liver, brain, the eNS, cardiovascular and immune systems in the physiological 
situation. ER seems also to be involved in pathological processes such as 
osteoporosis or breast cancer [10,11). 
ER is present in two isoforms (ERa and ER~) in humans that exhibit overlapping but 
distinct tissue distribution pattems and differ in their ligand-binding ability and 
transactivational properties [12,13]. 
8 
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. --AF-2 
..... 
AF-1-- . o 
o 
Zinc Finger DNA Binding Domain Ligand binding domain (LBD) 
Figure 1.1 Structural representation of the ER. Picture modified from NURSA: The Nuc lear Receptor 
Signaling Alias © 2003. (www nursa org) [14] . 
Three functional regions shown in Figure 1.1 can be identified in the ER structure 
[15]: 
The Ligand binding domain (LBO) [16] 
The LBO constitutes the eOOH-terminal region of ER and mediates ligand 
binding to the endogenous hormone E2. The binding cavity of human ERa has 
an accessible volume of 450 A3, quite large compared to the natural ligand 
(250 A3) [17] . Other chemicals that share a relatively law similarity with E2 can 
bind with different degrees of affinity and sometimes with a diverse specificity 
to ER subtypes. Figure 1.2 reports some examples of different categories of 
SUbstances known to bind ER. Beside the natural hormone (1) other chemicals 
binding in the LOB of ER include some drug-like synthetic hormones (2) , 
antioestrogens (3) , oestrogens produced by plants (4) or fungi (5) and 
chemical contaminants like peBs (6) and alkylphenols (7) . 
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(1) (2) 
HO OH 
E2 DES 
5=0.634 
HO 
(4) 
HO 
OH 
Genistein 
5 = 0.617 
0 OH 
0 s:::::: 
W (5) F 
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5"0.702 5 -0.66 
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CH3 
S - 0.52 
Figure 1.2 Examples of chemical groups known to bind to ER: natural hormones (1). synthetic 
hormones (21 and anfioestrogens (3). phytoestrogens (4. 51 and xenoestrogens (6. 71. S Indicates the 
Tanimoto simDarity coefficlentl calculated using E2 as reference In ACO/Lobs 9.0. 
J The Tanimoto coefficient is calculated with the following formula: S = Ncl/Nq+Nt-Nc) where 
Nq Nt and Nc are respectively the number of bit screens set in the query structure. in the 
target structure, and those in common to both structures. 
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The LDB also contains an Activation Function (AF-2). whose structure and 
function are governed by the binding of ligands. Crystallographic 
investigation of the LBD has shown that. when ER is bound to an agonist. this 
region is responsible for recruiting coactivator pep tides and starting the 
cascade of events that provoke the transcription of oestrogen-regulated 
genes. This process includes receptor dimerisation. receptor-DNA interaction. 
interaction with coactivators and other transcription factors. and formation of 
a preinitiation complex [18J. On the other hand. binding to compounds with 
antagonistic activity causes a conformational change in the position of Helix-
12 that occupies the space devoted to the interactions with coactivators 
blocking the transcription process [19]. 
- The DNA binding domqin (DBD) 
DBD contains two zinc ions. each co-ordinated by the tetrahedral 
arrangement of thiol groups from four cysteine residues. in a zinc finger 
structure. This area plays an important role in receptor dimerisation and in 
binding of receptors to specific DNA sequences called estrogen response 
elements (EREs) [20]. ERa and ERP can also modulate the expression of genes 
without directly binding to DNA. 
- The NH2-terminql region contains a ligand-independent activation function 
(AF-l) that is again involved in the interaction with transcription factors [18]. 
Since the ER is involved in pathological processes. the receptor. the ligands. and 
all relevant accessory proteins have often been considered as targets in 
pharmaceutical research to develop therapeutic drugs for hormone-related 
diseases. For this reason the ER was investigated in depth with a series of in silico 
techniques in order to facilitate the drug discovery process. In this kind of study 
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usually a small. quite homogeneous group of synthetic compounds is taken into 
account and the highest grade of mechanistic information is included. This 
implies that not only the chemical itself but also the receptor is considered in the 
analyses (e.g. virtual docking studies) and these studies are coupled with other 
methods like crystallography and site-directed mutagenesis techniques [21]. Even 
if these experiments are outside the purposes of the present project. the interest 
from the pharmacological point of view was the driving force to elucidate key 
aspects of the ER functioning. briefly introduced above. and to provide a 
mechanistic insight on the receptor-ligand binding and the agonist/antagonist 
interactions. 
Today the interest in nuclear receptors is no longer limited to the drug discovery 
process but includes also the endocrine disrupters issue. A more detailed analysis 
of the modelling studies already conducted in this field will be provided in 
Chapter 2. 
To detect endocrine-disrupting effects. different in vivo and in vitro experiments 
have been set up. Since the system itself and the variety of targets is very large 
and variable among different species. a battery of tests has been proposed to 
analyse different possible interactions with the endocrine system, organised in a 
tiered approach [22,23]. Among them, some in vitro tests have been designed to 
detect the direct binding with the LBD (receptar binding assay), or the 
transcriptional activation of DNA (cell proliferation and reporter gene assays) [24]. 
Despite there being many experimental methods, both in vivo and in vitro, for 
encoding information on the disruption activities of chemicals, only a few 
experimental protocols are fully standardised and validated, so computational 
chemistry can be a complementary tool to characterize properties of endocrine-
disrupting chemicals. 
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QSAR AND OTHER COMPUTATIONAL MODELLING METHODS 
Nowadays the interest in employing computational modelling techniques to 
predict the activity of chemicals is constantly growing. Many computational 
methods can be used to analyse the toxicity or biological activity of chemical 
compounds, in particular in relation to their interaction with biological 
macromolecules (Le. receptors) as well as for modelling other physico-chemical 
properties. An overview of these methods will be provided along with some 
examples of different techniques applied to the prediction of oestrogen receptor 
(ER)-mediated responses. The applications involve studies in drug design, for 
selecting lead compounds to develop new drugs, and others involving a wide 
range of substances, called endocrine disrupters, which can interfere with the 
mechanisms of hormone regulation as described in Chapter 1. Molecular 
modelling techniques such as Quantitative Structure-Activity Relationships (QSAR) 
and related methods like Comparative Molecular Field AnalYSis (CoMFA) and 
virtual docking have been used to investigate these phenomena and will be 
described here. Implications concerning the regulatory acceptance and use of 
these methods and the derived models for hazard identification and priority 
setting will be also addressed. 
2.1. IN SILICa TOOLS AS AN ALTERNATIVE TO ANIMAL TESTING 
In recent years interest in computer-aided methodologies and in silico techniques 
applied to the investigation of biological activities has significantly increased. In 
silico tools are becoming more and more accessible to researchers because of 
13 
Chapter 2 - Modelling methods 
their decreasing cost and increasing speed of computational calculation; for 
these reasons interest in their application is spreading to a wide range of 
biological problems. Frequently data-mining techniques are used to analyse a 
wide range of biological data like. for example. those from genomics [25.26] or 
proteomics [27.28]. 
Among them. one challenging application is the modelling and characterisation 
of the (bio)activity of chemical compounds. A variety of techniques is included in 
this area. and among them QSAR has been widely used in characterizing many 
properties of chemical compounds. using information derived from chemical 
structures. Many studies have been published addressing for example ecotoxicity 
[29.30]. human health [31-33]. physico-chemical [34.35] and Absorption 
Distribution Metabolism Excretion (ADME) properties [36.37]. 
Nowadays an (eco) toxicological characterisation of the risk associated with the 
use of industrial chemicals is still incomplete. Two elements are required to 
address this issue: an evaluation of the intrinsic properties of the chemical - hazard 
assessment. and an estimation of the exposure. The primary constraint in 
completing the hazard assessment is the lack of adequate experimental data 
required to cover all relevant effects of chemicals associated with human health 
or ecological safety. A study on the availability of the toxicity data for High 
Production Volume (HPV) existing substances revealed significant gaps in publicly 
available knowledge about these chemicals [38.39]. 
In the near future the situation is going to change since new requirements have 
been introduced by the legislation recently approved in the EU called REACH 
[40]. REACH (Registration. Evaluation. Authorisation and restriction of CHemicals) 
will modify the current authorisation scheme for commercialising chemical 
products within the EU market. Previous legislation distinguished between 
"existing" and "new" chemicals (Le. those placed on the market after 1981); 
while "new" chemicals have to be tested before they are placed on the market. 
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there were no such provisions for "existing" chemicals. Thus. although some 
information exists on the properties and uses of existing substances. this system has 
not produced sufficient information about the effects of the majority of existing 
chemicals on human health and the environment. With REACH it is foreseen to fill 
this data gap but. as a consequence of the increased need of experimental 
tests. a number of problems have to be faced. ranging from economic - in terms 
of either time or intrinsic costs - to ethical ones. It is for example estimated that 
10.7 million laboratory animals are sacrificed in testing each year in Europe. and 
10% of these tests are for regulatory purposes [41]. The economic costs are also 
very high: over the next 11 years the estimated costs for testing the approximately 
30.000 existing substances produced above 1 tonne/year would be nearly 2.5 
billion € [42). 
In silico techniques can play a key role in this process. being a valuable 
complement to in vivo and in vitro studies in assessing hazard of chemicals. Of 
course they cannot substitute for laboratory experiments. but they can be 
adequately integrated with them. In this way they can provide a prioritisation of 
compounds needing deeper in vitro and in vivo investigations. allowing a more 
rational use of resources by better planning of experimental testing. 
General rules are set out in the REACH legislation for waiving of tests through the 
use of existing information. techniques such as (QJSARs and read-across. Some 
studies have estimated that by implementing the use of these altematives. 
including (Q)SARs. it is possible to reduce the additional costs due to the REACH 
implementation by about one billion € [43J and the use of these alternatives can 
potentially save 1.3 - 1.9 million animals [44). 
Some efforts have still to be made to facilitate the regulatory acceptance of 
QSAR as an alternative approach [45] by increasing the transparency and 
reproducibility of the models generated with QSAR. and by taking into account 
regulators' needs. 
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Even though in view of REACH legislation the interest in computational chemistry 
to replace experimental testing has increased significantly. it should be noted 
that this is not the only case where QSAR is accepted in a regulatory framework. 
In the U.S.A •• Canada. Japan and some of the EU counties. at a national level. 
these methods are already accepted and used [46.47]. 
In silico technology can also represent a valid instrument to improve the safety of 
newly synthesised chemical compounds or even chemicals in a pre-synthesis 
phase. since only the chemical composition of the compounds is required. This 
can help in evaluating safer alternatives to be put on the market. 
2.2. COMPUTATIONAL MODELLING METHODS 
In this section an overview of different computational modelling methods will be 
provided. Based on a literature search. all promising studies on ER interfering 
chemicals through the use of computational chemistry were reviewed. This part 
of the work served as a basis to identify pros and cons of the different 
approaches and to give background on what was already achieved in this area. 
and on the most promising approaches already adopted. the better to set the 
experimental scene. 
Computational studies dealing with EDs have to some extent a different 
perspective and use generally slightly different tools from those in the 
pharmacological area. The main objective is to provide a tool for prioritising 
chemicals. so detailed information on the specific binding mode of different 
chemical categories is often not available. For the same reason the primary 
concern in screening environmental contaminants for their possible interference 
with endocrine systems is to identify all potential EDs: the target is to avoid the so-
called false negatives. In contrast. pharmaceutical industries in their virtual HTS 
stUdies want to focus on the most likely active compounds. avoiding false 
positives. 
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The ER was one of the first targets studied with computer-aided methodologies 
specifically for EDs. The use of QSAR applied to endocrine disrupters became in 
recent years quite widespread [48-50) and the U.S. Environmental Protection 
Agency (U.S.-EPA) was involved in the endocrine disrupters screening programme 
[51). with the goal of developing models to predict receptor-mediated response 
[52.53). 
2.2.1. (Q}SAR 
Many attempts have been made in the past to relate. in a qualitative manner 
with SAR. or quantitatively with QSAR. molecular characteristics to some observed 
properties. Usually in the term (Q}SAR both approaches are included. 
In the '60s a fundamental contribution was made by Corwin Hansch [54.55). 
Hansch's paradigm was based on the study of congeneric series of chemicals. 
The activity. expressed in the logarithmic form. was assumed to depend on the 
substituent contributions to the parent compound in terms of hydrophobicity. 
electronic and steric terms. The biological relevance of these terms was 
correlated with the ability of a compound to penetrate into a biosystem and to 
reach the target site for the required interaction [56). 
To move from the requirement of congeneric series. a large variety of molecular 
descriptors have been proposed over the years to encode the structural features 
of chemical compounds [57). 
The workflow of the QSAR process can be schematically represented in Figure 2.1. 
The assumption behind the development of a QSAR model is that a quantitative 
relation exists between molecular features and the studied biological activity. 
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Figure 2.1 Schematic representation of the steps for developing (Q)SAR models. 
To find this relationship the requested steps are: 
r 
Validation 
of QSAR 
J 
<D Calculation of chemical descriptors: As already mentioned, several types of 
descriptors can be used to encode different properties of chemicals (e.g.: 
electrostatic, hydrophobic, steric, topological, etc.) [57]. They can include 
experimentally calculated physico-chemical properties (e.g. boiling point) , 
but in the majority of the studies they are constituted by a numerical 
evaluation of properties that can be computed on the basis of the chemical 
structure. A very practical approach for grouping the descriptor categories is 
to consider the structural information required to calculate them. Some kinds 
of descriptors encode very simple characteristics of the molecules that do not 
depend on the 3D conformation of the molecule and can be easily 
computed on the basis of 20 structure only. Other characteristics, such as 
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energetic terms. require the knowledge of the structure in terms of its 3D 
shape. This is not a straightforward process because each molecule can exist 
in multiple conformations with different levels of stability and occurrence. The 
solution commonly adopted is to use as reference conformation the 
energetically most stable one under fixed conditions. To obtain it, 
conformational space should be sampled (conformational search) and the 
global minimum structure found through geometry optimisation via common 
force fields. semi-empirical or ab-initio methods [58]. Then, 3D descriptors are 
computed on this structure. For 20 descriptors it is relatively easy to set up a 
procedure to make them reproducible, ensuring in this way that it will be 
possible to calculate them for new compounds later on, and to apply the 
QSAR model; however it is more complex to guarantee this for 3D descriptors. 
Firstly, the optimisation can include non-deterministic steps, and secondly it 
has been observed that sometimes small changes in the 3D conformation can 
have a large effect on the 3D descriptors [59]. Moreover what can be 
obtained is only a reference 3D structure. not necessarily representing the 
bioactive conformation assumed by a molecule in its interaction with the 
biological environment. Despite these limitations 3D descriptors have been 
used successfully in many studies [60.61] even though on large and 
heterogeneous datasets they have sometimes shown to be no better than 20 
descriptors [62J. 
<2> Preparation of the Y-block yariable: Along with the X matrix containing the 
independent variables. a Y matrix containing the target property or properties 
to be studied should be collected. If the target is a single activity this matrix 
consists of a single column containing the activity value associated to each 
chemical. The property to be modelled can be a continuous variable 
modelled in a quantitative manner or a categorical one modelled with 
classification techniques. One of the major problems in preparing the activity 
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data is that any algorithm adopted during the modelling relies on data to 
extract rules describing the activity trend. If these data are unreliable the 
resulting model will be misleading. So careful attention should be paid in 
preparing a dataset suitable for modelling purposes. by pruning ambiguous 
data. It should also be noticed that. despite all efforts in using only reliable 
data. there is an intrinsic variability within the experimental data that cannot 
be avoided. especially if they involve biological systems [59]. In this way a 
certain degree of noise is introduced in the system and the modelling step 
should distinguish between the relevant information contained in the data 
from the noise and redundancy introduced with either X or Y-block variables. 
@ Statistical analysis: This is the central step of the modelling task. It includes pre-
processing of data matrix. variable selection to include only statistically 
relevant descriptors. and the application of specific algorithms to find the 
relationship between chemical descriptors and the target property. 
Pre-processing is a preliminary but essential stage where data matrix is pruned 
of redundant information. incomplete variables are deleted and the scaling 
procedure is applied to the dataset. 
Selection of important variables can be done in two ways: hypothesis driven. 
including only variables considered a priori relevant for the endpoint to be 
modelled. or statistically driven using mathematical algorithms to search for 
the most relevant solutions. A stepwise approach or multivariate data 
exploratory methods such as Principal Component Analysis (PCA) may be 
used. However if the number of initial variables is too large these methods do 
not efficiently explore all possible combinations of variables and more 
sophisticated tools are required. Genetic Algorithms (GA). based on the 
Darwinian evolutionary theory. have been shown to be one of the most 
promising algorithms in this field. The best individuals in a population of models 
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are crossed over. merged. mutated and then iteratively evaluated against a 
fitness function which gives a statistical evaluation of the model performances. 
The variety of methods available to derive a model is also rather wide. A first 
distinction can be made between QSAR and SAR. While QSAR is searching for 
a quantitative relationship. SAR is a qualitative association between a 
molecular substructure and the presence or absence of a certain activity or 
the capacity to modulate that activity. The algorithms used for the modelling 
may vary depending on the kind of study: some studies deal with categorical 
target properties. which employ classification tools. and others with continuous 
variables. using regression approaches. Beside the more classical multivariate 
techniques that use linear methods, in recent decades neural networks INN) 
have frequently been used as a non-linear statistical data modelling tool. NN is 
inspired by the way biological nervous systems. such as the brain, process 
information. It is a system of interconnecting neurons in a network. working 
together to produce an output function [63). 
G) Vglidgtion of the model: 
Whatever is the technique chosen to model a specific dataset, one of the 
most important issues in the QSAR field is that of validation of the models. 
When a qualitative or quantitative model has to be assessed, several 
characteristics of the model have to be analysed focusing in particular on 
three main aspects: (i) intemal validation, (ii) prediction ability and (iii) 
applicability domain. 
(i) Internal validation is based on the assessment of goodness-of-fit and 
robustness. The first concept applies to the ability of the model to describe the 
variation in the training set, while the latter provides an indication on the 
model stability in terms of how sensitive it is to perturbation in the training set. 
Commonly, for models based on continuous responses. the main statistical 
parameter to assess the goodness-of-fit is the coefficient of determination R2: 
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n L(Yi -V" 
R2 = 1- -!-1=...:..I __ _ 
n L(Y' -V) 
i=1 
where y. Vi and yare respectively the observed. calculated and mean 
values of the Y dependent variable. The closer is R2 to 1 the better the model is 
in fitting the data. 
For classification models the quality of the model can be assessed by 
measuring its accuracy: the ratio between correctly classified compounds 
and the total number of compounds included in the dataset. 
Robustness is usually assessed by the cross-validation procedure: the training 
set is iteratively perturbed in its composition by excluding one or more 
compounds and the other compounds are used to generate a model 
predicting the excluded chemicals with this sub-model. This procedure is 
usually repeated for all compounds. Statistical parameters similar to accuracy 
or R2 (usually called Q2 or R2cv) are then calculated based on the predicted 
values and should maintain a value comparable to R2. Randomisation of the 
Y-response can be also performed to evaluate whether with a dataset 
containing Y-scrambled responses the model statistics decrease significantly. 
as expected. or if not. it is an indication of chance correlation. 
(ii) Traditionally QSAR models have been developed to describe a 
phenomenon. suitable to identify a rational relationship between a given 
parameter and the property. However, later on the emphasis has been put on 
the use of these relationships to predict the properties of unknown compounds 
and consequently different tools become necessary to avoid over-fitting. 
Indeed, in many cases, especially when many descriptors and complex 
algorithms are used, there is a risk of obtaining an over-fitted model that 
follows too close the behaviour of the training set not being able to generalize 
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and capturing the activity trend in a more general way. For these reasons 
statistical tools should prove the capability of the model to be valid in a 
general way, i.e. to be predictive upon compounds not used in development 
of the model. There is a debate in the scientific community on the most 
suitable way to assess the robustness and predictive performances of a model 
[64-66]. The use of an extemal set for the validation has been indicated in 
some cases as the most appropriate solution to assess the predictive power of 
a model [67] even though some difficulties may arise in designing it as 
representative of the training set, covering all its main structural and physico-
chemical characteristics [68]. This issue is also related to the applicability 
domain problem. 
(iii) The concept of applicability domain (AD) is an increasing consideration in 
the QSAR field due to the need to define better areas where is it possible to 
use the models practically with an increased confidence about the prediction 
so obtained [69]. It is based on the assessment of similarity for the new 
chemical to be predicted with the group of compounds used to develop the 
model. Among the available approaches there are series of chemometric 
tools based on the comparison of the descriptors used to develop the models 
of the new molecules to be tested, with those of the molecules in the training 
set. Another approach involves comparison of the structural features of the 
compounds in an a priori way, without necessarily using the descriptors 
selected in the models. In this case structures are encoded in fingerprints or by 
taking into account relevant fragments and using them to assess the similarity 
with the training set. A review of these approaches has been recently 
published [70]. 
Overall the validation should ensure that the model is statistically significant, 
reliable and robust against noise and data perturbation, and maintains its 
validity when the relationship is tested on compounds sharing similarity with 
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the training data. at least within a defined chemical space. For these reasons 
the judgment of model validity is based on the evaluation of a series of 
aspects. here summarised. sometimes assessed with a variety of different 
methods. 
2.2.1 .1 . Models on ER with (Q)SAR 
ER has been widely studied with QSAR techniques in respect of the EDs issue. 
Many of the studies were focused on the binding assay data. The datasets used in 
these studies are relatively heterogeneous in terms of both the number of 
compounds used - from a few dozen up to a few hundred - and the source for 
binding activity data - utilizing different species (rat. mouse. human. calf) and 
subtypes (alpha. beta or both mixed) -. 
Some studies have employed structural features to discriminate binders versus 
non-binders in a SAR. The ability of compounds to bind the ER was associated by 
Fang et a/. in a qualitative manner. to the presence of certain characteristics 
(e.g. a phenolic ring) [48] while Klopman et 01. used the occurrence of certain 
groups among active or inactive chemicals to characterize recursively the most 
relevant fragments in the two groups in a semi-quantitative way [71]. 
Classification methods have also been used to categorize the data in two 
classes. employing different cut-offs to discriminate binders from non-binders or 
chemicals exhibiting marginal activity from strong binders. The most interesting 
approaches have employed Bayesian probability analysis [72]. decision trees [73]. 
soft independent modelling by class analogy (SIMCA) and spline-fitting with 
genetic algorithm [74]. 
Moving to quantitative studies. linear regression models have been produced in 
particular using PlS [61.75]. a regression method based on the use of "latent 
variables" generated by a linear combination of the original set of descriptors. 
Other non-linear techniques have been explored and sometimes compared to 
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linear methods. One of them is a non linear QSAR technique which is based on 
the concept of molecular similarity and K-nearest neighbour principle [76.77]. 
Other non-linear methods have relied on the NN technique and different kinds of 
NN architectures have been explored. including probabilistic NN [78]. back-
propagation and counter-propagation NN [75]. 
To complete this overview. another approach has to be mentioned: it involves 
the use of multiple energetically reasonable conformations for each chemical to 
overcome the limitations of using a single 30 global minimum as reference 
structure to calculate descriptors [79]. Then. the distribution in the population of 
values for the descriptors calculated on the active compounds is compared with 
that obtained on the inactive compounds and it is used to derive a classification 
model. 
Some studies have dealt with a different endpoint for oestrogenicity: instead of 
developing models focused on binding affinity data. the ER transactivation 
properties were investigated in terms of reporter gene assay or cell proliferation 
assay. Classification models have been produced by using classification trees 
[80]. SAR approach [81] and a 30-QSAR method based on Molecular Quantum 
Similarity Measures (MQSM) [82]. 
It is difficult to compare the results of different approaches since often these 
models relied on different datasets or at least on different validation parameters. 
Regarding the chemical information. it has to be highlighted that several of the 
paper here mentioned used 20 descriptors or even compared performances with 
30 deSCriptors. The majority of these studies found that with 2D descriptors. which 
are simpler to be calculated and allow for a relatively faster analysis. it is possible 
to obtain comparable results with those involving more complex 3D descriptors 
[73.83.84]. This observation is somewhat surprising since the weakness of 20 
descriptors is that they ignore the 30 nature of chemical interaction with a 
receptor. which is an important ingredient in the binding. A possible explanation is 
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that this kind of trend was especially noticed in more heterogeneous datasets or 
in classification studies where a lower level of detail in the chemical information is 
required to obtain for instance a binary classifier. This finding can surely be an 
advantage for having models more easily exploitable for new chemicals. and 
hence more useful in practical terms for prioritising new compounds. On the other 
hand. the interpretability of the selected descriptors is sometimes less explicit. 
especially if the models use a relatively large number of variables. 
Comparing the different modelling approaches adopted, slight improvements 
were obtained with non-linear methods but often the statistical significance of the 
improvements was too limited compared to the increased complexity. 
Some attempts have been made for improving the regulatory acceptance of 
these models, in particular in starting to address the problem of defining better 
the applicability domain [73.801. A few of the models here briefly described will 
be analysed in more detail in the next chapter of this work. focusing especially on 
these aspects. 
2.2.2. 3D-QSAR 
3D-QSAR includes a variety of methods which basically differ from the classical 
QSAR analysis because of the descriptor types used within the modelling. These 
methods are based on the concept of Molecular Interaction Fields (MIF) [851. 
Molecular features are derived by mapping the environment surrounding the 
molecules in terms of energetic interactions of various natures. mainly steric and 
electrostatic, but sometimes hydrophobic or hydrogen bonding potential may be 
included. This is obtained by placing the molecule within a lattice and calculating 
the interaction energies of this molecule with a probe (e.g. a Sp3 carbon atom) at 
each point of the grid. as shown in Figure 2.2. 
Since field-based descriptors are directionally dependent, a very critical step in 
the 3D-QSAR analysis is the alignment in the Euclidean space of all the molecules 
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in the dataset accordingly to various methodologies of superposition. The 
alignment can be based on the electrostatic and/or steric field overlap, based 
on a common skeleton superposition, evaluating docking or crystallographic 
information, or based on pharmacophoric hypothesis. 
Moll 
Mol2 
Moln I 
figure 2.2 Representation of the lattice used to calculate field-based descriptors. 3D-QSAR descriptors 
are calculated by placing appropriately over1apped molecules within a lattice and calcula ting with a 
probe (placed in the upper left hand comer in the figure) the steric and electrostalic field 
contributions of the molecule at that point. Each matrix column contains the contribution to the field 
for each molecule at a specific grid point. 
Each deSCriptor column is made up of the values of the interaction field assumed 
for the compounds included in the dataset in a certain point of the grid. Then 
these field energy terms are used as a very large pool of descriptors - hundreds or 
thousands - to search for a relationship with the property of interest, usually by a 
PLS analysis, thus the variation from molecule to molecule in the fields they 
generated in some areas of the grid are usually related to the variation in the 
modelled activity. Since these interactions are clearly placed in the 3D space 
surrounding the molecules, a regression map can be created by mapping back 
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into the box the regression coefficient of the model. Therefore the method allows 
the identification of the most important regions in the molecule responsible for 
modulating the target properties. 
The most popular method in 30-QSAR studies is CoM FA [86] but other methods 
have been developed based on different force fields adopted to calculate the 
energy terms. and considering more heterogeneous probe definitions to capture 
more complex interactions, for example CoMSIA [87] or GRIO MIF [85], coupled 
with PLS analysis. 
The most attractive feature of 30-QSAR compared to classical QSAR is that the 
biological environment surrounding the molecules is talcen into account even if 
only implicitly. This happens especially when direct interaction with a target 
macromolecule is considered (e.g. activity against a specific receptor) and a 
hypothesis about these interactions can be made on the basis of the derived 
relationship. The model can be interpreted so that the conformations of ligands 
are representative of the bioactive conformation assumed in the binding poclcet 
of the receptor and the alignment represents the different possibilities of the 
molecule's binding to the receptor. For this reason the choice of the bioactive 
conformation and proper alignment are essential phases and often information 
on these characteristics is derived from crystallographic or docking studies. 
Traditionally, linear PLS method has been used to derive CoMFA models since this 
method is tolerant to the inclusion of a large number of variables in the model, 
although other methods can be used to investigate nonlinear relationships, such 
as neural networles. However, including into the model a large number of 
variables, even if condensed in a few principal components, can increase the risk 
of chance correlation. For this reason the validation procedure is an essential step 
to test the model performances, particularly for the 30-QSAR method. Commonly 
the cross-validation procedure is adopted and sometimes a randomisation test is 
included. Often the model performances are verified by evaluating the 
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prediction for new compounds. included in a test set. However neither results 
from cross-validation nor performances on the test set compounds can give a 
reliable estimation of model reliability if these parameters have been used to 
select the best architecture of the models. A more extensive discussion about 
these issues can be found in a review paper by Y. Martin [88]. 
The attention to the biological environment along with the ease of interpretability 
of chemical features through the regreSSion maps are two of the major 
advantages of 30-QSAR. 
On the other hand. the principal drawback is the increaSing complexity of the 
models. which requires 30 conformations. their alignment and a large number of 
variables. This can sometimes make it more difficult to reproduce a model. or at 
least to apply it to new compounds. if the alignment rules are too specific or are 
not suitable for other chemical classes. thereby limiting the range of chemicals 
that can be analysed with the model. 
To overcome the limitations due to the superposition procedure some alignment 
independent extensions of 30-QSAR descriptors have been developed that do 
not require aligned structure. such as VolSurf and GRINO derived from GRIO/PLS 
[85]. 
2.2.2.1. Models on ER with 3[)..QSAR 
30-QSAR methodologies have been widely applied in the study of receptor-
ligand interactions. since the presence of a defined biological reaction site 
makes the determination of a proper alignment more likely. 
Often modelling exercises have been conducted using both 30-QSAR and 
classical QSAR approaches and comparing their outcomes based on the 
investigation of a common dataset [83.89]. For instance. a comparative study 
was performed using CoMFA and CoMSIA. classical 20/3D deSCriptors. and 
fingerprint type descriptors that characterize chemical structures in a string of bits 
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indicating the presence or absence of specific 20 or 3D structural characteristics 
[83]. Another study proposed CoMFA in combination with 20-QSAR 
methodologies based on fingerprints descriptors (HQSAR. and FREO/SKEYS). 
providing a helpful comparison of their predictive power [89J. 
Overall these studies demonstrated that for heterogeneous datasets 3D and 
classical QSAR approaches exhibit similar performances. not necessarily justifying 
the use of 30-QSAR which implies an increased complexity. It has to be noted 
that this kind of assessment is often based on a limited set of validation 
parameters. provided in the original studies. and for this reason different 
conclusions may be derived if a larger pool of validation factors is used. On the 
other hand 30-QSAR can provide a more easily interpretable model in terms of 
chemical features. especially if compared to other less intuitive and less 
transparent molecular descriptors. 
3D-QSAR can be used to highlight differences in receptor affinity and to model 
the selectivity of the ligands for some receptor subtypes. Tong et 01. [90J 
employed CoMFA maps to identify and differentiate the structural features of 
ligands responsible for the selective binding to ER alpha and beta. Although the 
receptor crystal structure is available. CoMFA provides an additional source of 
information about the receptor from the perspective of the ligands. 
Other successful applications were for series of relatively homogeneous 
compounds where proper alignment rules can be more easily detected. This 
approach is commonly used also within the pharmaceutical industry for 
optimising the characteristics of a lead compound among homogeneous series. 
CoMFA. CoMSIA and HQSAR were used to investigate a series of Bisphenol A 
analogues. considering not only the binding but modelling also other properties 
such as transactivation potency [91]. Again. statistical performances of the 
different methods seem similar even if their respective outcomes are more 
complementary than alternative. Interestingly this study provided an example 
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where instead of the minimum conformation, the most probable bioactive 
conformer identified by other in silico simulation was used, through virtual 
docking. 
2.2.3. VIRTUAL DOCKING 
Virtual docking is a methodology to predict computationally the binding 
between two molecules, usually a protein and another macromolecule (protein 
or DNA) or a small molecule (ligand). Here the focus will concentrate on protein-
ligand docking as a tool to estimate the interaction of chemical compounds with 
biological target sites. 
To perform this kind of study the chemical composition and 3D spatial 
organisation of the protein should be known along with the identification of the 
cavity defining the binding site of the protein, whose position and shape are used 
in the docking process. Usually the most suitable source is the structure solved 
through X-ray crystallography. If this is not available, a structure determined with 
NMR spectroscopy or by homology modelling may be used. The latter method 
consists in the reconstruction of the 3D shape of the protein of interest from other 
proteins, whose structure is known, that share similarity in the aminoacid 
sequences. The protein structure so obtained can be less reliable compared to 
the other methods mentioned above. 
It should be noted that using as starting point the crystal structure of a ligand-
receptor complex, means that the procedure begins from a single, low-energy, 
snapshot of an actual dynamic biological system. Then the first task to 
accomplish is to sample the conformational space of possible energetically 
reasonable structures of the protein-ligand complexes. This is not a trivial process 
since the conformational space to be examined is huge due to the intrinsic 
flexibility of both the ligands and the protein, including further forms of plasticity 
that can be introduced upon the mutual recognition between protein and ligand 
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by the induced fit process [92]. Nowadays the majority of the docking programs 
take into account ligand flexibility in contrast to rigid docking (where both the 
ligand and the protein are considered as rigid bodies). but protein flexibility is not 
yet fully integrated into docking protocols and is taken into consideration only 
marginally. Among the methods employed to perform the searching strategy 
there are molecular dynamics simulations. Monte Carlo methods. genetiC 
algorithms and fragment-based methods [93]. 
Once a pool of ligand-protein complexes has been generated. scoring functions 
are used by docking programs to indicate the likelihood that the orientation 
possesses a favourable binding interaction. The scoring function provides an 
estimation of the Gibbs free energy of binding. released when ligand and 
receptor bind. to evaluate their likely stability as a complex (see Figure 2.3) . 
+ L 
Figure 2.3 The process of mutual recognition between a protein (PI and a ligand (LI is governed by the 
Gibbs free energy of binding. released when ligand and receptor bind 
For each orientation ilGbinding can be used to assess whether a favourable 
opportunity of binding may exist through the following equation: 
ilGblnding = R Tin K 0 
where R is the gas constant. T the absolute temperature and Ko the dissociation 
constant. 
The dissociation constant can then be directly linked with the inhibition constant 
(KI) ar the inhibition concentration PCso) obtained in an in vitro binding assay. 
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Consequently, a proper scoring for the docked orientations is the second crucial 
step in the docking process. The scoring functions may rely on force fields to 
calculate energies or on knowledge-based or empirical functions (including 
QSAR relationships) [94]. 
Although fairly accurate ways for estimating these energies exist, based on free 
energy perturbation or thermodynamic integration methods, this level of 
accuracy in practice can be used only in a few, very focused studies. On the 
other hand. the most attractive application of virtual docking is its use in virtual 
high throughput screening (HTS), whereby large virtual libraries of compounds are 
reduced in size to a subset. which, if successful, includes molecules with high 
binding affinities to a target receptor [95]. This approach is often used in the drug 
discovery process to identify new lead compounds. One of the tests commonly 
adopted to verify whether a specific docking program works well with a protein 
system is to evaluate if it is able to reproduce the orientations of small ligands 
found in crystal structures. This kind of test is useful to evaluate if the solution 
identified by the program is reasonable and so whether the searching algorithms 
and scoring functions involved in the process are accurate enough to find the 
right solution Ian orientation close to the experimentally determined one) among 
many others and to score it properly, recognizing it as one of the favoured 
orientatons. This preliminary evaluation does not offer enough guarantee about 
the final docking output precision. For applications in virtual HTS the scoring 
function used to approximate the energies should be fast enough to accomplish 
this task in a reasonable time, but this is associated with a low level of accuracy. 
The typical level of accuracy reached by docking programs in virtual HTS does 
not allow a direct correlation of their scores with the binding affinity. Moreover 
they are hardly able qualitatively to rank the compound order properly in respect 
of binding strength (96]. 
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Normally the outcomes obtained with this task can be measured with the 
enrichment factor so that the subset selected with the docking procedure 
contains a larger number of compounds showing affinity for the studied receptor. 
A practical comparison of performances and features of the most popular 
docking programs can be found in the literature [97]. 
The calculation complexity of virtual docking, which also encodes the protein 
structure, is clearly larger compared to the use of ligands alone, due to the larger 
number of atoms involved in the calculation and the need for proper force field 
parameterisation for the interaction of small molecules with aminoacid residues. 
However, once the experimental protocol is set, docking methods are fast 
enough to screen very large libraries of chemical compounds in a reasonable 
time. 
Some limitations may arise from inaccurate energy estimation. Docking still 
remains effective in drug design, since it improves performances compared to 
random selection of possible hits, as indicated by the enrichment factor, whilst its 
application as a pre-screening tool targeted at the hazard assessment of less 
enhanced binding activities has been tested less often. 
This latter application may be more critical since in this case there is less tolerance 
of false negatives while virtual HTS is commonly biased by the intensive use in drug 
design where the attention is more focused to control the number of false 
positives. Some interesting applications of the EDs issue can be found in literature 
and are analysed below. 
2.2.3.1 . Models on ER with doc!dng 
Some docking studies have been published addressing more or less specifically 
the issue of EDs. In some of these investigations a quantitative assessment of the 
binding was provided with the docking approach for a limited number of 
compounds under investigation. 
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Some encouraging outcomes of docking simulations have been obtained with 
molecular dynamics and linear interaction energy methods to measure the 
interaction energies fairly accurately and link them with the experimental binding. 
The validity of the approach has been also tested for predicting a few new 
compounds [98]. 
In another study a small group of steroids, phytoestrogens and PCBs were docked 
into the alpha ER and into a homology model of ER beta receptors. The 
calculated energies correlated very well for the investigated chemicals with the 
experimental binding affinities for both subtypes, recognizing different selectivity 
for the two subtypes [99]. 
For a larger set of heterogeneous compounds, binding affinities were correlated 
with docking scores less accurately but the approach can be considered 
successful for evaluating the enrichment factors in the screening. Interestingly, to 
account for receptor flexibility a subset of receptor crystal structures were used in 
parallel in the docking process and this approach increased the accuracy 
gained in comparison with the use of a single complex [100]. 
Other studies demonstrated that the docking methodology failed to provide 
enough accuracy in estimating binding strength as previously explained, but 
confirmed its validity as a complementary tool to develop more powerful 3D-
QSAR models. Thus, the use of docking conformers to generate a more 
biologically plausible alignment creates a link between the two methods [101 J. 
Some authors showed that, although docking itself failed to predict the binding 
affinities quantitatively, the use of docked orientations for the ligand and, with a 
minor influence, the inclusion of scores as additional parameters, allowed the 
development of a superior model compared to the classical CoMFA model using 
lowest energy conformer for ER alpha. However, this approach failed for ER beta 
[102J. 
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There are also examples where direct calculation of binding energies based on 
docking runs gave poor results compared to classical CoMFA models, but the use 
of docked orientations instead of minimum energy conformer significantly 
increased the performances of 30-QSAR, including encouraging activity 
prediction of new chemicals [103J. 
The docking approach has been used as a starting point to develop multi-
dimensional QSAR model for ER [104J. The multiple dimension ali ties were given by 
the inclusion of multiple conformations (40), induced fit (50) and solvation effects 
(60). Receptor surrogates were derived by mapping the different properties on a 
surface surrounding the molecules and selecting the most appropriate ones to 
assess the binding affinity using GA. Very good quantitative results were obtained 
with this method for a large dataset of a hundred heterogeneous compounds. 
2.3. CONCLUSIONS 
Oifferent ways for assessing the properties of chemical compounds in silico have 
been illustrated here. The characteristics of the different approaches are 
summarised in Table 2.1. The first distinction can be made between receptor-
dependent and independent methods. 
Traditionally, in environmental and health safety the phenomena under 
evaluation are more general ones and do not necessarily represent the explicit 
interaction with a well characterised, specific receptor (e.g. systemic toxicity or 
carcinogenic process); thus receptor-based methods can be applied only in 
some circumstances such as for investigating NR interactions or metabolic 
processes mediated by the cytochrome P450 family. In other contexts, when 
more general multi-step toxic effects of chemical compounds are studied, or a 
defined mode of action cannot be recognised, the modelling must rely on the 
chemical structure alone. In these cases QSAR and 30-QSAR can be applied also 
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when the target macromolecule is not known or toxic effects cannot be linked 
with a specific receptor. 
Table 2.1 Overview of the methods that can be adopted to study the biological effect of chemical 
compounds. 
TECHNIQUES 
Receptor-independent 
Receptor-
dependent 
QSAR 3D-QSAR Docking 
(Q)SAR seorches for a 
quantatlve or It uses field-based quantitative relationship descriptors to The binding affinity of describing the Influence 
represent the a ligand with a 
of small molecule receptor is inferred by 
DESCRIPTION feotures. encoded In energetic environment an energetic 
molecular descrfptors. In of the molecules. It evaluation of the 
requires 3D conformers producing a certain 
which should be complex through biological effect trough property aligned. scoring functions. 
a statistically significant 
model. 
Quite fast and Considers the 
reproducible especially if biological Closer to reollty: It descriptors depending 
environment explicitly Includes a 
onlyon2D 
surrounding small description of the 
characteristics of the biological 
molecules are used. molecule although macromolecules 
PROS Implicitly. responsible for the Widely applicable to It allows for a observed activity. 
new compounds: 
visualisation of most 
although the model itself Important molecular It allows a deeper 
can be complex to be mechanistic 
generated. easy rules characteristics through understanding. 
can be derfved. the regression maps. 
It allows modelling the 
less reollstlc: It Ignores 
binding strength of 
ligands with proteins 
the 3D biologically but not more complex 
active conformation of Requires 3D and global biological 
the ligand and ignores conformers and It Is effects. 
CONS the chemical structure of generally very sensitIve 
biological to the alignment The accuracy that 
macromolecules procedure. can be gained often 
responsible for permits only 
producing the effects. quaRtatlve output or 
ranking of compounds 
for their activity. 
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Moving from classical QSAR to 30-QSAR to docking there is an increasing 
attention to the biological side and this increases the "biological plausibility" of 
the results obtained by statistical methods. 
Explicitly introducing a description of the biological receptor increases the 
accuracy of the biological environment description, and can provide more 
insights of the mechanistic interpretation. On the other hand, the increased 
complexity (e.g. the computational one), although it may improve the 
comprehension of the studied process, often does not produce more statistically 
significant models, indicating that the noise introduced in the system may be 
greater than fhe additional informative content. 
It is not worth estimating a priori whether one technique is superior fo another. 
What is frequently observed is that depending on the problem to be addressed 
some techniques can be more beneficial than others. Moreover it has been 
proven that complementary outcomes can be derived, so that a more complete 
description of a phenomenon can be obtained by integrating different 
techniques. 
Literature sources describing relevant modelling exercises for endocrine disrupters, 
in terms of oestrogen receptor interferences, have also been reviewed, focusing 
the attention on possible applications to screen large chemical inventories for 
environmental and health safety. 
In the remaining part of this research project. since the main goal was to provide 
some widely applicable models, the focus will be on classical QSAR tools. 
38 
PART II 
VALIDATION OF EXISTING MODELS 
39 
CHAPTER 3 
CRITICAL ASSESSMENT AND SELECTION OF EXISTING MODELS 
FOR EDs ACCORDINGLY TO THE OECD PRINCIPLES 
Based on the literature review conducted at the beginning of this research, a 
number of interesting models were identified. Therefore the first part of this project 
was intended to analyse the existing information and models prior to developing 
new ones in order to: i) assess what level of accuracy was already obtained and 
ii) identify the most promising methods to be further explored. 
Even though a huge number of models for oestrogen receptor binding have 
been published, developed using many different algorithms, little attention has 
generally been paid to the practical use of these models. More efforts are now 
required not only to derive new models but also to have a deeper understanding 
of their applicability to real world problems and particularly in relation to the 
regulatory use of QSAR [45,105-1071. In order to have a model accepted and 
used in the context of a regulatory framework five principles have been identified 
by OECD2 as important steps for its validation and acceptance; in particular the 
following pieces of information to ensure the reproducibility of the model and its 
robustness and predictivity have to be provided: 
1) a defined endpoint, 
2) an unambiguous algorithm, 
3) a defined domain of applicability, 
4) appropriate measures of goodness-of-fit, robustness and predictivity, 
2 http://www.oecd.org/documentl231O.2340.en264934365339570151JJLoa.html 
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5) a mechanistic interpretation, if possible. 
Along with the precise definition of the protocol, ECV AM suggests that other steps 
are required to ensure QSAR validity from a regulatory point of view [108]. 
Basically it should be verified that the model itself is transferable by other scientists 
who can reproduce the model, evaluate its variability and apply it to new 
compounds. 
This kind of external assessment may be very difficult to perform since it should rely 
on information made available in the public domain. On the other hand this 
practical proof of concepts is the only way to evaluate to what extent a given 
model is really applicable and suitable to address the specific activities taken into 
consideration. 
The aim of the specific task presented here, was to identify relevant criteria for 
selecting promising (Q)SARs to perform an independent evaluation for a subset of 
interesting models. Due to the intrinsic difficulties and constraints mentioned 
earlier, it would not be possible to evaluate all the models identified in literature so 
this assessment intends to analyse essential information concerning the (Q)SAR 
models under investigation, and to select a reasonable subset of models to 
perform this extemal judgment. 
3.1. CRITERIA FOR MODEL SELECTION 
Two parallel evaluations were conducted to identify relevant criteria for model 
selection; first of all, from a theoretical point of view, the OECD principles were 
analysed in respect of the current status of researches on endocrine disrupters. In 
a second instance the reverse process was followed, considering the concrete 
information available in the models identified in the literature and evaluating how 
they fit within the OECD principles and the areas needing a further independent 
assessment. 
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3.1.1. PRELIMINARY EVALUATIONS OF THE OECD PRINCIPLES 
Firstly some general considerations about the OECD principles were derived. 
evaluating their translation from a theoretical point of view to their practical 
application by considering the overall pool of models identified in the literature. 
1 st OECP principle: a defined endpoint. Regarding this principle it is interesting to 
note that there is great interest in endocrine disrupters from a regulatory point of 
view but validated tests and guidelines do not already exist. 
Some preferred protocols for testing have been suggested by ICCV AM [24] but 
overall the available models in literature rely on existing. available data. For 
instance, most workers chose to investigate endpoints related to ER compared to 
other NRs; this is probably due to the interest on ER as a pharmaceutical target. 
and because of an earlier development and standardisation of the test 
procedures for ER. that made available a larger number of data to model. 
So. the scientific relevance of this endpoint is certainly clearly characterised but it 
can be more difficult properly to identify its relevance in the context of the 
regulatory framework. 
For instance. the receptor binding affinity (the endpoint most often studied), 
represents just the first step in a cascade of events and other endpoints 
downstream of receptor-ligand interactions may be more suitable properly to 
evaluate the effects. Moving from the binding experiments to the transcriptional 
activation properties or even to the in vivo characterisation of the effect. the 
biological relevance of the endpoint surely increases. However some criticisms 
may arise in defining whether these endpoints are appropriate to assess the risk 
posed by EDs, since it is extremely difficult to evaluate the significance of low-
dose effects of weak xenoestogens [109]. 
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All these considerations are behind the development and validation of QSAR 
models but should be taken into account in the future when more details about 
the toxicological perspective become available. 
2nd GEeD principle: an unambiguous algorithm. This principle refers to all 
considerations about the equation encoding the final model itself but it includes 
also a definition of other characteristics such as the descriptors used in the model. 
Some critical aspects for the application of this principle can arise from both the 
chemical and mathematical side. From the chemical point of view it is crucial 
that the method to calculate the descriptors is disclosed so that it can be 
unambiguously applied to new chemical structures. This can be especially 
difficult for 3D-QSAR models. strongly depending upon the alignment. since it 
should be verified that the alignment rules are reproducible and applicable to 
new chemicals. Regarding the explicit definition of the equation or rules 
describing the final model. they can be easily accessible if the model itself has a 
simple structure. or they can be more complex and so more difficult to 
reproduce. 
3rd GEep principle: a defined domain of applicability. The third principle. dealing 
with the definition of the applicability domain. has been explored in literature only 
marginally and no precise definition of the AD is available for almost all the 
models in literature. A related issue that on the other hand has been sometimes 
addressed is the assessment of the portion of the chemical space of interest that 
can be evaluated with the proposed model. which reflects the practical value of 
the model as a screening tool. 
4th GEeD princjple: gppropriate megsures of goodness-of-fjt, robustness and 
predictivity. Within this statement all issues concerning the model statistics 
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themselves can be found, including the access to background information 
regarding training and test set, modelling and validation procedures. Even 
though within this principle a number of essential statistical measures for a realistic 
assessment of the model are included, in practice all models published in 
literature deal with these topics in a very heterogeneous way and adopt ad hoc 
parameters to assess their performances, making it difficult to compare them with 
the others. 
5th OECP principle: a mechqnistic interpretation. if possible. In the specific case 
of oestrogen receptor interaction, a number of pieces of evidence are coming 
from other fields of research that can support a mechanistic interpretation of the 
models sometimes prior to model development, guiding the descriptor selection, 
more often a posteriori, after the descriptors have been selected to rationalize 
their importance and justify their use. 
In conclusion, there are certainly some critical areas that require a deeper 
evaluation of the OECD principles with their application to some concrete 
examples. 
3. 1.2. DEFINmON OF THE CRITERIA SUITABLE FOR SHORT-LISTING OF QSAR 
To highlight critical factors that can prevent the specific models to be 
independently assessed and validated, the OECD principles were re-evaluated 
before analysis from a more practical point of view. 
The main criteria used to select the fQ)SAR models to be validated were: 
a. Experimental biological data 
b. Chemical information on structures 
c. Chemical information on descriptors 
d. Chemical domain 
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e. Modelling approach and feasibility of the model 
In particular the rationale behind the choice of these criteria was the following: 
a. Experimental biological data should be reported for each chemical in the 
exact terms of the modelled output or detailing the necessary transformation 
(e.g.: range of activity for defining classes, logarithmic transformation of the 
continuous values). Data can be reported from a different source from that 
used to develop the model, but should be available in the public domain. 
This will be a minimum requirement to consider the model for the next steps. 
b. Chemical information on the structures should be given: at least in terms of 
sketched 20 structure or chemical name to identify the substances under 
evaluation in order to be able to derive the data matrix associating 
chemicals to the activity data. Again, this will be a minimum requirement to 
consider the model for the next steps. 
c. Chemical information on the descriptors and how they were calculated 
should be given. If the calculated descriptors and in particular the descriptors 
used to build the model are only generally defined (e.g.: reactivity 
parameters without any further detail) they cannot be recalculated so the 
model itself is not reproducible. A discrete scale to assess this parameter is 
necessary, in particular some primarily characteristics have to be considered, 
for instance: i) the ease of reproducing the descriptors (e.g.: CoMFA 
descriptors depending on the alignment) and ii} if the table with the 
calculated descriptors is given, in order to check for consistency with the new 
recalculated values. 
d. A specific parameter to consider is the chemical domain, identifying with this 
term a different concept from the domain of applicability. Even in case of 
formal acceptability, i.e. the model is sufficiently transparent, its utility can be 
limited because it is too restrictive in its chemical space. In this way it is 
possible to encode for the real utility of the model for screening industrial 
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chemicals. based on a qualitative assessment of the chemical diversity and 
the representation of chemical classes relevant from an environmental and 
toxicological point of view. This k:ind of approach is essential when dealing 
with ER models to evaluate their utility in terms of endocrine disrupters 
screening since many models were more pharmaceutical-oriented: 
developed using small datasets of very similar synthetic candidate drugs. 
whose utility for a large screening of industrial chemicals will be dubious. 
e. This issue refers to several aspects connected with the modelling task. 
Basically it encodes for the availability of sufficient information on the 
parameters of the model. which allow for it to be reproduced. A further point 
relates to the feasibility of the modelling approach; it means that easier 
models are more acceptable, but more complex models can be selected as 
well. Finally an overall evaluation of the models is given in terms of their 
performances, simply to avoid the selection of models which have already 
been shown to be relatively weak in their performances or have failed some 
validation attempts in the original work:. 
Information on the mode of action and on the applicability domain in a proper 
sense was not considered for the reasons explained in section 3.1 .1 . 
3.2. SELECTED MODELS 
Considering all criteria here exposed three models were selected from the 
literature [48.61,73] as candidates for an independent and complete validation 
(see Chapter 4). The selected models are reported in Table 3.1 with a brief 
description of their characteristics. 
The intrinsic characteristics of the criteria that guided the model selection ensure 
that models using relatively large and diverse dataset were preferred, and this will 
help in better evaluating the applicability domain definition. Enough supporting 
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information is available for these models in the original publications or are easily 
accessible (i.e. biological data and descriptors originally used). Moreover it 
maximised the selection of models employing different techniques, e.g. regression 
and classification, quantitative or qualitative SAR to take into account also this 
variable. 
Table 3.1 Models selected for extemal validation. 
studied endpoint Modelling technique 
Model 1 ER Relative Binding Affinity (RBA/ for rat MlR equation using 8 descriptors 
Prediction of continuous values for 16 20 descr. + 2 3D descr.) 
Ref. [61] 
active compounds n= 131 
Model 2 Decision Forest model (combination of ER classification model for rat RBA 
2D descriptors IMolconn-Z) used to develop a 
Prediction of two classes: active (any mulHple DeCision Trees) Ref. (48] detectable activity) versus Inactive 
n = 232: 131 Active and 101 Inactive 
Model 3 SAR model for rat RBA 
this SAR model Identifies six features used in a 
flowchart to discriminate active versus Inactive 
Ref. [73] Prediction of two classes: active (any compounds 
detectable activity) versus inactive 
n = 232: 1131 Acllve and 101 Inactive) 
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INDEPENDENT VALIDATION Of SELECTED (Q)SARS ON THE 
BASIS Of THE OECD PRINCIPLES 
Several aspects of the three models selected in the previous Chapter have been 
considered in order to perform an independent validation of their performances 
accordingly to the OECD principles. 
In particular the following characteristics were considered in detail: 
1) The transparency and reproducibility of all steps were carefully evaluated: 
2) Performances in prediction with new compounds identified in literature; 
3) Assessment of the AD; 
These issues do not completely cover all the OECD principles for QSAR validation 
but consider them from a more practical point of view analysing those aspects 
that can limit the application of the models. In this way it will be possible to assess 
how easily and quickly the models can be transferred from the original 
developers to other users and their predictive performances. 
4.1. MATERIALS AND METHODS 
4.1.1. SELECTED MODELS TO VAUDATE 
4.1 .1.1 . Sources for experimental activity data of the models 
Experimental activity data, used in all three Original models in Table 3.1, are from 
the NCTRER dataset (FDA's National Center for Toxicological Research - Estrogen 
Receptor Binding Database). It contains oestrogen receptor binding affinity data 
relative to 17~estradiol (RBA), calculated as the ratio of ICso values of 1713-
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estradiol and the test substance. multiplied by 100. A group of 232 chemicals was 
tested in a radioligand competitor in vitro assay. using rat uterine cytosol. It 
consisted of 131 active compounds (activity ranges from - 4.5 to 2.6. log unit) and 
101 inactive compounds with no detectable activity in the assay. Toxicity data 
were published in several papers and publicly accessible through intemet 
sources! [110. Ill}. 
Model 1 used only the subset of 131 active compounds while the others provide a 
binary classification for the entire dataset (131 active vs. 101 inactive chemicals). 
4.1 .1 .2. Descriptors 
The chemical information was treated differently in the three models. Model 1 
used 8 molecular descriptors calculated with TSAR [112] and QSARis (now MOL 
QSAR) [113]. two of them being quantum-chemical descriptors depending on the 
optimisation of the 3D structure. 
About the description of molecules. the SAR model (Model 2) identifies the 
following six features used in a flowchart to discriminate active versus inactive 
compounds: 
Fl Ring: Presence or absence of a ring in the chemical structure; 
F2 Aromatic Ring: Presence or absence of an aromatic ring in the 
chemical structure; 
F3 Phenolic Ring: Presence or absence of a phenolic ring in the chemical 
structure; 
F4 Heteroatom: Presence or absence of a H-bond capable heteroatom 
(O.S.N) attached to a non-aromatic ring structure; 
F5 Phenol 3n-Phenyl: Presence or absence of a phenolic ring linked by 1-3 
bridging atoms (e or O) to another aromatic ring system; 
I http://edkb.fdo.govlwebstartledlcb/jndex.html 
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F6 Other Key Features: Presence or absence of a key structural feature 
conferring activity, more precisely: H-bonding ability, Precise 0-0 distance 
(J 1 A), Rigid structure, Steric moieties mimicking 7a and 11/3 position of E2 
and Satisfactory hydrophobicity (LogP). 
In Model 3 only 2D descriptors were used for the dataset named ER232. and these 
were computed using Molconn-Zl, version 4.07. After removing descriptors that 
were constant across all chemicals in a data set. more than 270 descriptors 
remained and were used in model development. 
The spreadsheets with the originally calculated molecular descriptors or features 
for all three models were made available directly by the authors. or were freely 
accessible through the internet. 
4.1 .1 .3. Mathematical formulation of the models 
Modell 
In the paper by Ghafourian & Cronin [61] several linear models, based on MLR 
and PLS techniques. are reported. Among them, the stepwise MLR model was at 
the same time the least complex (fewest descriptors) and most predictive one 
and was chosen for this validation exercise. Confidence limits are also reported. 
Log RBA = +0. 14(± 2.6)+ 0.S93(± O.OS)Nc + 1.94(± 0.28)lphenol - 0.OO13(± 0.OOO2)W-
+ 14.9(± 2.1)6 Xch +0.98S(± 0.26)EHOMO + 0.0743(± 0.02)Etoolon -
+ 0.262(± 0.08)3Ka + 0.414(± O.OB)Nhalogen 
n = 131 s = 0.96S R2 = 0.723 R2cv = 0.679 F = 39.B p = 0.000 
For a complete definition of descriptors see Table 4.1. 
1 http://www.edusoft-lc.com/molconn/ 
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Model 2 
The SAR analysis is shown in Figure 4.1, where the six key features of Model 2 are 
inserted in a flowchart, whose flux identifies compounds likely or unlikely to bind to 
the ER. 
The binding polential Is 
YES delermined by these 
>----'--"-"--.1 structural fealures: 
• H·bond ability 
• Precise 0-0 dislance 
F6 • Rigid structure 
• Slene moieties mimic 7 a 
and 11~ position 
• Satisfadory 
hydrophobicity (IogP) 
Figure 4.1 The flowchart shows the rules for the SAR model as reported in the DSSTox database [111) . 
Model 3 
The Decision Forest (DF) method was used to develop classification models. It is a 
consensus modelling technique that combines multiple Decision Tree models, 
maximizing the diversity of the descriptors included in each tree. The final model 
published on the ER232 dataset combines six trees and is based on about 80 
descriptors. 
4.1.2. INTERNAL VALIDATION AND MODEL REPRODUCIBILITY 
Following the OECD principles, models for regulatory purposes have to be 
transparent. To accomplish this requirement an important step is that of 
reproducing and verifying the models and the associated statistical parameters. 
In this context the recalculation of chemical descriptors is very important to verify 
the model reproducibility and the likelihood of obtaining the descriptors using 
different tools employing Slightly different procedure/software (sensitivity study). 
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4.1 .2.1 . Re-calculation of the models and stgtistical gssessment 
The equation of Model 1 was recalculated with Statistica [114] starting from the 
original descriptor spreadsheet; rules for Model 2 were implemented directly in MS 
Excel while to re-calculate Model 3 the original program developed by the 
authors was used. as it is freely downloadable from the web). 
For the quantitative model. R2 and R2cv parameters were used to assess their 
statistical validity and compared with the parameters provided by the original 
publication. 
Several parameters. including Cooper statistics [115]. have been used far 
evaluating performances of classifiers based on the number of correctly classified 
active (true positive = TP) and inactive (true negative = TN) compounds and the 
number of misclassified active (false negative = FN) and inactive (false positive = 
FP) compounds; 
1. Prediction Accuracy = (TP + TN) x 100 
Tot 
2. Sensitivity = TP x 100 
TP+FN 
3. SpecifiCity = TN xl 00 
TN+FP 
(TP. TN) - (Fp. FN) 4. Matthews correlation coefficient (MCC) = ~(TP + FP). (TP + FN). (TN + FP). (TN + FN) 
MCC [116] is a robust measure to evaluate a method that accounts for 
unbalancing (both over-prediction and under-prediction). It is generally 
regarded as a balanced measure which can be used even if the classes are of 
very different sizes. MCC is a number between -1 and 1. A coefficient of 1 
represents a perfect prediction. 0 an average random prediction and -1 the 
worst possible prediction. Thus, higher the correlation coefficient the better is 
the prediction performance. 
1 http://www.fda.gov/nctr/science/centers/toxjcoinforrnotjcs/DecisionEorestlindex.htm 
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5. Performance with respect to random prediction (S) = (TP+ TN)-RTOI 
Tot-RTOI 
h . R _ ~(T_P +_F_P )<-. (>-TP_+_F--,N}=-+~(T_N_+ F_P.L-) ...>...(TN_+_F--LN} 
were. Tol - Tot 
With this parameter the accuracy is compared with respect to a randomly 
generated prediction (RTol) and to the normalised percentage better-than-
normal (S) [117]. 
4.1.2.2. Sensitivity study 
For Modell, which relies on a limited number of descriptors, some of them 
depending on the 3D optimisation process, a more detailed sensitivity study was 
performed to assess descriptor variability and their influence on the model 
performances. 
Chemical descriptors were re-calculated starting from chemical structures 
publicly available through the Distributed Structure-Searchable Toxicity (DSSTox) 
Public Database Network [111]. 
Compared to the original procedure and software other slightly different methods 
were used, as described and compared in Table 4.1. 
This task permitted the evaluation of how much influence the procedural tasks 
have in introducing a certain amount of variability in the model and allowed the 
testing of whether the procedure used for calculating chemical descriptors for 
the new compounds in the external set can have a large influence on the 
predicted activities. 
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Table 4.1 List of descriptors used In Model 1 and explanation of the procedure used to recalculate 
them. 
Name 
Nc 
Nhalogens 
Iphenol 
W 
3Ka 
6Xch 
Elorslon 
EHOMO 
DescripHon 
Number of carbon 
atoms 
Number of halogen 
atoms 
Indicator variable for 
phenol group 
(presence/absence) 
Wiener Topological 
index 
3rd order kappa alpha 
shape Index 
6th order simple chain 
molecular 
connectivities 
Energy of torsion for the 
molecule by COSMIC 
Force field 
Energy of the highest 
occupied molecular 
orbital calculated by 
VAMP (using the AMI 
Hamntonlan) In TSAR 
Type 
Constitutional 
(10) 
Constitutional 
(10) 
Functional 
groups (10) 
Topological 
(20) 
Topological 
(20) 
Topological 
(20) 
Quanlum-
chemical (3D) 
Quantum-
chemical (3~) 
4.1.3. EXTERNAL VALIDATION PROCEDURES 
Model' 
Original 
software 
Tsar 
Tsar 
Tsar 
Tsar 
QSARls 
QSARls 
Tsar 
Tsar 
RecalculaHon procedure 
Calculated with COOESSA [118] 
from the sdf file provided in the 
OSSTox database 
Calculated with COOESSA 1118] 
from the sdf me provided In the 
OSSTox database 
Visual Inspection 
Calculated with COOESSA [118] 
from the sdf file provided in the 
OSSTox database 
Calculated with QSARls [113J 
Calculated with QSARls (113] 
CORINA conversion In 3D 
structure, full COSMIC optimisation 
with TSAR [112] 
Calculated with /WO methods: or 
1) CORINA conversion In 3D 
structure, full COSMIC optimisation 
and affer that AM I optimisation 
performed with TSAR (HomoTSAR) 
(112) or 21 automatic optimisation 
with MOPAC AMI In the 
OpenMolGRIO environment (119) 
and extraction of the quantum-
chemical parameters with 
Codessa (HomoCOOESSAI [118J 
The literature was investigated to identify other suitable sources of ER binding 
activity data in order to perform an external validation with new chemical 
compounds. This task implied an assessment of the correlation existing between 
new data and those used to develop the model for compounds already present 
in the NCTRER dataset. 
For Model , three further groups of compounds were used as external sets: 
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- A first check was done with 95 inactive compounds belonging to the NCTRER 
dataset. Of course this test set is only partially representative (from the activity 
point of view) of the original training set. because it involves only inactive 
compounds. On the other hand. this set was initially chosen because it was 
obtained under the same experimental conditions as the compounds used in the 
training set. and for the availability of the originally calculated descriptors. The 
model equation was implemented in MS Excel. 
- A further 45 compounds were extracted from the EDKB database' and their 
activity data were taken from an aggregation of data from the literature for ER 
RBA [73]. No further details about test conditions were provided. Chemical 
descriptors were calculated on the basis of the procedure described in 
paragraph 4.1.2 and the model equation was implemented in MS Excel. 
- In the literature another possible source of data was made available by the 
Japanese Ministry of Economy. Trade and Industry (METI) [120]. Some limitations 
are implicit in the choice of these data: they refer to human ER. not to rat. and 
data were obtained using a specific subtype of the receptor (ERa) while the data 
source for Model 1 is the NCTRER dataset which used rat uterine cytosol ER. In 
uterine cytosol a subtype is predominant but ER(3 is also present and this can 
affect results. especially for compounds having selectivity for one of the subtypes 
such as phytoestrogens. 
For all these reasons. before these data could be used as a test set a 
mathematical evaluation of the correlation between the two sources of activity 
data was conducted. Results are shown in Figure 4.2: the first series of data 
contains only the 68 compounds with defined activity values for both databases 
(indicated as defined series). The second series contains compounds inactive in 
, http://edkb.fda.goy/webstort/edkblindex.html 
55 
Chapter 4 - Validation of selected QSAR 
at least one of the two sources. The correlation line reported in the graph is 
calculated on the basis of the "defined" series alone. 
CIO 
¢ -
0\ 
II 
..:. 
-III 
... 
III 
1ii 
~ 
NCTRER (n = 232) 
y = 0.840x + 0.379 
R2 = 0.829 
Figure 4.2 Correlation of the activity data found in the NCTRER database. used to develop Model I . 
and the METI database. In the graph - 5 value was arbitrarily assigned to inactive compounds. The 
"undefined" series contains 9 compounds which are inactive in the Japanese database but active in 
the NCTRER database (with activity values < -3.25) . 36 compounds inactive in both databases and 10 
compounds inactive in the NCTRER database but active in the Japonese database (with activity 
values < - 1.15). 
Overall there is a relatively good correlation among the two database but values 
are somewhat scattered around the ideal correlation line (within ± 1 log unit). A 
lower correlation is observed if inactive compounds are considered as well in the 
analysis. Bearing in mind these limitations, 212 compounds with a defined activity 
value in the METI database were used as external test set. excluding those 
already present in the NCTRER database. Also for fhis test set. chemical 
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descriptors were calculated on the basis of the procedure described in 
paragraph 4.1.2 and the model equation was implemented in MS Excel. 
Model 2 
To validate Model 2 some data were selected from a paper by Sutherland et 01. 
[74] who studied a compilation of ER ligands from NTP fER-tox set). This 
compilation of binding affinities for 638 substances was prepared by the National 
Toxicology Program at the National Institute of Environmental Health Sciences, 
with the purpose of evaluating the performance of various in vitro ER binding 
assaysl. 
It was found that there was reasonable correspondence between binding 
affinities determined by the various assays. From this collection, the authors 
selected 616 single chemical substances that were non-redundant. If compounds 
were tested by multiple assays, an average RBA value was calculated, excluding 
assays that used ER~ or ER from non-mammalian species. The latter sources were 
excluded because they are reported for few substances, making the evaluation 
of their compatibility with other assays more difficult. Due to the heterogeneity of 
the experimental data sources the quality of these data was judged too poor for 
a quantitative analysis but satisfactory for a classification analysis. The activity 
classes and the structures were provided within the supporting Information. 
Among the 616 substances 225 were in common with the NCTRER dataset. For 
them, the activity class was compared in the two datasets using the presence or 
absence of any detectable activity. Results are shown in Table 4.2. 
A few compounds that were inactive in the NCTRER dataset, had slight activity in 
the NTP compilation, with an activity range of 0.00004-0.007 for RBA. For this 
reason, in order to have a higher consistency between the two data sources a 
1 http;/Iiccyam.njehs.njh.goy/docs/endo docs/final J 002/erbndbrd/ERBdQ345Q4.pdf 
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limited number of compounds having an activity In the NTP dataset within this 
range were excluded from the analysis. 
Table 4.2 Comparison of the activity class assigned to compaunds in common in the NTP compilation. 
as reported by Sutherland et 0/. (74). and NCTRER dataset. 
NCTRER 
Active Inactive 
Cl.. Active 127 16 
I-
Z Inactive 0 82 
The final test set extracted from NTP resulted in 368 compounds (124 inactive and 
244 active). In order to assign the activity class to the test set to decide whether 
or not a compound was active on the basis of Figure 4.1, the workflow procedure 
was applied by visual inspection of the compound structures. In particular no 
special difficulties were raised in assigning features Fl. F2. F3, F4 and F5, because 
the requirements (a ring, a phenolic ring, presence of heteroatoms) were very 
simply detected. More problematic was the assignment for F6, since several 
aspects (logP. H bonding. rigid structure, etc ... ) had to be taken into account 
contemporaneously. It also implies a more subjective assignment of this feature 
by balancing several considerations. In order to make this assignment as 
objective as possible a specific strategy was adopted. All compounds were 
grouped based on their chemical classes and then within each class specific 
reasons for F6 assignment were investigated on the basis of compounds 
belonging to the NCTRER dataset. By examining the characteristics for F6 
assignment in each chemical class for the training compounds a rationale for 
extending the F6 value to all the other compounds was derived. The complete list 
of assigned features is available in Annex A. 
Model 3 
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In the original publication (73] a second data set. designated as ERIOn. was also 
investigated by the authors. It is an aggregation of data from the literature 
containing 1092 chemicals. of which 350 are active and 736 are inactive. For this 
large dataset the authors provided Molconn-Z descriptors. After eliminating the 
compounds already contained in the NCTRER dataset, 860 compounds were 
used as external set (225 active and 635 inactive). For this specific model no 
further analysis of the 2D descriptors originally calculated by the authors was 
done and the file provided by the authors was used directly. 
4. 1.4. ApPLICABILITY DOMAIN ASSESSMENT 
Another important issue relates to the definition of the applicability domain (AD) 
and possible solutions for defining it. Different concepts and methods to define 
the AD have been applied and tested on the extemal sets used to validate the 
models, in order to verify their utility in increasing the confidence on the predicted 
results. and to determine the boundaries for the validity of the models. 
PrinCipal Component Analysis was used to represent training and test sets and to 
compare visually their relative distribution. To calculate the principal components, 
the descriptors used in developing the model were normally selected. except for 
Model 2. where the six features were not descriptive enough. In this case a 
restricted pool of Dragon descriptors [121J were instead adopted. Only some 
classes of 20 descriptors were computed (constitutional, topological, walk and 
path counts, connectivity and information indexes. topological charge indexes 
and few molecular properties). Constant and near constant descriptors and 
deSCriptor pairs correlated with r > 0.95 were excluded and consequently 125 
deSCriptors were used for the PCA analysis. 
To explore more completely the AD definition a program specifically designed for 
this purpose was tested. AMBIT Disclosure (122] is a program implementing several 
methods to assess similarity between a group of training compounds and test set 
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compounds. They include both structure-based methods, based on a predefined 
set of fingerprints and fragments, and descriptor-based methods, where 
descriptors can be imported from other sources. Different thresholds can be 
tested to focus more precisely the training set space. 
Finally, in the case of Model 3 there is a probability level associated with each 
prediction and the span of this probability was used to assign a reliability measure 
to the results. 
4.2. RESULTS AND DISCUSSION 
4.2. 1. MODEL 1 
4.2.1 .1 . Internal validation 
Model I was recalculated with Statistica [114] using the original descriptors and its 
validity and the associated statistical parameters were confirmed. 
4.2.1 .2.Sensitivjtv study 
A few differences were noticed in the recalculated descriptors. due probably to 
the software used and the procedure adopted. As expected. 3D parameters 
were found to be sensitive to the optimisation procedure, reducing their 
reproducibility. In the diagrams below the recalculated descriptors for Eloolon 
(Figure 4.3) and EHOMO (Figure 4.4) are compared. A very good reproducibility was 
obtained for EHOMO while lower consistency was found for Elmon. 
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Figure 4.3 Correlation for the values of "Energy of torsion" deSCriptor. Three compounds in red in the 
plot are outliers and were not considered to derive the correlation coefficient. 
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Figure 4.4 Correlation for the values of "HOMO Energy" descriptor calculated with TSAR or CODESSA 
with AM 1 porameterization. 
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To complete the sensitivity study the influence of the descriptor variation on the 
model was tested. The plat in Figure 4.5 compares the experimental activity with 
that calculated using the original descriptors. or the set of newly computed ones. 
Two series are shown for the recalculated descriptors: in one case EHOMO 
computed with MOPAC [123] in the OpenMolGrid environment [119] and 
extracted by CODESSA software [118] was used. while in the second one TSAR 
software [I 12] was used. It is clear that uncertainty in the descriptors values does 
not appear to affect significantly the activities calculated with the model 
proposed by Ghafourian & Cronin. 
log RBA 
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Figure 4.5 Experimental versus calculated activity for the model equalions using Ihe original descriptor 
set or those recalculated with EHOMO from alternatively TSAR or CODESSA. 
4.2. I .3. Extemal validation w ith new test sets 
For the inactive compounds of the NCTRER dataset. constituting the first test set. 
the predicted activity is reported in the histograms in Figure 4.6. The majority of 
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compounds (78%) are predicted with a relatively low activity (logRBA<-2) , a 
further 19% fall in the range from - 2 to 0 and three are predicted highly active. 
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Figure 4.6 Predicted activity (logRBA range) distribution for the test set of inactive chemicals of NCTRER 
dataset. 
The correlation coefficient obtained by applying the model to the EDKB set was 
R2 = 0,48 and consistently lower for the Japanese set. The diminished accuracy 
obtained for the Japanese set can be due to the activity data of the second test 
set that are relatively diverse from the data used to derive the model. 
Even though the model is not good enough to capture the data trend, the 
predictions are better if analysed in more qualitative terms. In Figure 4.7 a 
graphical comparison of the residuals between training and test sets is reported. 
Overall residuals for the predictions in both the test sets are within two log units for 
about 80% of the compounds; approximately 9% of compounds have residuals 
larger than 3 log units in both EDKB and Japanese test sets. 
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Figure 4.7 Comparison of the error extents for the training set and the two external test sets. Prediction 
performances are superior for EDKB test set. 
4.2.1 .4. Applicability domain analysis 
AD was evaluated by exploring different possible definitions for outliers. In the 
case of inactive chemicals belonging to the NCTER dataset the main target was 
to identify possible reasons to account for the three compounds predicted highly 
active. The analysis was performed in terms of similarity assessment based on 
deSCriptor range (Table 4.3) or PCA score scatter plot (Figure 4.8) . No special 
trend appeared to justify these three wrong predictions but the PCA score scatter 
plot highlights a differential distribution of active and inactive compounds. 
Tabte 4.3 Descriptor range and outlier descriptor values. 
Name Min-Max range Sitosterol Cholesterol 4.4'-Methylenebis (2,6-di-t-butvlohenoll 
Nc 7734 29 27 29 
Nhologens 0710 0 0 0 
Iphenol 071 0 0 1 
W 627 7474 2463 2022 2524 
31<0 0.6478.83 3.88 3.56 5.79 
6XCh 0.0670.31 0.16 0.16 0.11 
Etoolon 0.000114722.94 8.41 15.67 10.02 
EHOMO -1 0.89 7 -8.16 -9.34 -9.35 -8.61 
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Figure 4_8 PCA score scatter plot for the first two PC (explained variance: 59.4%). calculated on the 
basis of the eight descriptors. for the training set (active compounds. blue triangles) and the test set of 
inactive compounds (red triangles) . Three outliers are indicated by red circles. 
For the other two external test sets, AMBIT Disclosure and the similarity measures 
there implemented were used. In Table 4.4 the RMSE for EDKB and Japanese sets 
is reported for compounds included or excluded in the applicability domain. 
Some of the methods (e.g. probability density distribution) seem more effective in 
separating compounds with a lower RMSE (i.e. with a good predicted value) from 
those having a higher RMSE. 
A further analysis was done to determine whether, by using only compounds 
within the applicability domain, the percentage of c ompounds predicted within 
one or two log units increases. In Figure 4.9 and Figure 4.10 the results are shown: 
no substantial increase in these percentages was observed for both test sets. 
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Table 4.4 Applicability domain evalualion wilh AMBIT Disclosure. 
Method Threshold+ Domain Train Test ER1092 RMSE (N° comp.) RMSE (N° comp.) 
Descrip tor 100 In 0.93 (131) 1.45 (32) Range· Out - 1.68 (13) 
Euclidean 99 In 0.93 (130) 1.59 (41) Distance· Out 0.76 (1) 0.44 (41 
Euclidean 95 In 0.95 (124) 1.39 (35) Distance· Out 0.77 (7) 1.91 (l0) 
Probability 100 In 0.93 (131) 1.31 (38) Density" Out - 2.35 (7) 
Probability 99 In 0.94 (130) 1.31 (38) Density· Out 0.76 (1) 2.35 (7) 
Probability 95 In 0.95 (124) 1.06 (29) Density· Out 0.76 (7) 2.11 (16) 
City-block 99 In 0.93 (130) 1.44 (4 1) Distance" Out 0.76 (I) 2.2 (4) 
City-block 95 In 0.95 (124) 1.33 (31) Distance· Out 0.73 (7) 1.88 (14) 
Missing 100 In 0.93 (13 1) 1.31 (24) Fingerprin ts Out - 1.73 (2 1) 
Fingerprints In 0.94 (131) 1.44 (38) 
Tanimoto 100 
distance Out - 1.91 (7) 
.. .. 
+ Percentage of the training set used for denvlng applicability domain . 
• Da ta standardised and PCA p erformed for pre-processing data . 
• Wilhln 2 log unit _ Wilhln 1 log unit 
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Figure 4.9 Percentage of compounds with residuals within one o f two Log units for the first test set. 
Different ways for estimating applicability domain are compared with Ihe reference values (pole blue 
and turquoise green doffed lines) where all compounds belonging to the test set are used. 
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Figure 4.10 Percentage of compounds with residuals within one of two Log units for Ihe second lesl 
set. DiHerent ways for estimating applicability domain are compared wilh the reference values (pole 
blue and turquoise green dotted lines) where all compounds belonging 10 the test sel are used. 
4.2.2. MODEL 2 
4.2.2.1 . Internal validation 
The application of the flowchart to the compounds in the training set. by using 
the feature assigned in the DSSTox database gave the following statistical 
parameters: 
Accuracy ::= 82.3% 
Sensitivity ::= 90.8% 
Specificity ::= 71 .3% 
MCC::= 0.64 
S::= 63.3% 
67 
Chapter 4 - Validation of selected QSAR 
4.2.2.2. External validation with a new test set 
By applying the flowchart to test set compounds and comparing the assigned 
activity with that available in the ER-tox set, results were as follows: 
TP = 218 TN = 108 FP = 16 FN = 26 
Statistical parameters for training set and the test set are compared in Figure 4.11. 
Statistical performances 
100% • Training 
80% 
60% 
40% 
20% 
Figure 4.11 Comparison of the classification performances for the training and the test set. 
The model seems quite stable, performing on the test set even better than on the 
training set. The main reason for this good performances can be based on the 
limited structural complexity of compounds belonging to the ER-tox set: a lot of 
chemicals belong to few chemical classes (PCBs, PAHs, Steroids, Stilbenes and 
Triphenylethylenesj so that for chemical classes well represented both in the 
training and in the test set the predictions are very good and this can affec t the 
overall resulting performances. 
At the same time a main drawback of this model is the subjective way of 
assigning the very complex feature F6. 
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4.2.2.3. Applicability domain analysis 
Dragon 20 descriptors were used to represent training and test set in a PCA 
analysis (Figure 4.12). 
A group of 30 compounds are outside the Hotelling ellipse (significance level = 
0.05) - figure not shown - but the predictions for them are reasonably similar to 
those for the remaining test set compounds (TP = 3, TN = 22; FN = 5) with an 
accuracy of 83.3%. 
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Figure 4.12 peA score scatter plo1 for the training and test set using the first 1hree c omponents 
(explained variance = 47.2%) . 
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4.2.3. MODEL 3 
4.2.3.1. Internal validation 
The model was re-developed starting from the original dataset provided as txt file 
and using the default options in the OF program. The model is a combination of 
six individual trees, giving comparable results with those reported in the original 
publication: 
TP = 127 TN =97 
With the follOwing classification statistics: 
Accuracy = 96.6% 
Sensitivity = 96.9% 
Specificity = 96.0% 
MCC=0.93 
S=93.0% 
FP =4 FN=4 
The only significant difference is the selection of 84 descriptors in the model 
instead of 79. 10-Fold cross-validation (10 runs) gave similar performances to those 
reported in the original paper for a more extensive cross-validation exercise (10-
fold, 2000 runs). Greater attention was then paid to an extemal validation to 
evaluate the predictivity of the model. 
4.2.3.2. External vaUdation with a new test set 
By applying the OF model to predict the ER 1 092 test set the classification results 
were: 
TP= 161 TN = 420 
Statistical parameters for the test set were: 
Accuracy = 67.6% 
Sensitivity = 71.6% 
Specificity = 66.1 % 
FP = 215 FN = 64 
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MCC =0.33 
S = 31.0% 
Performances are considerably lower than those on the training set. indicating 
the risk of an overfitted model. To judge better about this possibility. the influence 
of chemical structural diversity was analysed through the AD assessment. 
4.2.3.3. Applicability domain analysis 
Several approaches for evaluating the applicability domain were used: 
1) A PCA analysis on the 84 selected descriptors was performed and reported in 
Figure 4.13 but from this plot is it difficult to draw conclusions about 
representativeness of the test set. 
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2) In the original paper it was suggested that by using only those compounds with 
a higher level of confidence, performances increased. This concept was applied 
by using a subset of the test set excluding compounds with probability in the class 
assignment between 0.3-0.7. In Figure 4.14 the results for these two subsets are 
compared with the entire test set and a slightly improvement is shown for the 
latter but this is not really significant. At the same time this increased accuracy 
implies a reduced number of compounds to be considered in the AD (178 
compounds excluded). 
Statistical performances 
Accuracy Sensitivity Specificity MCC S 
• Training set 
• Test set 
Test (out of 
0.3-0.7 range) 
Figure 4.1 4 Comparison of the classification performances for the training and Ihe test set. 
3) The AMBIT Disclosure program was also applied to define the applicability 
domain and classification performances were evaluated as shown in Table 4.5 by 
using only compounds belonging to the AD. Performances for the compounds in 
or outside the applicability domain were very variable depending on the 
technique used to define the AD but still none produced a significant 
improvement. 
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Table 4.5 Closslfication performances for the compounds belonging to the test set considered In or 
outside the AD. 
Total Range Range Euclidean Euclidean City-block City-block Probabllfty Probability T100ln T1000ut T951n T95 out T951n T950ut TlOOln TlOOout 
Accuracy 67.6 71.0 66.8 67.0 75.4 68.5 61.7 67.3 67.7 
Sensitivity 71.6 83.3 66.7 70.8 100.0 73.6 54.2 81.5 64.7 
Specificity 66.1 62.5 66.8 65.6 72.5 66.6 63.5 60.3 68.6 
MCC 33.4 45.4 28.5 32.6 46.7 36.0 14.5 39.4 28.7 
S 31.0 43.3 26.2 30.4 35.7 33.6 12.9 36.0 26.7 
4.3. CONCLUSIONS 
Different kinds of model (regression and classification, SAR and QSAR models) 
have been analysed in detail and they were externally validated with new data 
found in literature. 
Models relying on bi-dimensional descriptors alone seemed more user-friendly 
and more reproducible. The inclusion of 3D parameters - providing a more 
complete structural characterisation - required a detailed definition of the 
protocol used for their calculation and the evaluation of the prediction sensitivity 
to procedural steps. In the example presented here the model was robust and 
reproducible in a satisfactory way. 
The linear model was able in prediction to detect the activity range for a 
substance but did not completely catch the activity trend. Concerning the 
hypothesis of using computational models as pre-screening tools for large 
inventories of chemicals, - many of them probably inactive - SAR or classification 
models may be preferable. 
To avoid overfifting especially when the model complexity is increasing, an 
accurate validation is essential, including an external test set. 
Several ways for assessing the applicability domain have been evaluated 
depending on the available information. Although some methods seem better 
than others no efficient way to detect poor predictions has been identified. 
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CHAPTER 5 
BINARY CLASSIFICATION MODELS FOR SCREENING 
HETEROGENEOUS DATASETS FOR THEIR OESTROGENIC ACTIVITY 
5.1. INTRODUCTION 
Based on the analysis conducted in Chapter 4 the experimental setting for 
developing new models for oesfrogenicify was decided. Preference was given to 
classification models since the modelling performances achievable so for can be 
considered more qualitative than quantitative, due probably to data quality. 
Possibly the classification approach here adopted can be coupled with 
quantitative models. 
The most efficient solution for providing a prioritisation tool is to develop simple 
models. easy to use, so preference was given to the use of 20 descriptors. 
Moreover, it has already been observed that often similar performances can be 
achieved with the use of 20 and 30 descriptors [62J. 
In this way it was possible also to rely on a large dataset, close to a thousand 
heterogeneous compounds. to derive robust models accurately validated. The 
focus was given to multiple endpoints the better to characterize the effects of EDs 
evaluating both binding and transcriptional activity. 
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5.2. MATERIAL AND METHODS 
5.2.1. DATASET 
Activity data 
As a source of activity data the Japanese METI database was used (120]. Previous 
studies showed that these data are in relatively good agreement with other 
databases (see Paragraph 4.1.3). This database is one of the largest collections of 
data for ER publicly available, with more than 900 compounds. It contains 
experimentally determined values of human ER alpha for both receptor binding 
(RBA) and reporter gene (RA) assays expressed as molar percentage of activity 
using 171>-estradiol as reference. To develop binary classification models any 
detectable activity in the test was associated with the "active" class while those 
compounds with no detectable activity were labelled "inactive". The dataset is 
reported in Annex B. It represents a heterogeneous dataset of compounds, 
including natural and synthetic steroids, drugs and chemical contaminants such 
as pesticides, PCBs and phthalates. 
Chemical mucrores and descriptors 
Chemical structures were sketched and, for salts, the free acid or basis form was 
used. Adopting a very simple approach only a 20 configuration of the molecules 
was used while the 30 conformation and stero configuration were ignored. For 
this reason 2D duplicates of different 30 isomers were included only once, 
verifying that the associated activity class was comparable for all possible forms 
sharing the same 2D structure {only 2 structures did not satisfy this requirement 
and were discarded}. A further 100 compounds whose RBA values were not 
determined were excluded to consider both the endpoints on a similar basis. The 
final dataset comprised 806 single 20 structures, with the majority of the 
compounds considered inactive (see Figure 5.1). 
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Figure 5.1 Compounds distribution in the classes of activity for RBA and RA. 
Active (RBA+RA) 
. Active (RBA only) 
OActive (RA only) 
O lnoetive 
Dragon software [121] was used to compute 929 20 descriptors. This number was 
reduced by excluding constant and nearly constant variables (diverse for less 
than 6% of compounds) . pairwise correlated variables (with a K correlation 
greater than 0.95) and those with missing values. to reduce redundant and 
useless information. Finally a total of 250 descriptors were retained and submitted 
to the autoscaling procedure. 
The dataset so collected was split into three parts: the training set constituted by 
the examples provided to the learning algorithm. the validation set used to assess 
which are the best parameters and architecture for the models. and a test set to 
assess independently a group of compounds never used to validate the model 's 
performances in prediction. To perform this selection an unsupervised learning 
method based on a Kohonen map. also called self -organizing map (SOM), was 
used. This type of NN is trained to produce a bi-dimensional representation of the 
input space in a map. preserving its topological properties. This makes SOM useful 
for visualizing high-dimensional data. After the training the input samples are 
located in the map in the neurons on the basis of the similarity of their input 
vectors. 
A Kohonen map of 15x 15 neurons dimension was trained for 500 epoc hs using the 
descriptor matrix previously prepared. On the basis of the distribution of the 
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compounds in the top map the data set was split into training. validation and test 
sets. each containing respectively 506. 150 and 150 compounds. The correct 
proportion of objects belonging to the different categories in Figure 5.1 was 
maintained and the composition of the sets is reported in Table 5.1. Unfortunately 
the distribution of compounds in the two classes is not well balanced since the 
majority are inactive for both end points. 
Table 5.1 Compounds reportitlon In training validation and test sets. 
TRAINING SET 
VALIDATION SET 
TeST SET 
Active 
180 
54 
54 
5.2.2. MODELLING METHODS 
RIA 
Inactive 
326 
96 
96 
Active 
117 
35 
35 
RA 
Inactive 
389 
115 
115 
Different modelling methods were investigated, ranging from simpler and more 
intuitive models such as classification trees to more sophisticated architectures, 
including NN. 
5.2.2.1. Classification and Regression Tree (CARII 
The classic CART algorithm, developed by Breiman et a/. [124,125], uses the 
methodology of tree building as a hierarchical classification method. The purpose 
of this analysis is to determine a set of if-then logical (split) conditions that permit 
accurate classification and prediction of cases that are easy to interpret. yet it 
takes into account the fact that different relationships may hold among variables 
in different parts of the data. CART formulates simple if-then rules for binary 
recursive partitioning of all the objects into smaller subgroups, where the 
compounds belonging to the dataset, represented by a "node" in a decision 
tree, can be split into only two groups. Thus, each node can be split into two new 
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"branches". The goal of this process is to maximize homogeneity of the values of 
the dependent variable Y in the various subgroups. The CART technique is 
essentially non-parametric, and does not rely on any particular assumptions 
about the type of dependence of the dependent variable Y on predictors X, (in 
contrast to various regression techniques) or about statistical properties of the 
data. Thus, CART can handle numerical data that are highly skewed or multi-
modal, as well as categorical predictors with either ordinal or non-ordinal 
structure. 
CART is scale-invariant, extremely robust with respect to outliers, and does 
automatic stepwise variable selection. It performs well when the pattern space 
can be separated into pure class subspaces. 
The process of computing classification trees can be characterised as involving 
four basic steps: 
1. Specifying the criteria for predictive accuracy. The most accurate prediction is 
defined as the prediction with the minimum costs, an extension of the 
misclassification rate modulated by the hazard associated with wrong 
predictions. The cost for the errors was considered equally important for the two 
classes while the a priori probability for the two classes was set as equal so that 
the relative size of the prior assignments to each class can be used to "adjust" the 
importance of misclassifications for each class. 
2. Selecting splits. In general terms, the best split at each node is determined in 
terms of the reduction in impurity (heterogeneity) giving the greatest 
improvement in predictive accuracy. All the splits are ranked and the variable 
that achieves the highest purity at root is selected. The exhaustive search for 
univariate splits method worlcs by searching for the split that maximizes the 
reduction in the value of the selected goodness of fit measure. This is usually 
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measured with some type of node impurity measure. which provides an 
indication of the relative homogeneity of cases in the terminal nodes. The Gini 
measure of node impurity was used. It is a measure which reaches a value of zero 
when only one class is present at a node. 
Each node is assigned to a predicted class based on the following criteria: 
COli) is the cost of classifying i as j; 
x(i) is the prior probability of i; 
Ni is the number of class i in the dataset; 
Ni (t) is the number of class i in a node; 
Node is class i. if: 
for all values of j. 
3. Determining when to stop splitting. The tree is allowed to grow until all terminal 
nodes are pure or contain no more misclassified cases than a specified minimum 
fraction of objects. 
4. Selecting the ''right-sized'' tree. The "right-sized" tree should be sufficiently 
predictive. but at the same time it should be as simple as possible. It should exploit 
information that increases predictive accuracy and ignore information that does 
not. The performances on the validation set were used to select efficiently the 
well-dimensioned tree; then the best tree was evaluated on the test set. 
The software implementing the CART algorithm used in this study was Statistica 
[114J. 
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5.2.2.2. Decision Forest (OF) 
As an extension of normal classification trees, OF was also used since it has 
already been proposed as an algorithm for modelling oestrogenicty. The basic 
idea of the method has already been introduced in Chapter 4 and it is described 
in more detail elsewhere in the literature [126]. 
OF is a consensus modelling technique that combines multiple Decision Tree 
models, maximizing in their construction the use of diverse descriptors. Different 
parameters can be optimised including the minimum and maximum number of 
trees, and the minimum number of compounds allowed to enter in a node. 
An application implementing the OF method was used that was available on the 
web). 
5.2.2.3. Adaptive Fuzzy Partition (AFP) 
To select, amidst the molecular deSCriptors series, the best parameters for 
classifying the data. a hybrid selection algorithm (HSA) based on Genetic 
Algorithm (GAl concepts was used, specifically designed to select relevant 
deSCriptors for classification aims [127]. GA methods, inspired by population 
genetics. consist of a population of individuals competing on a "survival of the 
fittest" basis. Each individual, or chromosome, represents a trial solution of the 
problem to solve. In the context of descriptor selection, the structure of the 
chromosome is very simple. Each descriptor is coded by a bit (0 or J) and 
represents a component of the chromosome: 0 defines the absence of the 
descriptor. and 1 defines its presence. The algOrithm, transforming the 
chromosome population into a new population with more adapted individuals, 
proceeds in successive steps called generations. During each generation, the 
population evolves by means of a "fitness" function that selects individuals by 
) http://www.fda.govlnctrlscjencelcenters/toxicojotormotics/DecisjonEorestljndex.htm 
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standard crossover and mutation operators. Crossover phase takes two 
chromosomes and produces two new individuals, by swapping segments of 
genetic material. i.e. bits in this case. Mutation randomly removes bits with a small 
probability of success from the chromosome population. 
GA is very effective for exploratory search, applicable to problems where little 
information is available. but it is not particularty suitable for local search. Thus, a 
stepwise approach was combined with GA in order to reach local convergence. 
as it is quick and adapted to find solutions in "promising" areas already 
identified. 
The index proposed as fitness function to evaluate the discrimination power of a 
selected subset of descriptors is based on a Fuzzy Clustering (FC) procedure [128]. 
A FC algOrithm, where clusters are derived from fuzzy sets, can be considered as 
a generalisation of the traditional cluster procedure. These clusters are derived by 
assigning to each compound a number between 0 and 1, called degree of 
membership. A compound is defined by its degree of membership to each 
cluster, while a cluster can be characterised from the list of associated 
compounds with the highest membership degrees. 
This index has the advantage that it can be quickly calculated and that one can 
also estimate the descriptor relevance by analysing complex molecular 
distributions, in which finding boundaries between the different categories is 
difficult. 
To prevent over-fitting and a poor generalisation, a cross-validation procedure 
was included in the algorithm during the selection procedure, randomly dividing 
the database into training and validation sets. The fitness score of each 
chromosome was derived from the combination of the scores of the training and 
validation sets. More details about the HSA procedure and the proprietary 
software used can be found in Ros et 0/. [127). 
The following parameters were used in the data processing: 
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(i) fuzzy parameters: weighting coefficient = 1.5; tolerance convergence = om; 
number of iterations = 100; cluster number = 10. 
(ii) genetic parameters: chromosome number = 20; chromosome size = total 
number of descriptors used; initial active descriptors in each chromosome = 8; 
crossover point number = 1; probability of selection = 0.5; probability of crossover 
= 0.5; probability of mutation = 0.1; probability of rejection = 0.2; number of 
generations = 10. 
(iii) stepwise parameters: ascending coefficient = 0.02; descending coefficient = -
0.02. 
After the descriptor selection with HSA algorithm. the Adaptive Fuzzy Partitioning 
(AFP) method was used for classification purposes. 
AFP is a supervised classification method implementing a fuzzy partition algorithm 
[129J. Fuzzy logic (FL) mimics human reasoning in its use of approximate 
information and uncertainty to generate decisions about intrinsically imprecise 
problems. The FL concepts indeed provide mathematical rules and functions able 
to calculate intermediate values between "absolutely true" and "absolutely false". 
called degrees of membership and ranging from 0 to 1. 
It models relations between molecular descriptors and chemical activities by 
dynamically dividing the descriptor space into a set of fuzzy partitioned 
subspaces defined by fuzzy rules. The aim of the algorithm is then to select the 
deSCriptor and the cut position which allows one to achieve the maximal 
difference between the two fuzzy rule scores generated by the new subspaces. 
The score is determined by the weighted average of the chemical activity values 
in an active subspace A and in its neighbouring subspaces. Only the best cut is 
selected to divide the original subspace. For instance. in Figure 5.2. a graphical 
representation of fuzzy partitioning is presented. Three cuts per axis are tested 
from the original bi-dimensional descriptor space. As cut Xl is the best, two 
subspaces are generated and considered to be further divided. Then. cut Y3 is 
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selected, but the procedure evaluates useful partitioning only in subspace S2; 
finally, three subspaces are built. 
: 
Dy 
---.X'---__ 
Figure 5.2 Example of adaptive fuzzy partitioning of a bi-dimensional space. 
These techniques of rule generation are very simple as all the fuzzy rules can be 
formulated by linguistic labels. However, their performances in a database 
classification depend on the choice of partition selected. Generally, a coarse 
partition leads to a generalist system but also to a model where prediction results 
are too approximate; a fine partition leads to an accurate model of classification 
but also to a non-generalist system. To overcome this drawback, a fuzzy 
classification method was proposed, which simultaneously uses several fuzzy 
partitions of different sizes in a single fuzzy rule-based classification system. This 
approach allows one to obtain a good compromise between generalist and 
specialist systems, thereby improving the classification performances. 
Assuming that the working space is a N-dimension hyperspace defined by N 
molecular descriptors, each dimension i can be partitioned into L intervals hi, 
where j represents an interval in the partition selected. Indicating w ith Plx1, )(2, ... 
Xn) a molecular vector in the hyperspace, a rule for a subspac e Sk, d erived by 
combining N intervals hi, is defined by: 
"if xl is associated with ,.mlxl) and X2 is associated with ).12k lx2) .. , 
and XN is associated with ).1NklxN) => the score of the activity ° for P is O"P" 
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where Xi represents the value of the ith descriptor for the molecule P. ~k is a 
trapezoidal membership function related to the descriptor i for the subspace k. 
and OkP is the biochemical activity value related to the subspace Sk. The "and" of 
the fuzzy rule is generally represented by the Min operator. which selects the 
minimal value amidst all the J.Uk components. 
All the rules created during the fuzzy procedure are considered to establish the 
model between descriptor hyperspace and biochemical activities. The degree of 
membership to the subspace Sk can be represented by: 
M 
I(Min~Jlidxi)Pj ·APj) 
O _ .j=_I _______ _ k -- M L (Min~Jlik (Xi )Pj) 
j=1 
where M is the number of molecular vectors in a given subspace. N is the total 
number of descriptors. Jlik (Xi )p. is the fuzzy membership function related to the 
J 
descriptor i for the molecular vector PI. and ApI is the experimental activity of the 
compound PI. A classic procedure of centroid defuzzification is implemented to 
determine the chemical activity of a new test molecule. All the Ie subspaces are 
considered and the general formula to compute the degree of membership of 
the activity 0 for a generic molecule Pj is: 
Nsu~ L (Min~ Jlik (Xi)pj . Ok) 
o (Pj) = ---,,:k~:::-t-subsp:--------
~::CMin~Jlik (Xi)pj) 
k-t 
where N_subsp represents the total number of subspaces. 
The follOwing AFP parameters were used to process the data set: maximal 
number of rules for each toxicity class = 30; range for the number of compounds 
for a given rule = 2-10; range of cuts for each axis = 2-10. prange: 1.05-1.6; q 
range: 0.4-0.95 (where pond q allow defining the trapezoidal membership 
function). 
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5.2.2.4. Multilayer perceptron (MLP) 
A multilayer perceptron (MLP) is a feedforward network of neurons called 
perceptrons. introduced by Rosenblatt in 1958 [130]. 
The perceptron computes a single output from multiple real-valued inputs by 
forming a linear combination according to its input weights and then generating 
the output through some nonlinear activation function: 
n 
y=tp(Lwjxj +b)=9'(wTx+b) 
j=1 
where w denotes the vector of weights. x is the vector of inputs. b is the bias and 
cp is the activation function. The activation function chosen is the hyperbolic 
tangent tanh(x). This function is used because it is mathematically convenient 
and close to linear near the origin while saturating rather quickly away from the 
origin. This allows MLP networks to model well both strongly and mildly nonlinear 
mappings. While single-layer networks composed of parallel perceptrons are 
rather limited in what kind of mappings they can represent. the power of an MLP 
network with only one hidden layer is surprisingly high. 
A typical MLP network consists of a set of source nodes forming the input layer. 
one or more hidden layers of computation nodes between the input and output 
nodes. and an output layer of nodes. The interconnection matrix is restricted to 
feedforwarding activations (neither feedback nor self connections). Feedforward 
networks are instantaneous mappers; i.e. the output is valid immediately after the 
presentation of an input. The input signal propagates through the network layer 
by layer. 
The computations performed by such a feedforward network with a single hidden 
layer with nonlinear activation functions and a linear output layer can be written 
mathematically as: 
x = f(s) = B qJ(As + a) + b 
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where s is a vector of inputs and x a vector of outputs. A is the matrix of weights of 
the first layer, a is the bias vector of the first layer. B and b are, respectively, the 
weight matrix and the bias vector of the second layer. The function <p denotes the 
nonlinear activation function [131]. 
Figure 5.3 illustrates a simple MLP with one hidden layer. The circles are the 
neurons arranged in layers. The left column is the input layer. the middle column is 
the hidden layer. and the right column is the output layer. The lines represent 
weighted connections between neurons. 
Input 
layer 
Hydden 
layer 
Output 
layer 
Figure 5.3 A MLP neural network structure. Perceptrons ore arranged in layers. 
o 
MLP networks are typically used in supervised learning problems. This means that 
there is a training set of input-output pairs and the network must learn to model 
the dependency between them. 
A neuron simply multiplies an input by a set of weights, and nonlinearly transforms 
the result into an output value. The power of neural computation comes from the 
massive interconnection among the neurons, and from the adaptive nature of 
the weights that interconnect the neurons. By adapting its weights, the neural 
network works towards an optimal solution based on a measurement of its 
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performance. For supervised leaming, the performance is explicitly measured in 
terms of a desired signal and an error criterion. 
The supervised leaming problem of the MLP is solved with the back-propagation 
algorithm, which consists of different steps. In the forward pass, the predicted 
outputs corresponding to the given inputs are evaluated, with 0/1 connections 
feeding forward from inputs towards outputs. As a result the error between the 
desired output and actual output is computed. Then, in the backward pass, the 
error signal at the output units ;s propagated back through the network. Finally 
the synaptic weights and biases are updated using the results of the forward and 
backward passes using any gradient-based optimisation algorithm. The whole 
process is iterated until the weights have converged r 131 J. 
Table 5.2 Parameter setting used for GA and MLP. 
GA parameters 
GA setting 
Progression: generational (entire population is replaced with each iteration) 
Selection for the next generation: Roulette. rank-based 
crossover point number = 1. probabnlty of crossover = 0.9 
Mutation operator: uniform. probabHlty of mutation = 0,01 
GA training options 
Nr. Epochs: 1000 
Population size: 50 
Max generation nr.: 100 
Termination criteria: terminate offer 250 epochs wlo Improvement on validation set 
Class Importance: use classes equally weighted 
MLP parameters 
HydcJen Lavers 
Nr. hidden layers: 1; 
Nr. perceptrons in the hidden layers: .. 
Transfer function: Tanh 
Learning rule: Momentum (Step size: I. Momentum: 0.7) 
Output Layer 
Nr. perceptrons In the output layer. 2 
Transfer function: Tanh 
learning rule: Momentum (Step size: 0.1. Momentum: 0.7) 
Supervised learning Control 
Max or. Epochs: 1000 
Termination criteria: Increasing In MSE on the validation set 
Weight update: batch 
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To derive the predictive models based on MLP, NeuroSolutions software was used 
[1 32]. Relevant descriptors were selected w ith GA in combination with MLP by 
optimizing as fitness function the costs on the validation set. The specific 
parameters used for GA are reported in Tab le 5.2 together with those used for 
MLP. 
5.2.2.5. Support Vector Machine (SYM) 
The support vector machine (SYM) is a classifier searching for a decision 
boundary - a hyperplane - that discriminates between the two classes [133]. In 
particular, as shown in Figure 5.4, SYM is designed to find the hyperplane with the 
largest distance to the closest points from the two classes, the maximal margin 
classifier. This is motivated by the concept of using only those inputs that are near 
the decision surface since they provide more information about the classification 
[134]. 
I 
I 
+ 
+ 
-
Figure 5.4 Exemplifica tion of the SVM process for identifying the support vec tors and Ih maximal 
margin clossifier hyperplane. Adopted from [134] . 
A limitation of this approach is that in many cases classes cannot be separated 
by a hyperplane and a non-linear decision surface is required. This problem can 
be addressed with SYM by mapping the da ta from the original input space into a 
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feature space where a linear separator can be found. In this case SVM transforms 
the data into a high-dimensional space so that it can transform complex 
problems (with complex decision surfaces) into simpler problems that can use 
linear discriminant functions. 
This mapping is obtained through a kemel function, which can be viewed as a 
distance between samples in feature space. In this study, this is done using as 
kemel a Radial Basis Function (RBF) network that places a Gaussian at each data 
sample. Thus, the feature space becomes as large as the number of samples. The 
RBF, however, uses backpropagation to train a linear combination of the 
Gaussians to produce the final result. The learning algorithm is based on the 
Adatron algorithm extended to the RBF network. After adaptation only some of 
the OJ are different from zero (the so called support vectors). They correspond to 
the samples that are closest to the boundary between classes. The output for 
testing is given by: 
f(x) = sign( LyjajG(x - X j,20"2)- b) 
i=support 
vccton 
where OJ are the lagrange multipliers, yi are the class label, the kernel function is 
represented by the Gaussian distribution G, and b defines the hyperplane [135]. 
The strict constraint of searching for the perfect separation between classes can 
be softened by introducing a parameter C to tolerate errors. 
SVM models were obtained with Neuro$olutions software [132]. 
To shorten the computational time required to select relevant descriptors, a pre-
reduction step based on the model sensitivity was introduced. Sensitivity analysis Is 
a method for extracting the cause-and-effect relationship between the inputs 
and outputs. After the leaming phase the parameters are kept fixed. The basic 
idea is that the inputs are shifted Slightly and the corresponding change in the 
output is the sensitivity of model outputs to the inputs. The SVM was trained with all 
inputs. This sensitivity analysis, which is different from sensitivity as a statistical 
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measure of classifiers, provides feedback about which inputs are the most 
significant. Those with a reduced or null effect on the outputs were removed to 
prune the number of initial variables. This process reduced the size of the input 
decreasing the complexity and the training time of the model. 
After that, a GA procedure combined with SVM was performed by optimizing as 
fitness function the costs on the validation set. The specific parameters used for 
GA and SVM are reported in Table 5.3. 
Tobie 5.3 Parameter setting used for GA and SVM. 
GA parameters 
GAsettjng 
Progression: generational (entire population is replaced with each Iteration) 
Selection for the next generation: Roulette, rank-based 
crossover point number = I, probobHify of crossover = 0.9 
Mutation operator: uniform, probabRlfy of mutation = 0.01 
GA training options 
Nr. Epochs: 1000 
Population size: 50 
Max generation or.: 100 
Termination criteria: terminate after 100 epochs w/o Improvement on validation set 
Class importance: use classes equally weighted 
SVM parameten 
Step size: GA optimisation in the range 0-1 
Supervised Legrnjng Control 
Max or. Epochs: 1000 
Termination criteria: Increasing In MSE on the validation set 
Weight update: batch 
5.2.3. PERFORMANCE EVALUATION 
For all the methods the best model was selected on the basis of Copper statistics 
and the other parameters - already introduced in Chapter 4 (§4.1.2.1), for both 
training and validation sets. The robustness of the models was evaluated by cross-
validation with a 100fold leave-several-out (LSO). Then, the real prediction ability 
of the models was assessed with the help of the external test set never used to 
build or select the best model. To visualize better the models' behaviour the 
Receiver Operating Characteristic (ROC) curve was used to compare graphically 
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performances on the training, validation and test sets obtained with the different 
modelling techniques. ROC graph represents an alternative way to confusion 
matrices, to examine the classifier performances, by plotting I-specificity versus 
sensitivity. ROC curves have proven to be a valuable way to evaluate the quality 
of a two-class classifier. The point (0,1) is the perfect classifier, as all positive and 
negative cases are predicted correctly. The points (0,0) and (1,1) represent a 
classifier that predicts all cases to be negative and positive, respectively, whereas 
(1,0) is associated with a classifier that always predicts wrongly. The closer is the 
model to the point (0, 1) the better it is. The main advantage in using the ROC 
graph is that it incorporates all information contained in the confusion matrix, 
since FN is the complement of TP and TN is the complement of FP. It also provides 
a visual tool for examining the trade-off between the ability of a classifier 
correctly to identify positive cases and the number of negative cases that are 
incorrectly classified. ROC curves for classifiers have been exemplified in the 
recent Predictive Toxicology Challenge [136). 
5.3. RESULTS AND DISCUSSION 
For each method the best model was selected on the basis of training and 
validation sets' performances and then verified on the chemicals in the test set. 
Particular attention was paid to the balance between sensitivity and speCificity in 
the choice of the preferred model. The model characteristics for RBA are 
summarised in Table 5.4 and graphically compared through the ROC values in 
Figure 5.5. The selected descriptors (with the exclusion of those used in the OF 
model) are reported in Table 5.5. For all the methods it was possible to reach an 
accuracy around 85% or above, on all the three subsets. Due to the biased 
distribution in the two classes, sensitivity tends to be lower than speCificity. 
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Table 5.4 Overview of RBA results. 
Training set Validation set Test set 
{ 180P /326N 1 {54P/96Nl {54P/96Nl 
Acc. Spec. Sens. Acc. Spec. Sens. Acc. Spec. Sens. 
DF 97.04 98.77 93.89 88.67 92.71 81,48 85.33 88.54 79.63 
77 descriptors in a combination of 3 trees 
AFP 86.36 88.65 82.22 88.67 94.79 77.78 85.33 87.50 
81048 
6 descriptors (V64-V76-V'03-V2" -V22' -V2S0) generating 24 rules 
CART 85.38 84.36 87.22 84.00 87.50 77.78 85.33 85,42 85.19 
8 descriptors (V64-V97-Vl07-VI19-VI80-VI82-V221 -V2S0) , 11 terminal nodes 
MLP 84.39 89.26 75.56 87.33 91.67 79.63 84.00 87.50 77.78 
7 descriptors (V62-V70-V9' -V"' -VI97-V22' -V2S0) 
SVM 89.92 96.32 78.33 87.33 90.63 81.48 86.67 93.7 5 74.07 
12 descriptors (VI3-V23-V40-VS9-V6' -V77-V80-V83-V'OQ-V103-V"' -V22 ') 
Training set Validation set 
1 1 
0 .8 0.8 
> 0.6 > 0.6 ~ .. 
~ ~ 
'" 
v; 
c C 
eli 0.4 eli 0.4 III III 
0 .2 0.2 
Figure 5.5 ROC comparison of the RBA models obtained with diHerent algorithms. 
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Table 5.5 List of selected variables In the RBA models. 
No. Symbol OeflnHlon Class 
V 13 NS Number of Sulfur atoms consfilutional 
topological 
topological 
topological 
topological 
topological 
topological 
Information Indices 
information indices 
V23 MSD mean square distance Index (Balaban) 
V 40 P JI2 20 Petitjean shape Index 
V59 XOA Average connectivity index chj.() 
V61 X2A Average connectivity index chi-2 
V62 X4A Average connectivity index chl-4 
V64 X2v Valence connectivity index chl-2 
V70 AAC mean information index on atomic composition 
V76 Vindex Balaban V index 
V77 
V80 
V83 
V91 
V97 
Vl00 
VI03 
V 107 
Vll1 
V119 
VI80 
V182 
SICO 
SICI 
SIC2 
ATS8e 
MATS6m 
MATS 1 v 
MATS4v 
MATS8v 
MATS4e 
MATS5p 
BEHe2 
BEHpl 
structural information content (neighborhood information indices 
symmetry of ().order) 
structural information content (neighborhood information Indices 
symmetry of l-order) 
structural information content (neighborhood information indices 
symmetry of 2-order) 
Broto-Moreau autocorrelation of a topological 
structure - lag 8 I weighted by atomic Sanderson 20 autocorrelations 
electronegativitles 
Moran autocorrelation - lag 6 I weighted by 20 autocorrelations 
atomic masses 
Moran autocorrelation - lag weighted by 20 autocorrelations 
atomic van der Waals volumes 
Moran autocorrelation - lag 4 I weighted by 20 autocorrelations 
atomic van der Waals volumes 
Moran autocorrelation - lag 8 I weighted by 20 autocorrelations 
atomic van der Waals volumes 
Moran autocorrelation - lag 4 I weighted by 20 autocorrelations 
atomic Sanderson electronegativltles 
Moran autocorrelation - iag 5 I weighted by 20 autocorrelations 
atomic poiarizabilities 
highest eigenvalue n. 2 of Burden matrix I weighted Burden eigenvalues 
by atomic Sanderson electronegativities 
highest eigenvalue n. 1 of Burden matrix I weighted Burden eigenvalues 
by atomic polarizabDities 
V 197 JGI6 mean topological charge index of order6 topological charge indices 
V211 NCrq number of ring quaternary C(sp3) 
V221 NArOH number of aromatic hydroxyts 
V250 MLOGP Morlguchl octanol-water partition coeff. (IogP) 
functional group 
counts 
functional group 
counts 
physlco-chemlcal 
OF seems to be too complex a method for describing this dataset; it uses many 
descriptors, which is implicit in the philosophy of combining trees developed with 
diverse variables, and the performances in cross-validation are deCisively lower. 
94 
Chapter 5 - Binary classification models for oestrogenicity 
This large gap between fitting IAcc. = 97%) and cross-validation 110-fold LSO Acc. 
= 74%) can be a symptom of overfitting. This hypothesis is in part confirmed by the 
drop in accuracy for test and validation sets whereas the other methods maintain 
a better stability of this parameter for these sets but also in cross-validation (e.g.: 
10-fold LSO Acc. = 81 % for AFP; 10-fold LSO Acc. = 75% for CART). 
Above all, RBA models obtained with CART and AFP seem to be preferable 
achieving similar performances to the others but being based on a more intuitive 
syntax for the model codified in simple if-then rules. 
The nArOH descriptor was selected in all models, while MLOGP was present in all 
but DF and SVM models. The different selection strategies seem to perform wel/, 
converging in the selection of relevant descriptors, already identified in the 
literature to describe oestrogenic effects. In fact, nArOH, the number of phenolic 
rings, has already been demonstrated to be a valuable descriptor since it 
accounts for the possibility to create H-bonds with the aminoacids and the water 
molecules in the binding pocket. Similarly, lipophilicity is considered important to 
describe the hydrophobic central region of the binding pocket. nArOH is the most 
relevant descriptor for CART - responsible for the first splitting, see Figure 5.6 - and 
it is also present in all the rules identified by AFP, whereas it is more difficult to 
ascribe the correct importance to the different descriptors for the other models, 
since the relationship they identify is not so explicit. DF descriptors are even more 
difficult to interpret in view of the multitude of variables used. Two other groups of 
descriptors are often selected: connectivity indices and 2D autocorrelation 
descriptors. Moran 2D autocorrelation descriptors are measures of spatial 
autocorrelation that can be weighted by different atomic properties; those more 
frequently selected in RBA models are related to bulky properties. Moleculor 
connectivities are topological descriptors based on a count of groupings of 
skeletal atoms, weighted by degree of skeletal branching. Lower order indices 
are considered to encode mainly the bulk of a molecule, whereas higher order 
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indices encode more subtle features such as the presence of rings and branching 
patterns [137]. 
The CART model is preferable also in view of its simplicity and the tree is reported 
in Figure 5.6. 
r=oJ 
l=-.!.I 
132 
Figure 5.6 CART tree for RBA endpoint 
RBA ciassificalirn tree 
In the CART tree the node assignment can be used to evaluate the reliability of 
the predictions: some of the terminal nodes are characterised by a lower purity 
grade and this behaviour is maintained also in the test set as shown in Table 5.6. 
By excluding the compound assigned through the two most impure nodes (14 
and 18, both assigning compounds to the active class) the accuracy increases 
conSistently in all the three sets, up to 90%. On the other hand, in this way 
specificity increases but sensitivity decreases. 
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Table 5.6 Misclassification rates for the CART termInal nodes for RBA. Node purity can be used to assess 
prediction reliabifity. Asterisks identify nodes with a misclassification rate greater than 0.3. 
Terminal Node Misclasslflcatlon ratio 
node assignment Training Validation Test 
set set set 
4 0 0.04 0.02 0 
6 0.13 0.16 0.14 
8 0 0.1 0.26 0.17 
11 0.31* 0 0.25 
12 0 0.05 0.14 0.25 
14 I 0.47* 0.6r 0.25 
15 0 0.14 0.19 0.13 
18 I 0.32* 0.33* 0.55* 
19 0 0.2 0 0 
20 0 0.06 0.2 0.17 
21 0.44* 0.2 0.17 
The characteristics for RA models are summarised in Table 5.7 and graphically 
compared through the ROC values in Figure 5.7. The selected deSCriptors (with 
the exclusion of those used in the OF model) are given in Table 5.S. 
Table 5.7 Overview of RA results. 
Training set Validation set Test set 
(117P/389NI (35P/115NI (35P/115NI 
Acc. Spec. Sens. Acc. Spec. Sens. Acc. Spec. Sens. 
OF 98.62 100.00 94.02 86.67 93.91 62.86 85.33 89.57 71.43 
81 descriptors in a combination of 3 trees 
AFP 87.35 92.29 70.94 89.33 92.17 80.00 88.67 92.17 77.14 
6 deSCriptors (Vl 4-V 140-V 189-V211-V22/-V2S0l ~eneratin9. 29 rules 
CART 86.76 87.15 85.47 81.33 86.96 62.86 83.33 88.70 65.71 
9 descriptors (V"-V32-V35-V76-VI62-VI94-V22'-V234-V250l. 12 terminal nodes 
MLP 87.94 91.26 76.92 95.33 97.39 88.57 86.67 91.30 71.43 
8 deSCriptors (V4-VS6-V59-VIS3-VI82-V200-V221-V246j 
SVM 98.62 100.00 94.02 91.33 97.39 71.43 80.67 93.04 40.00 
10 descriptors (V2-V39-V70-VB6-V/30-V/46-V188-VI93-V19S-VI97j 
For all the methods it was possible to reach an accuracy greater than 80%. on all 
the three subsets. Due to the low proportion of active compounds in the dataset 
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(25% only) the different methods have difficulty in maintaining a stable behaviour 
in the sensitivity trend. AFP and MLP seem less affected by this problem while SVM 
and, to a lower extent, also DF and CART have a larger drop of sensitivity in the 
validation and/or test sets. 
Overall, RA models obtained with AFP and MLP seem to perform better. Again 
nArOH and MLOGP were often selected as relevant descriptors. Other descriptors 
present in all the models are those belonging to topological charge indices. They 
were proposed to evaluate the charge transfer between pairs of atoms and 
therefore the global charge transfer in the molecule. 
Training set Validation set 
1 1 
0 .8 0 .8 
> 0.6 ~ 0 .6 ~ 
~ ~ ~ 
.. Vi 
c c 
~ 0.4 ~ 0.4 
0 .2 0 .2 
Figure 5.7 ROC comparison of the RA mod els obtained with different olgori lhms. 
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Table 5.8 List of selected var/ables In the RA models. 
No. Symbol Definition Class 
V2 Mv mean atomic van der Waals volume (scaled on constitutional Carbon atom) 
V 4 Ms mean electrotopologlcal state 
V II nN number of Nitrogen atoms 
V32 MAXON maximal electrotopologlcal negative variation 
V35 TIE E-state topological parameter 
V39 PW5 pathtwalle 5 - Randlc shape Index 
V56 pliO conventional bond-order 10 number 
V59 XOA average connectivity index chl-O 
V70 AAC mean Information Index on atomic composition 
V74 HVcpx graph vertex complexity Index 
V76 Vindex 
constitutional 
constitutional 
topological 
topological 
topological 
walle and path counts 
topological 
information Indices 
Information indices 
information Indices 
V86 BIC3 
Balaban V Index 
bond information 
symmetry of 3-order) 
content (neighborhood Information indices 
VI30 GATSlv 
VI40 GATS3e 
VI46 GATSlp 
VI53 EEigl2x 
VI62 EEigl4d 
VI82 BEHpl 
Geary autocorrelation - lag I I weighted by atomic 20 autocorrelations 
van dar Waals volumes 
Geary autocorrelation - lag 3 I weighted by atomic 20 autocorrelatlons 
Sanderson electronegatlvitles 
Geary autocorrelation - lag I I weighted by atomic 20 autocorrelations 
poJarizabilitles 
8genvalue 12 from edge adj. matrix weighted by edge adjacency 
edge degrees Indices 
8genvalue 14 from edge adj. matrix weighted by edge adjacency 
dipole moments indices 
highest eigenvalue n. I of Burden matrix I weighted Burden eigenvalues 
by atomic polarizabDitles 
V 188 GGI7 topological charge Index of order 7 topological charge Indices 
V 189 GGI8 topological charge Index of order 8 
VI93 JGI2 mean topological charge Index of order2 
VI94 JGI3 mean topological charge Index of order3 
VI95 JGI4 mean topological charge Index of order4 
V 197 JGI6 mean topological chorge Index of order6 
V200 JGI9 mean topological charge Index of order9 
V211 nCrq number of ring quaternary C(sp3) 
V221 nArCH number of aromatic hydroxyls 
V234 C-026 R-CX-R 
V246 N-075 R-N-R I R-N-X 
V250 MlOGP Moriguchl octanol-water partition coell. (logP) 
topological charge 
Indices 
topological charge 
Indices 
topological charge 
Indices 
topological charge 
indices 
topological charge 
Indices 
topological charge 
indices 
functional group 
counts 
functional group 
counts 
atom-centred 
fragments 
atorn-centred 
fragments 
physlco-chemlcal 
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In the hypothesis of adopting binary classification as a screening tool to assess 
oestrogenic capabilities of chemical contaminants, emphasis should be placed 
to false negative results. In this context, lower sensitivity is not an advisable 
characteristic, so possible modification of this behaviour. exhibited by all classifiers 
for both endpoints, was also investigated, through combination of their prediction 
abilities. In the case of RBA a combination of CART and SVM was used. CART was 
chosen because it is characterised by the largest sensitivity on the training set 
(excluding the complex DF model). while SVM selected different FN from the 
other classifiers. Assigning a compound to the active class when at least one of 
the two models predicts it as active, increases the sensitivity significantly. 
maintaining an accuracy around 85% on all the three sets (see Table 5.9). 
Moreover the few FN compounds exhibit very marginal activity compared to 
those present in the single models, as highlighted in Figure 5.8. A similar situation 
can be proposed for RA: the SVM model is very specific, while MLP has a better 
sensitivity overall on the training and validation sets. The statistics improve even 
though sensitivity remains a little too poor on the test set (see Table 5.9). However, 
as already found for RBA, the experimental activities for FN present in the 
combined models are extremely low (one thousand times less than the reference 
compound) compared to those of FN in the single models (see Figure 5.9). 
Table 5.9 Perfonnances of the combined models for RBA and RA. 
Combined RBA model Combined RA model 
ICART+ SVM! (MLP+ SVM) 
Training set Validation Test set Training set Validation Test set set set 
FP 59 19 19 34 6 14 
FN 8 3 3 3 2 9 
TP 172 51 51 114 33 26 
TN 267 77 77 355 109 101 
Acc. 86.76 85.33 85.33 92.69 94.67 84.67 
Spec. 81.90 80.21 80.21 91.26 94.78 87.83 
Sens. 95.56 94.44 94.44 97.44 94.29 74.29 
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Figure 5.9 Comparison of miselassified FN for single and combined RA models. 
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5.4. CONCLUSIONS 
New predictive models were derived to assess oestrogenicity for a very large and 
heterogeneous dataset of chemical compounds. Both binding and 
transcriptional activities were investigated and very good accuracy was reached 
for both RA and RBA models, although a general weakness in sensitivity was 
observed. 
Performances on RA data are lower overall in terms of sensitivity then those on 
RBA. This is due to the unbalanced distribution of data in the two classes, a 
situation that is even more pronounced for RA. Furthermore, some of the methods 
seem able to cope with this peculiar data distribution better than others; for 
instance AFP shows good sensitivity in both RBA and RA. SVM on the contrary 
seems to be more disturbed by a poor class representation and consequently is 
characterised by lower sensitivity. 
All the methods were capable of developing satisfactory models even though DF 
and SVM seem somewhat less reliable than the others. The main drawback of DF 
is its complexity, which increases the chance of overfitting, while in the case of 
SVM the main problem was the above-mentioned lack of sensitivity. 
To use QSAR models as a screening tool for prioritising experimental testing, it 
would be essential to limit FN. For this reason a combination of models was 
explored to satisfy this requirement better. Interestingly, for both endpoints, SVM -
apart from its weakness - seems useful in improving the performances of single 
models and limiting the extent of FN. 
It is difficult to identify relevant descriptors for RA and RBA endpoints. Although 
overall RA and RBA models have some descriptors in common, such as NArOH or 
MLOGP, RA is characterised by the presence of a larger number of descriptors 
accounting for charge properties. This can be due to the fact that a proper 
interaction with the receptor is required to exhibit the transcriptional effect and 
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charge distribution is very important for that. once the ligand is in bound in the 
binding site. 
This dataset is at the basis of MultiCASE models for receptor binding assay and 
reporter gene as reported in the Danish database {138]. Although not too many 
details are available on these commercial models. results in crossvalidation (LSO 
of 50% of data) reported there yield an accuracy around 80% with a sensitivity 
lower than 80% for both endpoints. The models here obtained are slightly better 
and especially the combined models are characterised by an increased 
sensitivity also on the extemal validation set. 
Aside from the combined models. by globally evaluating both the performances 
and the easiness, the best RBA model is the CART classification tree; while. in the 
case of RA. the preferred model can be the one developed according to AFP 
algorithm. 
Overall the models so obtained are sufficiently robust and characterised by ease 
of use for their application in the regulatory context. 
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CONCLUSIONS 
This work aimed to explore the status. availability and reliability of non-testing 
methods applied to endocrine disruption mediated by the oestrogen receptor. 
and eventually to propose new models easily exploitable in regulatory contexts. 
Three existing QSAR models were selected in this work for a deeper evaluation on 
the basis of the OECD principles for QSAR validation. Different kinds of model 
(regression and classification. SAR and QSAR models) have been analysed in 
detail and they were externally validated with new data found in the literature. 
Models relying on bi-dimensional descriptors only seemed more user-friendly and 
more reproducible. The inclusion of 3D parameters - providing a more complete 
structural characterisation - required a detailed definition of the protocol used for 
their calculation and the evaluation of the prediction sensitivity to procedural 
steps. In the example presented in this study. the model was robust and 
reproducible to a satisfactory level. Several ways of assessing the applicability 
domain have been evaluated depending on the available information. Although 
some methods seem better than others. no efficient way to detect poor 
predictions has been identified. 
This piece of work explored a quite unusual aspect of QSAR modelling: often new 
models appear in the literature addressing a similar or identical dataset already 
investigated by other researchers. less frequently the focus is given to further 
applications of the model and the possibility to transfer it to other scientists is 
usually not considered. This does not necessarily mean that the model itself 
cannot be used practically by someone other than the original developer (a" the 
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models examined here were quite satisfactory from this point of view), but 
neglecting this aspect may decrease the chance to use the model in the future 
due to a lack of reproducibility and accessibility. 
Beside this necessary focus on what was already available in the scientific 
community, very useful indications were derived for continuation of the project by 
developing new classification models with ease of use as screening methods. In 
this framework, SAR or classification models can be a valid alternative to 
quantitative models. Further indications from this stage of the research were 
obtained: it appeared that to avoid overfitting especially when dealing with 
complex models, an accurate validation is essential. including an external test 
set. Moreover preference was given to the use of bi-dimensional descriptors in 
newly developed QSAR, since it was observed that similar performances can 
often be reached with the use of 2D and 3D descriptors respectively. 
Bearing all these considerations in mind, data collected have been used to 
develop QSAR binary classifiers based on different data-mining techniques such 
as classification trees and decision forest, adaptive fuzzy partition (AFP), neural 
networks and support vector machines (SVM). New predictive models were 
derived to assess oestrogenicity for a very large and heterogeneous dataset of 
chemical compounds. Attention was focussed on multiple in vitro endpoints to 
characterize better the effects of EDs evaluating both binding (RBA) and 
transcriptional activity IRA). 
A very good accuracy was achieved for both RA and RBA models laround 85% in 
all instances), although a general weakness in sensitivity was observed. 
Performances on RA data were lower overall in terms of sensitivity then those on 
RBA. This is due to the unbalanced distribution of data in the two classes, 
especially for RA. In addition, some of the methods seem able to cope with this 
peculiar data distribution better than others; for instance AFP shows good 
sensitivity in both RBA and RA. SVM on the other hand seems to be more 
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disturbed by a poor class representation and consequently is characterised by 
lower sensitivity. 
In this context. some more complex model architecture has been explored. such 
as NN. for consideration as a benchmark for the best obtainable results. 
Model performances were quite good. comparable to those available in the 
literature. and especially the combined models are slightly better. being 
characterised by an increased sensitivity. The validation procedure adopted was 
quite demanding. including both internal and external validation. 
The descriptors were statistically selected and a convergence to certain specific 
descriptors was observed in this selection. which supports the theoretical 
explanation for the relevance of some of these descriptors - such as presence of 
a phenolic ring - in the underlying mechanism that controls the strength of 
oestrogenic effects. 
A ttention was focused on some specific characteristics, to achieve the objective 
of developing models for regulatory purposes. For this reason. a first aspect 
considered was that in using QSAR models as a screening tool for prioritising 
experimental testing it would be essential to limit FN. For this reason a combination 
of models was explored to satisfy this requirement better. Other aspects such as 
simplicity and reliability of the models. have been emphasised in view of possible 
application in the regulatory framework. 
The errors observed were of a limited number and of limited extent and their 
presence is implicit in the underlying statistical approach at the basis of QSAR 
analysis. Nevertheless, any misclassified compound can be problematical for the 
acceptance of a model, and the definition of the applicability domain (AD) of a 
QSAR should help in addressing this issue. Some hints from the validation exercise 
indicate that similarity assessment is not sufficient to increase the reliability of 
predictions from QSAR models. The data here obtained during development of 
new models suggested that a more comprehensive way to define the AD would 
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be to include the model characteristics itself. The example of the CART model for 
RBA shows that some information about the reliability of predicted values can be 
derived by observing the specific node activated to generate the prediction. 
However. the AD concept requires further elucidation. particularly as regards to 
the applicative context. In the case of QSAR usage for regulatory purposes. still it 
has to be discussed if the accuracy reachable by QSAR would be considered 
acceptable by regulators. 
Beside the aspect of AD. other issues can be further explored in future work. A 
possible extension of this work is to couple the classification approach adopted 
here with quantitative models so as to include in the analysis the magnitude of 
the activity. Another possible direction for further analysis is to restrict the 
chemical domain under investigation. so as to assess a more focused chemical 
space. This can be of help in deriving some more detailed mechanistic reasoning 
and it can be an advantage for characterizing the AD. 
Overall the work conducted in this project holds out new predictive models 
addressing the effects of xenobiotics to the endocrine system. particularly 
mediated by the oestrogen receptor. They can be a valuable complement to in 
vivo and in vitro studies in the toxicological characterisation of chemical 
compounds. 
The original parts of the project conducted by the PhD candidate were the 
following: 
- Literature survey to search for promising models and data; 
- Selection of the models on the basis of criteria derived from the OECD 
principles; 
- Contribution to the datasets preparation for the validation and checking of 
chemical structures; 
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- Calculation of the majority of the descriptors needed to validate existing 
models; 
- Elaboration of the results of the validation exercise: 
- Data preparation and checking of structures for the dataset used for 
developing new models; 
- Descriptor calculation; 
- Dataset splitting in training test and validation set with self-organizing map; 
- Development of binary classification models for oesfrogenicity with 
classification trees. decision forest. AFP. neural network (MlPJ and support 
vector machines; 
- Discussion of the results and of the new models obtained. 
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ANNEX A 
This annex contains the NTP dataset provided as supplementary material by 
Sutherland et al. [74) used in Chapter 4 for the validation of Model 2. 
Features assigned according to the SAR model are reported. Compounds with 
light gray background were those belonging to the training set. Compounds with 
activity class U (undefined) were those excluded from this evaluation. 
Chemical class 10 Substance CAS Hr. 
ActlvHy Fl F2 F3 F4 F5 F6 Predicted 
class Ring Ar Phe He P3P Other Class 
Acetamide; tox-469 Metolachlor 51218-45-2 1 1 0 0 0 0 Anilide 
2-
Acrylate tox-386 Hydroxyethyl 868-77-9 0 0 - - - - - 0 
methacrylate 
Acrylate tox-438 Methyl 80-62-6 0 0 - - - - - 0 methacrylate 
Triethylene 
Acrylate tox-621 glycol 109-16-0 0 0 - - - - - 0 dimethacrylat 
e 
Bisphenol A 
diglycidyl 
Acrylate tox-72 ether 1565-94-2 0 1 1 0 - - - 0 
dimethacrylat 
e 
Bisphenol A 
Acrylate tox-75 ethoxylate 64401-02-1 U - - - - - - -
diacrylate 
Acrylate; Bisphenol A 
Bisphenol tox-73 dimethacrylat 
3253-39-2 1 1 1 0 - - 0 0 
e 
Alcohol tox-498 1.8- 629-41 -4 0 0 0 0 0 0 Octanediol 
Alcohol tox-55 Benzyl a lcohol 100-51-6 1 1 0 0 0 0 
Alcohol tox-364 n -Hexanol 111 -27-3 0 0 0 0 0 0 
Alcohol tox-433 MER-25 67-98-1 U - - - - - - -
Aldehyde tox-347 Heptanal 111 -7 1-7 0 0 0 0 0 0 
Alkoxyphenol tox-428 Isoeugenol 97-54-1 1 1 1 0 0 0 
Alkoxyphenol tox-631 Vanillin 121 -33-5 1 1 1 0 0 0 
Alkoxyphenol tox-314 Eugenol 97-53-0 1 1 1 0 0 0 
4-
Alkoxyphenol tox-346 (Heptyloxy)ph 13037-86-0 1 1 1 0 0 1 
enol 
Hexestrol 
Alkoxyphenol tox-367 monomethyl 13026-26-1 1 1 1 0 1 0 
ether 
Alkylbenzene tox-92 sec - 135-98-8 1 1 0 0 0 0 Bulvlbenzene 
Alkylphenol tox-499 4-n - 1806-26-4 1 1 1 0 0 0 Octvlohenol 
Alkylphenol tox-500 4-tert - 140-66-9 1 1 1 0 0 0 Octvlohenol 
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Chemical class 10 Substance CAS Nr. 
Activity fl f2 f3 f4 f5 f6 Predicted 
class Rln gA r Ph e He P3 Pother Class 
Alkylphenol tox-259 Dopamine 51 -61 -6 1 1 1 0 0 0 
Alkylphenol tox-22 4-tert - 80-46-6 1 Amylphenol 
1 1 0 0 1 
4-
Alkylphenol tox-525 Phenethylphe 6335-83-7 1 1 1 0 1 0 
nol 
Alkylphenol tox-308 2-Ethylphenol 90-00-6 1 1 1 0 0 0 
Alkylphenol tox-309 3-Ethylphenol 620-17-7 1 1 1 0 0 1 
4-
Alkylphenol tox-257 Dodecylphen 104-43-8 1 1 1 0 0 1 
01 
Alkylphenol tox-175 2,6-Di-tert - 128-39-2 0 1 1 1 0 0 butylphenol 
- -
Amide tox- l33 Colchicine 64-86-8 0 1 1 0 - - 0 0 
Anilide tox-4 Alachlor 15972-60-8 1 1 0 0 0 0 
4,4'-
Methylenebis( 
Aniline tox-455 N,N- 101 -61 -1 1 1 0 0 1 0 
dimethylanilin 
el 
Butyl 4-
Aniline tox-90 aminobenzoa 94-25-7 1 1 0 0 0 0 
te 
4,4'-
Aniline tox-454 Methylenedia 101 -77-9 1 1 0 0 0 0 
niline 
4-
Aniline tox-21 Aminophenyl 101-80-4 1 1 0 0 0 0 
ether 
Aromatic tox-432 heterocycle Melatonin 
73-31 -4 1 1 0 0 0 0 
Aromatic tox-489 Nonylbenzen 1081 -77-2 0 1 1 0 0 0 hydrocarbon 
- -
e 
Aromatic 
hydrocarbon; tox-91 n - 104-51 -8 1 1 0 0 0 0 
Alkvlbenzene Butylbenzene 
Azo compound tox-16 Amaranth 915-67-3 1 1 1 0 1 0 
2,2'-
Benzophenone tox-208 Dihydroxy-4- 131 -53-3 1 1 1 0 1 0 methoxybenz 
oohenone 
2,2'-
Benzophenone tox-209 Dihydroxyben 835- 11 -0 1 1 1 0 1 0 
zoohenone 
2-Hydroxy-4-
Benzophenone tox-394 methoxybenz 131 -57-7 1 1 1 0 1 0 
ophenone 
2,4-
Benzophenone tox-210 Dihydroxyben 131 -56-6 1 1 1 0 1 0 
zoohenone 
2,2',4,4'-
Benzophenone tox-607 Tetrahydroxyb 5394-98-9 1 1 1 0 1 0 
enzil 
Benzophenone; 4,4'-
Phenol tox-214 Dihydroxyben 
611 -99-4 1 1 1 0 1 0 
zophenone 
Biphenyl; Phenol tox-549 2- 90-43-7 1 1 1 0 0 0 Phenyl phenol 
Biphenyl; Phenol tox-551 4- 92-69-3 1 1 1 0 0 1 Phenvlohenol 
Biphenyl; Phenol tox-550 3- 580-51-8 1 1 1 0 0 0 Phenvlohenol 
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Chemical class 10 Substance CAS Nr. 
Activity Fl F2 F3 F4 F5 F6 Predicted 
class Rln gA r Ph e He P3 POther Class 
4,4'-
Biphenyldiol tox-215 Dihydroxybiph 92-88-6 0 1 1 1 - 0 1 1 
enyl 
Bisphenol tox-69 Bisphenol A 80-05-7 1 1 1 0 1 0 
Bisphenol lox-85 Bisphenol S 80-09-1 1 1 1 0 1 0 
Bisphenol lox-493 Nordihydrogu 500-38-9 1 ariarelic acid 
1 1 0 1 0 
Bisphenol lox-83 
2.2'-Bisphenol 2467-02-9 1 1 1 0 1 0 
F 
Bisphenol tox- l38 Cyclofenil diphenol 5189-40-2 1 
1 1 I - 1 - 1 
Bisphenol tox-271 Erythro -MEA 20576-52-7 1 1 1 1 - 1 - 1 
Phenol. 4,4'-
[1,2-
Bisphenol tox-529 bis(melhylene )-1.2- 107144-81-0 1 1 1 1 - 1 -
1 
ethanediyl)bis 
-
2,2-Bis(4-
Bisphenol lox-67 hydroxypheny 142648-65-5 U - - - - - - -
Ilprooanol 
Bisphenol A 
Bisphenol tox-70 bis(chloroform 2024-88-6 1 1 1 0 - - 0 0 
atel 
Bisphenol A 
Bisphenol lox-71 diglycidyl 1675-54-3 0 1 1 0 - - 0 0 
ether 
Bisphenol tox-77 Bisphenol A 37353-75-6 0 1 1 0 - - 0 0 propoxvlate 
Bisphenol: tox-76 Bisphenol A 0 1 1 0 - - 0 0 Glucuronide Qlucuronide 
Bisphenol; tox-562 Slilbene 
Pseudodiethyl 
stilbestrol 39011-86-4 
1 1 1 1 - 1 - 1 
Carbamate tox- l03 Carbofuran 1563-66-2 1 1 0 0 0 0 
Carbamate: tOX-40 Benomyl 17804-35-2 0 I 1 0 - 0 0 Imidazole 
-
Carbamate: 
Polycyclic tox- l02 Carbaryl 63-25-2 I 1 0 0 0 0 
aromalic 
hydrocarbon 
Carboxylic acid tox-576 Subericacid 505-48-6 0 0 0 0 0 0 
Carboxylic acid tox-129 Cinnamic 621-82-9 I 1 0 0 0 0 acid 
3-Ethyl-4-( p -
methoxyphen 
Carboxylic acid tox-306 yIJ-2-methyl-3-cyclohexene- 1755-52-8 1 
1 1 0 - - 0 0 
l -carboxylic 
acid 
Chalconoid tox-552 Phlorelin 60-82-2 1 1 1 0 1 0 
4-
Chalconoid tox-371 Hydroxychalc 20426-12-4 1 1 1 0 1 0 
one 
4'-
Chalconold tox-372 Hydroxychalc 2657-25-2 1 1 1 0 1 0 
one 
4.2'.4'-
Chalconoid tox-622 Trihydroxychal 961 -29-5 1 1 1 0 1 0 
cone 
Chalconoid tox- l06 Chalcone 94-41 -7 I 1 0 0 0 1 
Chalconoid lox-373 4'- 38239-52-0 U - - - - - - -
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Chemical class ID Substance CAS Nr. 
Activity Fl F2 F3 F4 F5 F6 Predicted 
class Rln gA r Ph eHe t P3 Pother Class 
Hydroxychalc 
one (cis- and 
trans~) 
Chlorinated 2.4,5-
aromatic tox-619 Trichlorophen 93-76-5 hydrocarbon;Org oxyacetic 
1 1 0 0 0 0 
anochlorine acid 
Chlorinated 
cycloalkane; tox-431 Lindane 58-89-9 1 0 0 0 0 0 
Organochlorine 
Chlorinated tox-122 2- 95-57-8 1 1 1 0 0 0 Qhenol Chloroohenol 
Chlorinated tox-120 2-Chloro-4- 6640-27-3 1 1 1 0 0 1 phenol methvlohenol 
Chlorinated tox-123 4- 106-48-9 U phenol Chlorophenol 
- - -
- - - -
Coumarin; Pheno I tox-136 Coumestrol 479-13-0 1 1 1 0 1 0 
Crown ether tox- l68 Dibenzo-l8- 14187-32-7 1 1 0 0 0 0 crown-6 
Cyclodiene tox-6 Aldrin 309...QO-2 1 0 0 0 0 0 
2,3,7,8-
Dioxin tox-603 
Tetrachlorodi 1746-01-6 0 1 1 0 - - 0 0 benzo-p-
dioxin 
Diphenolalkane tox-38 Aurin 603-45-2 1 1 1 0 1 0 
Diphenolalkane tox-248 Diphenolic 126-00-1 1 1 1 0 1 0 acid 
3,3'-
Diphenolalkane tox-213 Dihydroxyhex 79199-51 -2 1 1 1 0 1 0 
estrol 
2,6-
Diphenolalkane lox-239 Dimelhylhexe 334707-28-7 1 1 1 0 1 0 
strol 
Diphenolalkane lox-366 DL -Hexestrol 5776-72-7 1 1 1 1 - 1 - 1 
l.l -Bis-( 4-
Diphenolalkane tox-62 hydroxypheny 2081-08-5 U - - - - - - -
II e thane 
4,4-Bis(4-
Diphenolalkane tox-63 hydroxypheny 7425-79-8 1 1 1 1 - 1 - 1 
Ilheptane 
3.4-Bis(3-
Diphenolalkane lox-64 hydroxypheny 68266-24-0 1 1 1 1 - 1 - 1 
Ilhexone 
Diphenololkane; tox-365 Bisphenol Hexeslrol 
84- 16-2 1 1 1 0 1 0 
Diphenolalkane; tox-541 Phenol Red 143-74-8 1 1 1 0 1 0 Bisphenol 
Diphenolalkane; tox-79 Bisphenol B 77-40-7 1 1 1 0 1 0 Bisphenol 
Diphenolalkane; tox-82 Bisphenol E 6052-84-2 1 1 1 0 1 0 Bi~henol 
Diphenolalkane; tox-81 Bisphenol C 2 14868-03-2 1 1 1 0 1 0 Bisphenol 
Benzeneacel 
Diphenolalkane; onltrile 0 -
Bisphenol tox-42 [bis(4- 66422- 14-8 1 1 
1 1 - 1 - 1 
hydroxypheny 
I) methylene1 
Diphenolalkane; 3,3-Bis(4-
Bisphenol tox-65 hydroxypheny 
3600-64 4 1 1 1 1 - 1 - 1 
I)pentane 
Diphenolalkane; tox-66 1,I -BIs(4- 1576- 13-2 1 1 1 1 - 1 - 1 
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Chemical class 10 Substance CAS Nr. 
Bisphenol 
Diphenolalkane; 
Bisphenol 
Diphenolalkane; 
Bisphenol 
tox-78 
tox-SO 
hydroxypheny 
Ilprooone 
Bisphenol AF 
Bisphenol C 
1478-61-1 
79-97-0 
Diphenylalkene tox-195 Dienestrol 84-17-3 
Irons, trans -
Diphenylalkene tox-249 1.4-Diphenyl- 886-65-7 
1,3-butadiene 
Diphenylalkene tox-197 b-Dienestrol 35495-11 -5 
Di-2-
Ester tox-199 ethylhexyl 103-23-1 
Flavanone 
Flavanone 
Flavanone 
Flavanone 
Flavanone 
Flavanone 
Flavanone 
Flavanone 
Flavanone 
Flavanone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
Flavone 
adioate 
tox-320 Flavanone 17002-31-2 
tox-349 Hesperetin 520-33-2 
tox-105 (±)-Catechln 7295-85-4 
3'-
tox-387 Hydroxyflavan 92496-65-6 
one 
tox-479 Naringenin 480-41 -1 
6-
tox-389 Hydroxyflavan 4250-77-5 
one 
7-
tox-390 Hydroxyflavan 6515-36-2 
one 
tox-579 TaxifoHn 480-18-2 
tox-4SO Naringin 10236-47-2 
4'-
tox-388 Hydroxyflavan 135413-27-3 
one 
tox-565 Quercetin 117-39-5 
tox-319 Fisetin 528-48-3 
tox-321 Flavone 525-82-6 
tox-571 Rutin 153-18-4 
6-
tox-391 Hydroxyflavon 6665-83-4 
e 
7-
lox-392 Hydroxyflavon 6665-86-7 
e 
tox-395 
tox-39 
tox-34 
tox-127 
tox-429 
tox-475 
6-Hydroxy-2'-
methoxyflavo 
ne 
Baicalein 
Apigenin 
Chrysin 
Kaempferol 
Morin 
61546-59-6 
491 -67-8 
520-36-5 
480-40-0 
520-18-3 
480-16-0 
tox-477 Myricetin 529-44-2 
6,4'-
tox-220 Dihydroxyflav 63046-09-3 
one 
3,6,4',-
tox-623 Trihydroxyflav 253195-19-6 
one 
Annex A 
Activity fl f2 f3 f4 f5 f6 Predicted 
closs Ring Ar Phe Het P3P Other Class 
1 1 1 0 1 o 
1 1 0 0 0 0 
1 1 1 
o 0 0 o 0 o 
1 1 0 0 0 0 
1 1 1 0 1 0 
1 1 1 0 1 0 
1 1 1 0 1 o 
1 1 1 0 1 o 
1 1 1 0 1 o 
1 1 1 0 1 o 
1 1 1 0 1 o 
1 1 1 0 1 o 
1 1 1 0 I o 
1 1 o 1 o 
1 1 o 1 o 
1 0 o 0 o 
I 1 o 1 o 
1 1 1 0 1 o 
1 1 1 0 1 o 
o o 
o o 
o o 
o o 
o o 
o o 
1 1 1 0 1 o 
1 1 1 0 1 o 
1 1 1 0 1 o 
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Chemical class 10 Substance CAS Nr. 
Activity Fl F2 F3 F4 F5 F6 Predicted 
class Ring Ar Ph e He t P3 POther Class 
Heterocyclic 
aromatic tox-327 Furfural 98-01 -1 I 1 0 0 0 0 
aldehyde 
Indane tox-404 Indanestrol 71855-45-3 1 1 1 1 - 1 - 1 
1,3-Diethyl-4-
Indene tox-201 hydroxy-2- 1 1 1 1 - 1 - 1 
phenylindene 
1 ,3-Diethyl-6-
Indene tox-202 hydroxy 2- 1 1 1 1 - 1 - 1 
phenvlindene 
2,3-
Indene tox-251 Diphenylinde 1 1 1 0 - - 0 0 
none- l 
3-Ethyl-6,4'-
Indene tox-295 dihydroxy-2- 1 1 1 1 - 1 - 1 
phenvlindene 
3-Ethyl-4'-
indene tox-302 hydroxy-2- 1 1 1 1 - 1 - 1 
phenylindene 
3-Ethyi-6-
Indene tox-303 hydroxy 2- 1 1 1 1 - 1 - 1 
phenylindene 
3-Ethyl-4'-
Indene tox-304 
hydroxy 2-
phenylindeno 
1 1 1 1 - 1 - 1 
ne-l 
3-Ethyl-6-
Indene tox-305 hydroxy 2-phenylindeno 
1 1 1 1 - 1 - 1 
ne- l 
2-(2-
Fluorophenyl)-
Indene tox-316 3-phenyl-6- 1 1 1 1 - 1 - 1 
hydroxyinden 
e 
2-Phenyl-3-(2-
fluoro-4-
Indene tox-543 
hydroxypheny 
1)-6- 1 1 1 1 -
1 - 1 
hydroxyinden 
e 
2-Phenyl-3-(2-
fluorophenyl)-
Indene tox-544 6- 1 1 1 1 - 1 - 1 
hydroxyinden 
e 
3-Phenyl-4'-
Indene tox-545 hydroxy-2- 1 1 1 1 - 1 - 1 
phenylindene 
3-Phenyl-6-
Indene tox-546 hydroxy-2- 1 1 1 1 - 1 - 1 
, phenylindene 
2-Phenyl-3-(2-
methylphenyl) 
Indene tox-547 -6- 1 1 1 1 - 1 - 1 
hydroxyinden 
e 
2-Phenyl-3-( 4-
methylphenyl) 
Indene tox-548 -6- 1 1 1 1 - 1 - 1 
hydroxyinden 
e 
Isoflavone tox-328 Genistein 446-72-0 1 1 1 0 1 0 
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Chemical class 10 Substance CAS Nr. 
Activity fl F2 F3 F4 F5 F6 Predicted 
class Ring Ar Phe He t P3 POther Class 
Isoflavone tox-270 Equol 531 -95-3 1 1 1 0 1 0 
Isoflavone lox-142 Daidzein 486-66-8 1 1 1 0 1 0 
Isoflavone tox-326 Formononetin 485-72-3 1 1 1 0 1 0 
Isoflavone tox-329 Genistin 529-59-9 1 1 1 0 1 0 
Isoflavone tox-58 Biochanin A 491-80-5 1 1 1 0 1 0 
7.3'.4'-
Isoflavone tox-625 Trihydroxyisofl 485-63-2 1 1 1 0 1 0 
avone 
6.7,4'-
Isoflavone tox-624 Trihydroxyisofl 17817-31 -1 1 1 1 0 1 0 
avone 
Isoflavone tox-561 Prunetin 552-59-0 1 1 1 0 1 0 
Isoflavone tox-226 Dihydrogenlst ein 21554-71 -2 
1 1 1 1 - 1 - 1 
Iso flavone tox-330 Glyceollin 66241-09-6 1 1 1 1 - 1 - 1 
Isoflavone tox-331 Glycitein 40957-83-3 1 1 1 1 - 1 - 1 
Isoflavone tox-332 Glycitin 40246-10-4 U - - - - - - -
Isoflavone tox-427 Ipriflavone 35212-22-7 0 1 1 0 - - 0 0 
Nitrobenzene tox-393 Hydroxyflutam ide 52806-53-8 
U - - - - - - -
Nitrogen tox-426 Indole[3.2-b U - - - - - - -heterocycle 11 carbazole 
Organochlorine tox-442 p,p' - 72-43-5 1 1 0 0 1 0 Methoxychlor 
Organochlorine tox- l07 Chlordane 57-74-9 1 0 0 0 0 0 
Organochlorine tox-470 Mirex 2385-85-5 1 0 0 0 0 0 
Organochlorine tox-35O 
Hexachlorobe 118-74-1 1 1 1 0 0 0 
nzene 
Organochlorine tox-43O Kepone 143-50-0 1 0 0 1 0 1 
Organochlorine tox-632 Vinclozolin 50471 -44-8 I 1 0 0 0 0 
Organochlorine tox-472 Monohydroxy 28463-03-8 1 1 1 0 1 0 methoxychlor 
Monohydroxy 
Organochlorine tox-473 methoxychlor 75938-34-0 1 1 1 0 1 0 
olefin 
Organochlorine tox-436 Methoxychlor 2132-70-9 1 1 0 0 0 0 olefin 
Organochlorine tox- IOB a-Chlordane 5103-71 -9 0 1 0 - 0 - - 0 
Organochlorine tox- l09 Chlormequat 999-81 -5 0 0 - - - - - 0 chloride 
Organochlorine lox-143 m.p '-DOD 4329-12-8 0 1 1 0 - - 0 0 
3.5-Dichloro 2-
Organochlorine tox- 191 hydroxy-2- 16776-82-1 U - - - - - - -methylbut-3 
enonolide 
2-[[(3.5-
Dlchlorophen 
Organochlorine tox-193 yljominoj - 119209-27-7 U - - - - - - -carbamoyljox 
yj -2-melhyl-3-
bulenoic acid 
Organochlorine tox-262 a-Endosulfan 959-98-8 0 1 0 - 1 - 0 0 
Organochlorine lox-441 o.p' -Methoxvchlor 30667-99-3 
1 1 1 0 - - 0 0 
Organochlorine lox-612 Toxaphene 8001 -35-2 U - - - - - - -
Organochlorine lox-629 Trls(4- 27575-78-6 1 I 1 0 - 0 0 chloroohenvll 
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Chemical class 10 Substance CAS Nr. 
Activity fl f2 f3 f4 f5 f6 Predicted 
class Rln gA r Ph eHe t PJ Pother Class 
methane 
Tris(4-
Organochlorine tox-630 chlorophenyl) 30100-80-8 I 1 1 0 - - 1 1 
methanol 
2.2-Bis(p-
Organochlorine; hydroxypheny 
Bisphenol tox-68 1)-1.1.1 - 2971 -36-0 1 1 1 0 1 
0 
trichloroethan 
e 
Organochlorine; 
Chlorinated tox-333 Heptachlor 76-44-8 1 0 0 0 0 0 
cyclodiene 
Organochlorine; 
a.b-Chlorinated lox-263 115-29-7 1 0 0 1 0 0 
cyclodiene Endosulfan 
Organochlorine; 
Chlorinated lox-194 Dieldrin 60-57-1 1 0 0 1 0 0 
cyclodiene 
Organochlorine; 
Chlorinaled tox-264 b-Endosulfan 33213-65-9 U - - - - - - -
cyclodiene 
Organochlorine; 4-Chloro-2-Chlorinated tox-121 1570-64-5 1 1 1 0 0 1 
Iphenol methylphenol 
Organochlorine; lox-315 Fenvalerate Diphenyl ether 
51630-58-1 0 1 1 0 - - 0 0 
Organochlorine; tox-170 Diohenylalkane o.p '-DOE 3424-82-6 
1 1 0 0 0 1 
Organochlorine; tox-144 o.P '-DOD 53-19-0 1 1 0 0 0 1 Di~henylalkane 
Organochlorine; tox- l71 o.P '-DDT 789-02-6 1 1 0 0 0 1 Diphenylalkane 
Organochlorine; tox- l72 Diphenylalkane p.p '-DOD 72-54-8 
1 1 0 0 1 0 
Organochlorine; tox-173 P.P '-DDE 72-55-9 1 1 0 0 1 0 Diphenylalkane 
Organochlorine; tox-174 P.P '-DDT 50-29-3 1 1 0 0 1 0 Diphenylalkane 
Organochlorine; 
Nitrile; Diphenyl tox- 141 Cypermelhrin 52315-07-8 0 1 1 0 - - 0 0 
ether 
Organochlorine; tox-113 4-Chloro-4'- 28034-99-3 1 1 1 0 0 0 Phenol biohenylol 
Organochlorine; tox-114 4-Chloro-m - 59-50-7 1 1 1 0 0 1 Phenol cresol 
Organochlorine; lox-Ill 2'-Chloro-4.4'- 56858-70-9 I I I 1 - 0 1 1 Phenol biohenyldiol 
Organochlorine; lox-112 2-Chloro-4- 23719-22-4 1 1 1 1 - 0 I 1 Phenol biohenylol 
Organochlorine; tox-572 Simazine 122-34-9 1 1 0 0 0 0 Triazine 
Organochlorine;C 
hlorinated lox-487 bridged cis -Nonochlor 5103-73-1 0 
1 0 - 0 - 0 
cycloalkene 
Organochlorine;C 
hlorinaled tox-488 Irons - 39765-80-5 0 1 0 0 0 bridged 
-
- -
Nonachlor 
qcloalkene 
Paraben tox-94 Butylparoben 94-26-8 1 1 1 0 0 1 
Paraben lox-348 Heptyl4- 1085-12-7 1 1 1 0 0 1 paraben 
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Chemical class 10 Substance CAS Nr. 
Activity Fl F2 F3 F4 F5 F6 Predicted 
class Rln gA r Ph eHe t P3 POther Class 
Paroben lox-296 2-Ethylhexyl 5153-25-3 1 1 1 0 0 1 paroben 
Paraben tox-57 
Benzylparabe 94-18-8 1 1 1 0 1 0 
n 
Para ben tox-559 Propyl 94-13-3 I 1 1 0 0 1 paroben 
Paraben tox-307 Ethyl paraben 120-47-8 1 1 1 0 0 1 
Paraben lox-439 Methyl paraben 99-76-3 
1 1 1 0 0 1 
Phenol tox-95 
2-sec - 89-72-5 1 1 1 0 0 0 Butvlphenol 
Phenol tox-98 4-sec - 99-71 -8 1 1 1 0 0 0 Butvlphenol 
Phenol tox-99 
4-tert - 98-54-4 1 1 1 0 0 0 Butvlphenol 
meso-p -(a,b-
Phenol lox-203 
Diethyl-p -
methylphenet 267408-76-4 
I 1 1 0 1 0 
hvllohenol 
4-
Phenol lox-56 Benzyloxyphe 103-16-2 1 I 1 0 1 0 
nol 
Phenol tox-137 
p -Cumyl 599-64-4 1 1 1 0 I 0 
ohenol 
4.4'-( 1,3-
Phenol tox- l Adamantane 1 1 1 1 - 0 1 1 
divlldiohenol 
2-(1 -
Phenol tox-2 
Adamantyl)- 41031 -50-9 0 1 I 1 - 0 1 1 4-
methvlohenol 
4-(1 -
Phenol lox-3 Adomantyl)p 29799-07-3 1 1 1 1 - 0 I 1 
henol 
Phenol tox-96 2-tert -Butvlohenol 88-18-6 
U - - - - - - -
Phenol tox-97 3-tert - 585-34-2 U Butviphenol -
- - -
- - -
Phenol; lox-491 n - 25154-52-3 1 1 1 0 0 1 Alkvlphenol Nonvlohenol 
Phenol; tox-310 4-Ethylphenol 123-07-9 1 1 1 0 0 1 Alkvlphenol 
Phenol; tox-490 p - 104-40-5 1 1 1 1 0 1 1 Alkvlphenol Nonvlohenol 
-
Tosyl 
Phenol; nonylphenol 
Alkylphenol tox-611 (mixed U - - - - -
- -
branched 
isomers) 
Phenol; Bisphenol I ox-84 4,4'-Bisphenol 620-92-8 1 1 1 0 1 0 F 
2,4-
Phenoxy tox- l92 Dichlorophen 94-75-7 
carboxylic ocid oxyacetic 
1 1 0 0 0 0 
acid 
1.3-
Butanediol. 4-
[4-( 1.2,3.4-
Phenyt ether tox-87 tetrahydro-6- 107144-85-4 1 1 1 1 - 1 - 1 hydroxy-2-
phenyl-l -
naphthalenyt) 
phenoxy] 
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Activity Fl F2 F3 F4 F5 F6 Predicted 
class Rln gA r Ph e He tP3 POther Class 
1.3-
Butanedlol, 4-
[4-{1,2,3,4-
Phenyl e ther tox-88 tetrahydro-6- 107163-56-4 I I methoxy-2-
I 0 - - 0 0 
phenyl- I -
naphthenyl)p 
henoxy] 
Phenylalkene tox-294 Ethyl 103-36-6 I 1 0 0 0 0 cinnamate 
Phosphate ester tox-628 
Triphenyl 115-86-6 1 I 0 0 0 0 phosphate 
Phthalate tox-200 
Diethylhexyl 117-81 -7 1 I 0 0 0 0 phthalale 
Phthalate tox-204 
Diethyl 84-66-2 1 I 0 0 0 0 phthalate 
Phthalate tox-93 
Butyl benzyl 85-68-7 I 1 0 0 0 I phthalate 
Phthalate tox-176 
Dibutyl 84-74-2 1 1 1 0 0 0 phthalate 
Phthalate tox-247 
Di-n -octyl 117-84-0 1 1 0 0 0 0 phthalate 
Phthalate tox-241 
Dimethyl 131 -1 1-3 1 1 0 0 0 0 phthalate 
Phthalate tox-232 Diisononyl 28553-12-0 1 1 0 0 0 0 phthalate 
Phthalate tox-229 Diisobutyl 84-69-5 1 1 0 0 0 0 phthalate 
Butyl phlhalyl 
Phthalate tox- l00 n -butyl 85-70-1 0 I I 0 - - 0 0 
alycolate 
Phthalate tox-169 
Dibulyl benzyl 
ohthalate 
0 1 I 0 - - 0 0 
Phthalate tox-225 
Dihexyl 84-75-3 0 1 1 0 - - 0 0 
ohthalate 
Phthalate tox-230 Diisodecyl 26761 -40-0 0 I 1 0 - - 0 0 phthalate 
Phthalate tox-231 
Dilsoheptyl 
phthalale 41451 -28-9 0 
I 1 0 - - 0 0 
Phthalimide tox-609 Thalidomide 50-35-1 1 1 0 0 0 0 
Polychlorinated 
2',3',4',5'-
biphenyl tox-601 
Tetrachloro-4- 67651 -34-7 1 1 1 0 0 0 
biphenylol 
Polychlorinated tox-184 2',5'-Dichloro- 53905-28-5 1 1 1 0 0 0 biphenyl 4-biphenvlol 
3,3',5,5'-
Polychlorinated tox-597 Tetrachloro- 13049-13-3 1 1 1 0 0 0 biphenyl 4,4'-
biphenyldiol 
Polychlorinated 2,4'-
biphenyl tox- l ll Dlchloroblphe 
34883-43-7 1 1 0 0 0 1 
nyl 
Polychlorinated 2,2',4,4'-
biphenyl tox-584 Tetrachlorobl 
2437-79-8 t 1 0 0 0 0 
phenyl 
Polychlorinated 3,3',4,4'-
biphenyl tox-594 Tetrachlorobl 
32598-13-3 1 1 0 0 0 0 
phenyl 
Polychlorinated 4,4'-
biphenyl tox-181 Dichloroblphe 
2050-68-2 1 I 0 0 0 0 
nyl 
Polychlorinated tox-178 2,5- 34883-39-1 0 I I 0 - - 0 0 blQ.henyl Dichlorobiphe 
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nyl 
Polychlorinated 3,4- 0 tox-179 Dichlorobiphe 2974-92-7 0 1 1 0 - - 0 biphenyl nyl 
Polychlorinated 3,5- 0 0 tox-l80 Dichlorobiphe 34883-41 -5 0 1 1 0 - -biphenyl nyl 
Polychlorinated tox-182 2,5-Dichloro- 53905-30-9 0 1 1 1 - 0 0 0 biphenyl 2'-biphenylol 
Polychlorinated lox-l83 2,5-Dichloro- 53905-29-6 U - - - - - - -biphenyl 3'-biphenylol 
Polychlorinated tox-185 2,6-Dichloro- 79881 -33-7 1 1 1 1 - 0 1 1 biphenvl 4'-biphenylol 
Polychlorinated lox-186 3,4-Dichloro- 209613-97-8 0 I 1 1 - 0 0 0 biphenyl 2'-biphenylol 
Polychlorinated tox-187 3,4-Dlchloro- 14962-34-6 0 1 1 1 - 0 0 0 biohenyl 3'-biphenylol 
Polychlorinated tox- l88 3,4-Dichloro- 53890-77-0 1 1 1 1 - 0 1 1 biphenyl 4'-biphenylol 
Polychlorina ted tox-189 3,5-Dichloro- 0 1 1 1 - 0 0 0 biphenyl 2'-biphenylol 
Polychlorinated tox-190 3,5-Dichloro- 0 1 1 1 - 0 1 1 biphenyl 4'-biphenylol 
Polychlorinated 
2,2',3,3',4',5,5'-
0 1 1 lox-334 Heptachloro- 158076-64-3 1 1 1 1 -biphenyl 4- biphenylol 
Polychlorinated 
2,2',3,3',4,5,6-
0 0 tox-335 Heptachlorob 68194-16-1 0 1 1 0 - -biphenyl iphenyl 
Polychlorinated 
2,2',3,3',4',5,6-
0 0 tox-336 Heptachlorob 52663-70-4 0 1 1 0 - -biphenyl iphenyl 
Polychlorinated 
2,2',3,3',5,5',6-
0 0 tox-337 Heptachlorob 52663-64-6 0 1 1 0 - -biphenyl iphenyl 
Polychlorinated 
2,2',3' ,4,4',5,5'-
0 0 0 tox-338 Heptachloro- 158076-69-8 1 1 I 1 -biphenyl 3- biphenylol 
Polychlorinated 2,2',3,4,4',5',6- 0 0 tox-339 Heplachlorob 52663-69-1 0 1 1 0 - -biphenyl iphenyl 
Polychlorinated 
2,2' ,3,4,4',6,6'-
0 0 tox-340 Heptachlorob 74472-48-3 1 I 1 0 - -biphenyl iphenyl 
Polychlorinated 
2,2',3,4',5,5',6-
0 1 1 tox-341 Heptachloro- 158076-68-7 1 1 1 1 -biphenyl 4- biphenylol 
Polychlorinated 2,2'.3,4'.5,5'.6- 0 0 tox-342 Heptachlorob 52663-68-0 0 1 1 0 - -biphenyl iphenyl 
Polychlorinated 2,2',3,4',5,6,6'- 0 0 tox-343 Heptochlorob 74487-85-7 1 1 1 0 - -biphenyl lphenvl 
PolychlOrinated 2,3,3',4,4',5,6- 0 0 tox-344 Heptachlorob 41411 -64-7 0 1 1 0 - -biphenyl iphenyl 
PolychlOrinated 2,3,3',4' ,5,5',6- 0 0 tox-345 Heptachlorob 69782-91 -8 0 1 1 0 - -biphenyl iphenyl 
PolychlOrinated 
2,2',3,3',4,4'-
0 0 0 tox-351 Hexachlorobi 38380-07-3 0 1 1 - -biphenyl 
I phenyl 
Polychlorinated tox-352 2,2',3.4,4'.5'- 35065-28-2 0 1 1 0 - - 0 0 
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biphenyl Hexachlorobi 
phenyl 
Polychlorinated 
2,2',3,4,5,6'-
0 0 tox-353 Hexachlorobi 68194- 15-0 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2,2',3,4',5',6-
0 0 tox-354 Hexachlorobl 38380-04-0 0 1 1 0 - -biphenyl phenyl 
Polychlorina ted 
2,2',3,5,5',6-
0 0 tox-355 Hexachlorobi 52663-63-5 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2,2',4,4',5,5'-
0 0 tox-356 Hexachlorobl 35065-27-1 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2,2',4,4',6,6'-
0 0 tox-357 Hexachlorobi 33979-03-2 1 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2,3,3',4,4',6-
0 0 tox-358 Hexachlorobi 74472-42-7 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2,3',4,4'.5',6-
0 0 tox-359 Hexachlorobi 59291 -65-5 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
3,3',4,4',5,5'-
0 0 tox-360 Hexachlorobi 32774-16-6 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2,2',3,3',4',5-
0 I 1 tox-361 Hexachloro-4- 158076-62-1 1 1 1 1 -biphenyl biphenylol 
Polychlorinated 
2,2',3,4',5.5'-
0 1 1 tox-362 Hexachloro-4- 145413-90-7 1 1 1 1 -biphenyl biphenylol 
Polychlorinaled 
2',3,3',4',5.5'-
1 0 1 1 tox-363 Hexachloro-4- 158076-63-2 I 1 1 -biphenyl biphenylol 
2,2' ,3,3',4,4',5,5 
Polychlorinated tox-497 - 35694-08-7 0 1 1 0 - - 0 0 biphenyl Octachlorobl 
phenyl 
Polychlorinated 
2,2',3,3'-
0 0 0 lox-58 I Tetrachlorobi 3844-93-8 0 1 1 - -biphenyl phenyl 
Polychlorinated 
2,2',3,4-
0 0 lox-582 Telrachlorobl 52663-59-9 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2,2',3,6-
0 0 0 tox-583 Telrachlorobi 41464-47-5 0 1 1 - -biphenyl phenyl 
Polychlorinated 
2,2',4,5'-
0 0 tox-585 Tetrachlorobl 41464-40-8 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2,2',4,6'-
0 0 tox-586 Tetrachlorobl 68194-04-7 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 2,2',5.5'- 0 0 0 tox-587 Tetrachlorobi 35693-99-3 0 1 1 - -biphenyl phenyl 
Polychlorinated 2,2',6,6'- 0 0 0 tox-588 Tetrachlorobi 15968-05-5 0 1 1 - -biphenyl phenyl 
Polychlorinated 2,3,3'.5'- 0 0 0 tox-589 Tetrachlorobi 41464-49-7 0 1 1 -biphenyl phenyl 
Polychlorinated tox-590 2,3,4,4'- 33025-41 -1 0 1 I 0 - - 0 0 
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biphenyl Telrachlorobi 
phenyl 
Polychlorinated 2,3'.4,5"- 0 0 tox-591 Tetrachlorobi 73575-52-7 0 1 I 0 - -biphenyl phenyl 
Polychlorinated 
2,3'.4',5-
0 0 tox-592 Tetrachlorobl 32598-11 -1 0 1 1 0 - -biphenyl phenyl 
Polychlorinated 
2.4,4',5-
0 0 lox-593 Tetrachlorobi 32690-93-0 0 I I 0 - -biphenyl phenyl 
Polychlorinated 
3,3'.4,5-
0 0 tox-595 Tetrachlorobi 70362-49-1 0 1 1 0 - -biphenyl phenyl 
2',3',5',6'-
Polychlorinated tox-596 Telrachloro- 100702-98-5 I 1 1 1 - 0 1 1 biphenyl 4,4'-
biphenyldiol 
Polychlorinaled 
2,2',4',6'-
1 tox-598 Tetrachloro-4- 150304-08-8 1 1 1 1 - 0 1 biphenyl biphenylol 
Polychlorinated 2,2',6,6'- 0 1 1 tox-599 Telrachloro-4- 219952-18-8 1 1 1 1 -biphenyl biphenylol 
Polychlorinated 2',3'.4',5'- 0 0 0 lox-600 Tetrachloro-3- 67651 -37-0 1 1 1 1 -biphenyl biphenylol 
Polychlorinated 2',3.4',6'- 1 tox-602 Tetrachloro-4- 189578-00-5 1 1 I 1 - 0 1 biphenyl biphenylol 
Polychlorinated tox-604 Tetrahydrochr 104460-72-2 1 1 1 1 - 0 0 0 biphenyl I ysene 
Polychlorina led 2,2',5- 0 0 0 tox-614 Trichlorobiphe 37680-65-2 0 1 1 1 -biphenyl nyl 
Polychlorinated 2,4,6- 0 0 0 lox-615 Trichlorobiphe 35693-92-6 0 1 1 1 -biphenyl nyl 
PolychlOrinated 2',4',6'- 0 1 1 tox-616 Trichloro-4- 14962-28-8 1 1 1 1 -biphenyl biphenylol 
Polychlorinated 3,3'.4'- 0 1 1 tox-617 Trichloro-4- 124882-64-0 I 1 1 1 -biphenyl blphenylol 
Polychlorinaled 3,4',5- 0 1 1 tox-618 Trichloro-4- 4400 06-0 1 1 1 1 -biphenyl biphenylol 
Polycyclic 1.6-
0 0 0 0 aromatic tox-240 Dlmethylnaph 575-43-9 1 1 
hydrocarbon thalene 
Polycyclic 
aromatic lox-126 Chrysene 218-01 -9 1 1 0 0 0 0 
hydrocarbon 
Polycyclic Benlo[b I 1 0 0 0 0 aromatic tox-48 243-174 
hydrocarbon jfluorene 
Polycyclic a,a-Oimethyl-
aromatic to)(-238 b- 15372-37-9 1 1 1 0 0 1 
hydrocarbon elhylallenollc acid 
Polycyclic Dibenz[ahjant 0 1 1 0 - 0 0 aromatic tox-167 53-70-3 -
hydrocarbon hracene 
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Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
~drocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
h1drocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
tlYdrocarbon 
Polycyclic 
aromatic 
hydrocarbon 
Polycyclic 
aromatic 
h.l'.drocarbon 
Polycyclic 
aromatic 
~drocarbon 
Polycyclic 
aromatic 
5, II-trans -
Dimethyl-
tox-244 5,6, 11,12-
tetrahydrochr 
ysene-2,8-diol 
(5R ,IIR)-
5,II -Dimethyl-
tox-245 5,6, 11,12-
tetrahydrochr 
I ysene-2,8-diol 
(5S ,lIS )-5,11 -
Dimethyl-
tox-246 5,6,11.12-
tetrahydrochr 
ysene-2,8-diot 
5, II -trans -
Dipropyl-
tox-254 5,6,11.12-
tetrahydrochr 
: ysene-2,8-diol 
(5R, lIR)-
5,II -Dipropyl-
tox-255 5,6,11,12-
tetrahydrochr 
ysene-2,8-diol 
(5S ,lIS )-5,11 -
Dipropyl-
tox-256 5,6,11,12-
tetrahydrochr 
ysene-2,8-diol 
tox-322 Fluoranthene 206-44-0 
tox-323 Fluorene 86-73-7 
tox-33 Anthracene 120-12-7 
tox-369 
tox-374 
tox-396 
tox-397 
tox-41 
2-
Hydroxybenzo 
Ic 
)phenanthren 
e 
2-
Hydroxychrys 
ene 
2-Hydroxy-5-
methylchryse 
ne 
8-Hydroxy-5-
methylchryse 
ne 
Benzla 
)anthracene 
tox-425 Indeno[ 1 ,2,3-
cd )pyrene 
tox-43 
tox-44 
Benzo[a 
) carbazole 
BenzoIc 
1carbazole 
22717-94-8 
65945-06-4 
56-55-3 
193-39-5 
239-01-0 
Annex A 
Activity Fl F2 F3 F4 F5 F6 Predicted 
class Ring Ar Phe Het P3P Other Class 
o 1 0 o o 
o 1 0 o o 
o 1 0 o o 
o o o o 
1 0 o o 
o 1 0 o o 
o 1 0 o o 
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hydrocarbon 
Polycyclic Benzo[b 
aromatic lox-45 205-99-2 1 1 1 0 - - 0 0 
hydrocarbon jfluoranlhene 
Polycyclic Benzo[k 
aromatic lox-46 207-08-9 1 1 1 0 - - 0 0 
hydrocarbon 
jfluoranlhene 
Polycyclic Benzo[a 
aromalic lox-47 238-84-6 0 1 1 0 - - 0 0 
hydrocarbon 
jfluorene 
Polycyclic Benzo[b 
aromatic lox-49 jnaplho[2,1 - 239-35-0 0 1 1 0 - - 0 0 
hydrocarbon dllhiophene 
Polycyclic Benzo[b 
aromalic lox-50 jnaplho[2,3- 243-46-9 0 1 I 0 - - 0 0 
hydrocarbon dllhiophene 
Polycyclic 2,2',3,3',6-
aromatic tox-501 Penlachlorobi 52663-60-2 0 I 1 0 - - 0 0 
hydrocarbon phenyl 
Polycyclic 2,2',3',4',5'-
aromatic tox-502 Penlachloro- 150304-12-4 1 1 1 1 - 0 1 1 
hydrocarbon 4-blphenylol 
Polycyclic 2,2',3,4,5'-
aromatic tox-503 Penlachlorobi 38380-02-8 0 1 1 0 - - 0 0 
hydrocarbon phenyl 
Polycyclic 2,2',3',4',6'-
aromatic lox-504 Penlachloro- 150304- 10-2 1 1 1 1 - 0 I I 
hydrocarbon 4-biphenylol 
Polycyclic 2,2',3,4',6-
aromatic lox-505 Penlachlorobi 68194-05-8 0 1 1 0 - - 0 0 
hydrocarbon phenyl 
Polycyclic 2,2',3'.5'.6'-
aromalic lox-506 Penlachloro- 150304- 11 -3 1 1 1 1 - 0 I 1 
hydrocarbon 4-blphenylol 
Polycyclic 2.2'.3.5'.6-
aromatic lox-507 Pen lachlorobi 38379-99-6 0 1 1 0 - - 0 0 
hydrocarbon phenyl 
Polycyclic 2.2'.4,4'.5-
aromatic tax-50S Pen lachlorobi 38380-01 -7 0 1 1 0 - - 0 0 
hydrocarbon phenyl 
Polycyclic 2.2',4.5.5'-
aromatic lox-509 Penlachlorobl 37680-73-2 0 1 1 0 - - 0 0 
hydrocarbon phenyl 
Polycyclic Benzo[ghi 
aromatic tox-51 191 -24-2 0 1 1 0 - - 0 0 
hydrocarbon 
jperylene 
Polycyclic 2.2'.4'.6.6'-
aromatic tox-510 Penlachloro- 1 1 1 1 0 I 1 
hydrocarbon 4-biphenylol 
Polycyclic 2.2'.4.6.6'-
aromatic lox-51 1 Pentachlorobl 56558- 16-8 I 1 1 0 - - 0 0 
hydrocarbon phenyl 
PolYCYClic 2'.3.3'.4.4'-
aromatic tox-512 Pen tachloro- 150975-80-7 U - - - - - - -
hydrocarbon 2-blohenvlol 
Polycyclic 2',3,3',4'.5'-
aromatic tox-513 Pentachloro- 149589-55-9 1 I 1 I - 0 I 1 
hydrocarbon 4-blphenvlol 
Polycyclic 2.3.3'.4'.5-
aromatic tox-514 Pentachloro- 152969- 1 1-4 1 1 1 I - 0 1 1 
hydrocarbon 4-biphenvlol 
Polycyclic 2'.3.3'.4'.5-
aromatic tox-515 Pentachloro- 192190-09-3 1 1 1 1 0 1 1 
t)ydrocarbon 4-biohenvlol 
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Polycyclic 2',3,3',4',6'-
aromatic tox-516 Pentachloro- 192190-10-6 1 1 1 1 - 0 1 1 
hydrocarbon 4-biphenylol 
Polycyclic 2',3,3'.5',6'-
aromatic tox-517 Pentachloro- 189578-02-7 1 1 1 1 - 0 1 1 
hydrocarbon 4-biohenvlol 
Polycyclic 2,3,3',5,6-
aromatic tox-518 Pentachlorobi 74472-36-9 0 1 1 0 - - 0 0 
hydrocarbon ohenvl 
Polycyclic 2,3',4,4',5-
aromatiC tox-519 Pentachloro- 170946- 11 -9 1 1 1 1 - 0 0 0 
hydrocarbon 3-biphenvlol 
Polycyclic Benzo[c 
aromatic tox-52 )phenanthren 195-19-7 0 1 1 0 - - 0 0 
hydrocarbon e 
Polycyclic 2',3',4,4',5-
aromatic fox-520 Pentachloro- 150975-81-8 1 1 1 1 - 0 0 0 
hydrocarbon 3-biohenvlol 
Polycyclic 2,3,4,4',6-
aromatic tox-521 Pentachlorobi 74472-38-1 0 1 1 0 - - 0 0 
hydrocarbon phenvl 
Polycyclic 2' ,3,4' ,5.5'-
aromatic tox-522 Pentachloro- 149589-56-0 1 1 1 1 - 0 1 1 
hydrocarbon 4-biphenvlol 
Polycyclic 3,3',4,4',5-
aromatic tox-523 Pentachlorobi 57465-28-8 0 1 1 0 - - 0 0 
hydrocarbon phenyl 
Polycyclic 3,3',4',5,5'-
aromolic tox-524 Pentachloro- 130689-92-8 1 1 1 1 - 0 1 1 
hydrocarbon 4-biohenvlol 
Polycyclic 
aromatic tox-528 Phenanthrene 85-01 -8 0 1 1 0 - - 0 0 
hydrocarbon 
Polycyclic Benzo[a 
aromatic tox-53 50-32-8 1 1 1 0 - - 0 0 
hydrocarbon )pyrene 
Polycyclic Benzo[e 
aromatic tox-54 192-97-2 1 1 1 0 - - 0 0 
hydrocarbon )pyrene 
Polycyclic 
aromatic tox-563 Pyrene 129-00-0 0 1 1 0 - - 0 0 
hydrocarbon 
Polycyclic (5R ,11 R )-
aromatic 5,11-Diethyl-
hydrocarbon; tox-205 5,6,11.12-
1 1 1 1 - 1 - 1 
Phenol fetrahydrochr ysene-2,8-diol 
Polycyclic (55 ,115)-5,11 -
aromatic Diethyl-
hydrocarbon; tox-206 5,6,11 ,12- 1 
1 1 1 - 1 - 1 
Phenol fefrahydrochr I vsene-2,8-diol 
Polycyclic 5, ll -frans -
aromatic Diethyl-
hydrocarbon; fox-216 5,6,11.12- 1 
1 1 1 - 1 - 1 
Phenol tetrahydrochr ysene-2,8-diol 
Polycyclic 6-
aromatic 
hydrocarbon; tox-400 Hydroxytetrali 1125-78-6 0 
1 1 1 - 0 1 1 
Phenol n 
Polyether tox-74 Bisphenol A ethoxvlote 68140-85-2 0 
1 1 0 - - 1 1 
Pteridine tox-325 Folic acid 59-30-3 1 1 0 0 0 0 
143 
Annex A 
Chemical class 10 Substance CAS Nr. 
ActlvHy Fl F2 F3 F4 F5 F6 Predict ed 
class Rln 9 Ar Ph eH et P 3P Other Class 
Purine lox-10l Caffeine 58-08-2 1 1 0 0 0 0 
Pyrazole tox-560 Propylpyrazol 1 1 elriol 
1 0 - - 1 1 
Pyrethrin; lox-261 Empenthrin Pyrelhroid 
54406-48-3 0 1 0 - 1 - 0 0 
Pyrethrin; tox-403 Imiprolhrin ~ethroid 
72963-72-5 0 1 0 - 1 - 0 0 
Pyrelhrin; tox-527 Permethrin Pyrethroid 
52645-53-1 0 1 1 0 - - 0 0 
Pyrethrin; tox-542 d -Phenolhrin ~elhroid 
26002-80-2 0 1 1 0 - - 0 0 
Pyrelhrin; lox-553 Prallethrin Pyrethroid 
23031-36-9 0 1 0 - 1 - 0 0 
Pyrelhrin; tox-7 d-trans ~ethroid Allethrin 584-79-2 
0 1 0 - 1 - 0 0 
Resorcylic aci dtox-633 
lactone; Phenol 
a-Zearalanol 26538-44-3 1 1 1 0 0 0 
Resorcylic aci dtox-635 lactone; Phenol Zearalanone 
5975-78-0 1 1 1 0 0 1 
Resorcylic aci dtox-636 a-Zearalenol 36455-72-8 lactone; Phenol 
1 1 1 0 0 1 
Resorcylic acid lox-634 laclone; Phenol b-Zearalanol 
42422-68-4 1 1 1 0 0 1 
Resorcylic acid lox-638 b-Zearalenol 71030- 11 -0 lactone; Phenol 
1 1 1 0 0 I 
Resorcylic acid lox-637 Zearalenone locI one; Phenol 17924-92-4 
1 1 1 1 - 0 1 1 
1.3-
Siloxane lox-253 Diphenyllelra methyldisiloxa 56-33-7 1 1 0 0 
0 1 
ne 
1.3-
Siloxane lox-155 Dibenzyltetra methyldisiloxa 1 1 0 0 
0 0 
ne 
Steroid. tox-267 Epitestosteron 
nonphenolic e 481 -30-1 
1 0 0 1 0 1 
Steroid. 50-
non phenolic tox-218 Dihydrotestost 
521 -18-6 I 0 0 1 0 1 
erone 
Steroid. tox-554 Progesterone no~henolic 57-83-0 
1 0 0 I 0 I 
Steroid. tox-580 Testosterone 
nOnQhenolic 58-22-0 
1 0 0 1 0 1 
Steroid. 50-
nonphenolic tox-24 Androslane- 1852-53-5 
1 0 0 1 0 1 
30. 17b-diol 
Steroid. 50-
nonphenotic tox-25 Androstane- 571 -20-0 
I 0 0 1 0 1 
3b.17b-diol 
Steroid. tox-435 
non phenolic Mestranol 72-33-3 
1 1 0 0 0 1 
Steroid. tox-125 
nonphenolic Cholesterol 57-88-5 
1 0 0 1 0 1 
Steroid. tox-5 
non phenolic Aldosterone 52-39-1 
I 0 0 I 0 1 
Steroid. 3-
nonphenolic tox- 161 Deoxyestradio 2529-64-8 
1 I 0 0 0 1 
I 
St eroid. Dexamethaso 
no nphenolic tox-166 50-02-2 
1 0 0 I 0 1 
ne 
Ste raid. Corticosteron 
no nphenolic tox-134 50-22-6 
1 0 0 1 0 1 
e 
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Steroid. tox-573 b-Sitosterol 
nonphenolic 
83-46-5 1 0 0 1 0 1 
Steroid. 5b-
nonphenolic tox-219 Dihydrotestost 571 -22-2 
I 0 0 1 0 1 
erone 
Steroid. tox-162 3-
nonphenolic Deoxvestrone 
53-45-2 1 I 0 0 0 1 
16b-Hydroxy-
Steroid. 16-methyl-
nonphenolic tox-398 17b-estradiot 
3434-79-5 I I 0 0 0 1 
3-methyt 
ether 
Steroid. tox-495 non~henolic Norethynodrel 68
-23-5 1 0 0 I 0 1 
1.3-
Diacetoxy-
Steroid. 17a-ethinyt-
non phenolic tox-153 
7a-methyl- 1 1 I 0 - - 1 1 
1.3.5( 10)-
estratrien-17b-
01 
1.3-
Dibenzoyloxy-
Steroid. 17a-ethinyl-
nonphenolic tox-154 7a- methyl-
1 I 1 0 - - 1 1 
1.3.5(10)-
estratrien-17b-
01 
14-
Steroid. tox-157 Dehydroestra 
nonphenolic diol-17b 3-
35664-58-7 1 I 1 0 - - 1 1 
methvl e ther 
14-
Steroid. tox-159 Dehydroestro 
nonphenolic ne 3-methyl 
17550-11 -7 0 1 I 0 - - 0 0 
ether 
Steroid. lox- I 65 Dehydroepla 
nonphenolic ndrosterone 53-43-0 
1 1 1 0 - - 1 1 
Steroid. 2-
non phenolic tox-19 Amlnoestralri 
17522-06-4 1 1 1 0 - - 1 1 
en-17b-ol 
Steroid. 4-
nonphenolic tox-20 Aminoestralri 
17522-04-2 I 1 1 0 - - 1 I 
en-17b-01 
Steroid. 3b-
non phenolic tox-23 Androstanedi 
25126-76-5 1 I 0 - 1 - 1 1 
01 
Steroid. 5b-
nonphenolic lox-26 Androstane- 1851 -23-6 
0 I 0 - 1 - I I 
30. 17b-diol 
Sieroid. 5b-
non phenolic lox-27 Androstanedl 5982-99-0 0 
1 0 - I - 0 0 
one 
Steroid. tox-277 17b-Estradiol no~henolic 3-acelale 4245-41 -4 1 
1 I 0 - - I I 
Steroid. tox-278 Estradiol 
norlQhenolic benzoate 50-50-0 I 
1 1 0 - - I I 
St eroid. Estradiol 
no n..Q..henolic lox-279 dlocelate 3434-88-6 1 
I I 0 - - 0 0 
SI eroid. 50-
no nphenolic tox-28 Androstane- 846-46-8 
0 I 0 - I - 0 0 
3.17-dione 
Sle roid. 17b-Estradiol 
no nphenolic to x-280 3-methvl 1035-77-4 1 
1 1 0 - - I I 
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ether 
Steroid. tox-289 Estrone 3-
nonphenolic acetate 
901-93-9 1 1 1 0 - - 0 0 
Steroid. 50-
non phenolic tox-29 Androstane-
53-41-8 0 1 0 - 1 - 1 1 
3a-ol-17-one 
Steroid. tox-290 Estrone 3-
nonphenolic methyl ether 
1624-62-0 0 1 0 - 1 - 0 0 
Steroid. tox-291 Estrone-3-
nonphenolic sulfate 
481-97-0 0 1 1 0 - - 1 1 
Steroid. 
4-
nonphenolic tox-30 
Androstenedi 1156-92-9 1 1 0 - 1 - 1 1 
01 
Steroid. 5-
non phenolic tox-31 
Androstenedi 521-17-5 1 1 0 - 1 - 1 1 
01 
Steroid. 2-
nonphenolic tox-317 
Fluoroestratrie 101772-22-9 1 1 1 0 - - 1 1 
n-17b-01 
Steroid. 
4-
nonphenolic tox-318 
Fluoroestratrie 96607-54-4 1 1 1 0 - - 1 1 
n-17b-ol 
Steroid. 4-
nonphenolic tox-32 
Androstenedi 63-05-8 U - - - - - - -
one 
9a-Melhyl-14-
Steroid. tox-420 dehydroestro 
nonphenolic ne3- methyl 
0 1 1 1 - 0 1 1 
ether 
9a-
Steroid. tox-422 Methylestradi 
nonphenolic ol-17b3-
51242-32-1 0 1 1 0 - - 1 1 
methyl ether 
90-
Steroid. tox-424 Methylestrone 
nonphenolic 3-methyl 
31266-41 -8 0 1 1 0 - - 0 0 
elher 
9a-Methyl-14-
Steroid. tox-444 dehydroestra 
nonphenolic diol-17b 3-
88598-64-5 1 1 1 0 - - 1 1 
methyl ether 
7a-
Steroid. lox-446 Methylestrone 
nonphenolic 3-methyl 
10449-00-0 0 1 1 0 - - 0 0 
ether 
70-
Steroid. tox-448 Melhylestradi 
non phenolic ol-17b 3-
15506-01 -1 1 1 1 0 - - 1 1 
methyl ether 
70-Melhyl-14-
Steroid. tox-450 dehydroestro 
nonphenolic ne3-methyl 
35644-57-6 0 1 1 0 - - 0 0 
ether 
7a-Methyl- 14-
Steroid. tox-452 dehydroestra 
nonphenolic diol-17b 3-
35644-59-8 1 1 1 0 - - 1 1 
methyl ether 
Steroid. 
tox-456 3-
nonDhenolic Methoxvestriol 
1474-53-9 1 1 1 0 - - 1 1 
11b-
Steroid. tox-461 Methylestrone 
nonphenolic 3-methyl 
13667-04-4 0 1 1 0 - - 0 0 
elher 
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llb-
Steroid. tox-463 Methylestradi 18046-75-8 1 1 1 0 1 1 
non phenolic ol-17b 3-
- -
methyl ether 
11 b-Methyl-
Steroid. 
14-
non phenolic tox-465 
dehydroestro 88598-69-0 0 1 1 0 - - 0 0 
ne 3-methyl 
ether 
11 b-Methyl-
Steroid. 14-
non phenolic tox-466 
dehydroestro 88598-65-6 1 1 1 0 - - 1 1 
diol-17b 3-
methyl ether 
Steroid. tox-494 Norethindron 68-22-4 1 1 1 0 1 1 
nonphenolic 
- -
e 
Steroid. 
19-
non phenolic tox-496 
Noriestostero 434-22-0 1 1 1 0 - - 1 1 
ne 
Steroid. tox-556 Promegestero 34184-77-5 1 1 0 1 0 0 
nonphenolic 
-
-
ne 
Steroid. tox-61 Bisdesoxyestra 1217-09-0 1 1 1 0 0 
nonphenolic diol 
- - -
Steroid. phenolic tox-274 17b-Estradiol 50-28-2 1 1 1 0 0 1 
Steroid. phenolic tox-287 Estriol 50-27-1 1 1 1 0 0 1 
Steroid. phenolic tox-288 Estrone 53-16-7 1 1 1 0 0 1 
Steroid. phenolic tox-292 17o-Ethinyl estradiol 57-63-6 
1 1 1 0 0 1 
Steroid. phenolic tox-402 IC1182780 129453-61-8 1 1 1 0 0 1 
2-
Steroid. phenolic tox-380 Hydroxyestrad 362-05-0 1 1 1 0 0 1 
iol 
4-
Steroid. phenotic tox-381 Hydroxyeslrad 5976-61 -4 1 1 1 0 0 1 
iol 
Steroid. phenolic tox-476 Moxestrol 34816-55-2 1 1 1 0 0 1 
Steroid. phenolic tox-401 IC1164384 98007-99-9 1 1 1 0 0 1 
Steroid. phenolic tox-273 17a-Estradiol 57-91-0 1 1 1 0 0 1 
17-
Steroid. phenolic tox-160 Desoxyestrodi 53-63-4 1 1 1 0 0 1 
01 
3-
Steroid. phenolic tox-384 
Hydroxyestra-
1.3.5( 10)-trien- 3601 -97-6 1 1 1 0 0 1 
16-one 
Steroid. phenOlic tox-286 Estrotriene-3.6a.17b-triol 1229-24-9 
1 1 1 0 0 1 
llb-
Steroid. phenolic tox-119 Chloromethyl 71794-60-0 1 1 1 1 - 0 1 1 
estradiol 
Steroid. phenolic tox-135 Cortisol 50-23-7 0 1 0 - 1 - 1 1 
Cyc loprop[ 14 
R .150]estra-
Steroid. phenolic tox-139 1.3.5(10)- 73860-54-5 1 1 1 1 - 0 1 1 triene-3.17b-
diol. 3'.15-
dihydro-
Cycloprop[14 
Steroid. phenolic tox-140 S .15S]estro-1.3.5(10)- 105455-76-3 1 1 1 1 - 0 1 
1 
triene-3. 17b-
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diol. 3'.15-
dihydro-
14-
Steroid. phenolic tox- 156 Dehydroestra 58699-19-7 1 1 I 1 - 0 1 1 
diol-17b 
14-
Steroid. phenolic tox- l58 Dehydroestro 2119-18-8 1 1 I 1 - 0 I 1 
ne 
2-
Steroid, phenolic tox-17 Aminoestratri 107900-30-1 1 1 1 1 - 0 1 1 
ene-3,17b-diol 
4-
Steroid. phenolic tox-18 Aminoestratri 107900-31-2 1 1 I 1 - 0 1 1 
ene-3.17b-diol 
11 b-[2-(N.N -
Dimethylamin 
Steroid. phenolic tox-233 o)ethoxy)estr 1 1 a -1.3,5( 10) I 1 - 0 1 1 
triene-3.17b-
diol 
11 b-[3-(N.N -
Dimethylamin 
0)-
Steroid. phenolic tox-237 propoxy)estra 130043-38-8 1 1 I 1 - 0 1 1 
-1.3.5 (10)-
triene-3,17b-
diol 
Steroid. phenolic tox-265 16-Epiestriol 547-81 -9 1 1 1 1 - 0 1 1 
Steroid. phenolic lox-266 17 -Epiestriol 1228-72-4 1 1 1 1 - 0 1 1 
Steroid. phenolic tox-268 Equilenin 517-09-9 1 1 1 1 - 0 1 1 
Steroid. phenolic tox-269 Equilin 474-86-2 1 1 I 1 - 0 1 1 
Steroid. phenolic tox-272 16a-Estradiol 1090-04-6 1 1 1 1 - 0 1 1 
Steroid, phenolic tox-276 Estradiol 17- 1 I 1 1 0 1 1 acetate 
-
9-dehydro-
Steroid. phenolic tox-281 Estratetroene- 791-69-5 I I I 1 - 0 1 1 
3. 17b-diol 
Estro-
1.3,5( 10),6-
Steroid. phenolic tox-282 tetraen-17- 1 1 I 1 - 0 1 1 
one. 3-
hvdroxv-
Estro-
1.3.5( 10)-
Sieroid. phenolic tox-283 triene-3.1 7b- 7958 1-12-7 1 I I I - 0 1 1 
diol. 14a. 150-
eooxv-
Estro-
1.3.5(10)-
Steroid. phenolic tox-284 triene-3. 17b- 79645-49-1 0 I I 1 - 0 1 1 
diol.14b.15b-
eooxy-
Eslra-
Steroid. phenolic tox-285 1.3.5(10)- 16288-09-8 1 1 1 1 - 0 1 1 triene-
3.14. 17b-Irlol 
Steroid. phenolic tox-293 17b-Ethlnyl estradiol 4717-38-8 1 
1 1 1 - 0 1 1 
lla-
Steroid. phenolic tox-377 Hydroxyestrod 1464-61-5 1 1 I 1 - 0 1 1 
iol 
SterOid. phenoliC tox-378 llb- 5444-22-4 1 1 1 1 - 0 1 1 
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Hydroxyestrod 
iol 
14b-
Steroid, phenolic tox-379 Hydroxyestrod 60183-66-6 1 I I 1 - 0 1 1 
iol 
2-
Steroid. phenolic tox-382 Hydroxyestrotr 2259-89-4 1 1 1 1 - 0 1 1 
ien-17b-ol 
4-
Steroid. phenolic tox-383 Hydroxyestrotr 17592-89-1 1 1 1 1 - 0 1 1 
ien-17b-ol 
2-
Steroid. phenolic tox-385 Hydroxyes tron 362-06-1 1 1 1 1 - 0 1 1 
e 
(E )-170-
Steroid. phenolic tox-413 lodovinyles!ro 82123-96-4 1 1 1 1 - 0 1 1 
diol 
(Z )-170-
Steroid. phenolic tox-415 lodovinylestro 177159-09-0 1 1 1 1 - 0 1 1 
diol 
Steroid. phenolic tox-416 ll -Keto-9b- 0 1 1 1 0 1 1 estradiol 
-
Steroid. phenolic tox-417 16- 566-75-6 1 1 1 1 0 1 1 Ketoestrodiol 
-
Steroid. phenolic tox-418 160-lodoestrodiol 71765-94- 1 1 
1 1 1 - 0 1 1 
Steroid. phenolic tox-419 6- 571 -92-6 1 1 Ketoestrodiol 
1 I - 0 1 1 
90-
Steroid. phenolic tox-421 Methylestrodi 66463-44-3 1 1 1 1 - 0 1 1 
ol-17b 
Steroid. phenolic tox-423 90-Methvlestrone 71563-77-4 1 
1 1 1 - 0 1 1 
90-Methyl-14-
Steroid. phenolic tox-443 dehydroestro 88598-67-8 1 1 1 1 - 0 1 1 
ne 
90-Methyl-14-
Steroid. phenolic tox-445 dehydroestro 88598-63-4 1 1 1 1 - 0 1 1 
diol- 17b 
Steroid. phenolic lox-447 70-Methylestrone 10448-96- 1 1 
1 1 1 - 0 1 1 
70-
Steroid. phenolic tox-449 Methylestradi 10448-97-2 1 1 1 I - 0 1 1 
01- 17b 
70-Melhyl-14-
Steroid. phenolic tox-451 dehydroestro 88958-66-7 1 1 1 1 - 0 1 1 
ne 
70-Methyl-14-
Steroid. phenolic tox-453 dehydroestro 88598-62-3 1 1 1 1 - 0 1 1 
diol-17b 
Steroid. phenolic tox-462 lib-Methvlestrone 13667-06-6 1 1 
1 1 - 0 1 1 
llb-
Steroid. phenolic tox-464 Methylestradi 23637-93-6 1 I 1 1 - 0 1 1 
ol-17b 
(Z )-11b-
SterOid. phenolic tox-467 Methoxy-170- 177159-11-4 1 1 iodovinylestro 
1 1 - 0 1 1 
diol 
(E )- llb-
Steroid. phenolic tox-468 Methoxy- 170-iodovinylestro 90857-55-9 1 1 
1 1 - 0 1 1 
diol 
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2-
Steroid. phenolic tox-482 Nitroestratrien 6298-51 -7 1 1 1 1 - 0 1 1 
e-3.17b-diol 
4-
Steroid. phenolic tox-483 Nilroestratrien 6936-94-3 1 1 1 1 - 0 1 1 
e-3.1 7b-diol 
2-
Steroid. phenolic lox-484 Nilroestrotrien 5976-73-8 1 1 1 1 - 0 1 1 
-3-01- 17-one 
4-
Steroid. phenolic lox-485 Nitroestrotrien 5976-74-9 1 1 1 1 - 0 1 1 
-3-o1-17-one 
Steroid. phenolic tox-526 Pentolome 150748-24-6 1 1 1 1 - 0 1 1 
Steroid. phenolic tox-555 Prolome 99876-41 -2 1 1 1 1 - 0 1 1 
Steroid. phenolic tox-86 160-Bromo- 54982-79-5 1 1 1 1 0 1 1 17b-estrodiol -
Steroid. phenolic tox-89 Bufolame 150748-23-5 1 1 1 1 - 0 1 1 
Stilbene fox-221 Diethylstilbestr 56-53-1 1 1 1 0 1 0 01 
Stilbene tox-577 Tamoxifen 10540-29-1 1 1 0 0 0 1 
4,4'-
Diominosfilbe 
Stilbene tox-163 ne 66635-40-3 1 I 0 0 0 0 
dihydrochlori 
de 
0.0-
Stilbene tox-242 Dimethylslilbe 552-80-7 1 1 1 0 1 0 
strol 
Stilbene tox-434 Mestilbol 18839-90-2 1 1 1 0 1 0 
Diethylstilbestr 
Stilbene tox-222 01 dimethyl 130-79-0 1 I 0 0 0 1 
ether 
Stilbene 10x- l30 cis - 15690-55-8 1 I 1 0 1 1 Clomiphene - -
Stilbene tox- 131 trans - 911 -45-5 1 1 I 0 1 1 Clomiphene - -
(R )-4'-
Stilbene tox-147 Deoxyindenes 138515-00-1 1 I I 1 - 1 - 1 
Irol A 
(R )-5-
Stilbene tox- l48 Deoxyindenes 138515-02-3 1 1 1 1 - 1 - 1 
trol A 
(S )-4'-
Slilbene lox- lSI Deoxyindenes 138514-99-5 I 1 1 1 - 1 - 1 
Irol A 
(S )-5-
Stilbene lox-152 Deoxyindenes 138515-01 -2 1 1 1 1 - 1 - I 
trol A 
1,3-Diethyl-
Stilbene lox-198 6,4'-dlhydroxy- 1 1 1 1 - 1 - 1 2-
phenylindene 
3,3'-
Stilbene tox-212 Diethylstilbeslr 5959-71 -7 1 1 1 1 - 1 - 1 
01 
Stilbene lox-223 Diethylstilbestr 6052-82-0 1 1 1 1 - 1 - 1 01 epoxlde 
Diethylstilbestr 
Stilbene tox-224 01 1 1 1 1 1 1 1 phenonthren -
e 
Stilbene tox-228 Dihydroxydie t 7507-01 -9 1 1 1 1 - 1 - 1 
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hylslilbestrol 
Stilbene tox-405 Indanyldiethyl 1 1 1 1 - 1 - 1 
stilbestrol 
Stilbene tox-407 (R )- 115217-03-3 1 1 1 1 - 1 - 1 Indenestrol A 
Stilbene tox-409 (S )- 115217-04-4 1 1 1 1 - 1 - 1 Indeneslrol A 
Stilbene tox-411 (R )- 1 1 1 1 - 1 - 1 Indenestrol B 
Stilbene lox-414 (S )- 115217-06-6 1 1 1 1 - 1 - 1 Indenestrol B 
Stilbene tox-570 Resveratrol 501 -36-0 1 1 1 1 - 1 - 1 
Bis(m -
aceloxy) -
Stilbene tox-59 1.1.2- 100808-56-8 1 1 1 0 - - 1 1 
triphenylbut-
l - ene 
Stilbene lox-608 Tetramethylhe 74385-27-6 1 1 1 1 - 1 - 1 
xeslrol 
Stilbene; lox-574 4,4'- 659-22-3 1 1 1 0 1 0 Bisphenol Stllbenediol 
Stilbene; Phenol lox-575 4-Slilbenol 3839-46-1 0 1 1 1 - 1 - 1 
P -(7-Alloxyl) -
11 -
Stilbene; Phenol tox-8 ethyldibenzo- 85850-86-8 1 1 1 1 - 1 - 1 
[b,f )Ihiepin-
100yl)phenol 
Stilbene; 
tox-568 Raloxifene 84449-90-1 1 1 1 1 - 1 - 1 Piperidine; Phenol 
Stilbene; lox-260 Droloxifene 82413-20-5 1 1 1 0 1 0 TriRhenylethylene 
Sulfoxide lox-243 Dimelhyl 67-68-5 0 0 - - - - - 0 
sulfoxide 
Terpene lox-481 Nerolidol 7212-44-4 0 0 0 0 0 0 
Terpene lox-128 Cineole 470-82-6 1 0 0 1 0 0 
Telrahydrophena lox-258 Doisynoeslrol 15372-34-6 1 1 0 0 0 1 
nlhrene 
3-
Hydroxybenzo 
Thiophene lox-368 [b 1 1 1 1 - 1 - 1 
)naphlho[2.1-
d)lhiophene 
3-
Hydroxybenzo 
Thiophene lox-370 [b 1 1 1 1 - 1 - 1 ]phenanthro[ 
2.3-
d]lhiophene 
Triazine lox-557 Prometon 1610-18-0 1 1 0 0 0 0 
2-Chloro+ 
Triazine lox- ll0 amino-6- 6190-65-4 U isopropylamin - - - - - - -
0-1.3.5 Iriazine 
2-Chloro-4.6-
Triazine tox- 115 diamino-S - 3397-62-4 U - - - - - - -
Iriazine 
2-Chloro-4-
Triazine lox- 116 ethylamlno-6- 1007-28-9 0 1 1 0 - - 0 0 
amino-l .3.5-
Iriazine 
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2-Chloro-4-
ethylamino-6-
Triazine tox-117 
( 1-
hydroxyisopro 142179-80-4 0 
I I 0 - - 0 0 
pyllamino-
1.3.5-triazine 
2-Chloro-4-
isopropylamin 
Triazine tox-118 0-6-(1 - 142200-36-0 0 1 hydroxyisopro I 0 - - 0 0 
pylaminol-
1.3.5-triazine 
Triazine tox-558 Propozine 139-40-2 0 1 1 0 - - 0 0 
Triazine; Aromatic tox-37 
amine Atrozine 
1912-24-9 1 1 0 0 0 0 
Triphenylethylene tox-627 Triphenylethyl 58-72-0 I I 0 0 0 I ene 
4-
Triphenylethylene tox-399 Hydroxytamo 68047-06-3 1 1 I 0 I 0 
xifen 
Triphenylethytene tox-132 Clomiphene 50-41 -9 1 I 0 0 0 I citrate 
Triphenylethylene tox-610 Toremifene 89778-27-8 1 I 0 0 0 I citrate 
3-(Alloxyll - IO-
ethyt-ll -(4-
Triphenylethylene tox- II hydroxypheny 85850-85-7 I I I 1 - 1 - I 
I}dibenz[b.f 
loxepln 
3-(Alioxyl}- lO-
Triphenylethylene tox-12 ethyl- I 1- 85850-82-4 I I I 0 - - I I phenyldibenz 
orb.! lthiepin 
Triphenylethylene tox-124 Chlorotamoxif 77588-46-6 0 I I 0 I I en 
- -
3-(Alloxyll - ll -
ethyl- l 2-
Triphenylethylene tox-13 phenyl6H - 85850-84-6 I I 1 0 - - I I 
dibenzo[b.f 
lIhlocin 
3-(Alloxyll- IO-
Triphenylethylene tox- 14 ethyl- I 1- 83807-07-2 I I phenyldibenz[ I 0 - - I I 
b.floxeoin 
3-(Alloxyl}- ll -
ethyl-12-
Triphenylethylene t ox- IS phenyl 5.6-dihydroxydibe 85850-83-5 1 
I I 0 - - I I 
nz(a.e 
IlcYclooctene 
3-(2.3 
Dihydroxypro 
Triphenylethylene t oX-211 poxy} - IO-ethyl- I 1- 85850-89-1 I I I 0 - - I I 
phenyldibenz[ 
b.floxeoin 
5.6-Dlhydro-8-
[2-
( dlmethylamin 
Triphenylethylene t ox-217 olethoxy)-12- 85850-78-8 1 I 1 0 - - I 1 ethyl-ll-
phenyl-
dibenzo[a.e)c 
yclooctene.h 
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ydrale (1 :4) 
3-[2-
(Dimelhylomi 
no)elhoxy)-
Triphenylelhylene lox-234 l1 -elhyl-12- 85850-79-9 1 1 1 0 - - 1 1 
phenyl) -6H -
dibenzo[b.f 
lIhioctin 
3-[2-
(Dimelhylomi 
Triphenylethylene lox-235 
no)elhoxy)-
10- elhyl- ll - 85850-76-6 1 
1 1 0 - - 1 1 
phenyldibenz[ 
b.f 10xeoin 
7-[2-
(Dimelhylomi 
Triphenylethylene lox-236 
no)elhoxy)-
11 - elhyl- l 0- 85850-77-7 1 
1 1 0 - - 1 1 
phenyldibenz[ 
b.f Ithieoin 
4-[1 .2-
Triphenylelhylene lox-250 
( Diphenyl- l -
butenyl))phen 100808-55-7 1 1 1 0 - - 1 1 
01 acetate 
4-[1 -
(Diphenylmet 
II riphenylelhylene lox-252 hylene) propyl 82333-68-4 1 1 1 0 - - 1 1 
)phenol 
ocelole 
3-[( 100Elhyl-
11 -(p-
hydroxypheny 
Triphenylelhylene lox-298 I)dibenzo[b.f )oxepin-3- 85850-93-7 1 1 1 1 - 1 - 1 
yl)oxy)-1.2-
propanediol. 
hydrate (4 :1) 
3-[( 100Elhyl-
11 -(p-
hydroxypheny 
Triphenylelhylene lox-299 I) dibenzo[b.f 85850-94-8 1 1 1 1 - 1 - 1 
)thiepin-3-
yl)oxy)-1.2-
orooanediol 
3-[( ll -Elhyl-
12-(p -
hydroxypheny 
Triphenylelhylene 10x-300 1)-6H -dibenzo[b.f 85864-54-6 1 1 1 1 - 1 - 1 
)lhioc in-3-
yl)oxy)-1.2-
orooanediol 
3-[(6-Elhyl-5-
(p -
hydroxypheny 
1)-11.12-
Triphenyle lhylene I ox-3D 1 dihydrodibenz 85850-95-9 I 1 1 1 - 1 - 1 
o[o.e 
)cyclooc len2-
yl)oxy)-1.2-
orooonediol 
Triphenylelhylene I ox-324 Fluorolomoxif 7361 7-96-6 0 1 1 0 1 1 - -en 
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Chemical class 10 Substance CASNr, 
ActlvHy Fl F2 F3 F4 F5 F6 Predicted 
class Rln gA r Ph e He t P3 Pother Class 
4'-Hydroxy-
Triphenylethylen e tox-375 2,3- 1 1 diphenylinden 1 1 -
1 - 1 
one- l 
6'-Hydroxy-
Triphenylethylene tox-376 2,3-diphenylinden 1 
1 I 1 - 1 - 1 
one- l 
T riphenylethylene tox-437 Methoxytamo 1 1 I 0 - - 1 1 
xifen 
Triphenylethylene tox-440 Methylfamoxif 73617-95-5 1 1 1 0 - - 1 1 en 
3-Methoxy-10-
methyl- I 1-
Triphenylethylene tox-457 phenyldibenz 85807-06-1 U - - - - - - -
o[b,n thiepin 
i (l6bl 
2-(2-
Methylphenylj 
Triphenylethylene tox-458 -3-phenyl-6- 1 1 1 1 - 1 - 1 
hydraxyinden 
e 
l -Methyl-6-
Triphenylelhylene tox-459 hydraxy-2,3-diphenylinden 1 
1 1 1 - 1 - 1 
e 
Mono-m -
Triphenylethylene tox-471 aceloxy- l ,I ,2-trlphenylbut- 82333-69-5 1 
1 I 0 - - 1 1 
l -ene 
Triphenylethylene tox-474 Monahydroxy tamoxifen 68392-35-8 1 
1 I I - 1 - 1 
Triphenylethylene tox-486 Nitromifene 10448-84-7 1 1 I 0 - - 1 1 
Phenol. 4-[3-
(2dimethylami 
nojethoxy]-
Triphenylethylene tox-530 11 - 85850-81 -3 1 1 I 1 - 1 - I 
elhyldibenzo[ 
b.f ]thioctin-
12-vll 
Phenol,4-[7-
(2-
dimethylamin 
Triphenylethylene tox-531 ojethoxy]-II - 85850-74-4 1 1 1 1 - 1 - 1 
ethyldlbenzo[ 
b.f ] thiepin- IO-
I vll-
Phenol. 4- [2-(2 
dime thylamin 
oj-e thoxy]-6-
Triphenylethylene tox-532 ethyl- l 1,1 2-dihydro- 85850-75-5 I 1 
I 1 - 1 - I 
dibenzo[a,e 
]cycloocten-
5-vll -
Phenol, 3-[2-
dimethylamln 
oethoxy]- IO-
Triphenylethylene t ox-533 ethyl- 4- 85850-80-2 1 1 I 1 - 1 - 1 
hydroxypheny 
I dibenzo-[b.f 
Iloxeoin 
Triphenylethylene t ox-534 Phenol, 4-[1 -[4-[2- 96474-35-0 1 I I I - I -
I 
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Chemical class 10 Substance CAS Nr. 
Activity Fl F2 F3 F4 F5 F6 Predicted 
class Rln gA r Ph e He t P3 Pother Class 
(dimethylamin 
o)ethoxy)phe 
nyl)-2- phenyl-
l -butenyl)-3-
methvl-, (E )-
Phenol, 4-( I, 
Triphenylethylene tox-535 2-diphenyl- l - 69967-79-9 1 1 1 1 - 1 - 1 
butenvll-
Phenol, 4-(1 Z 
Triphenylethylene tox-536 )- 1.2-diphenyl- 69967-80-2 1 1 1 1 - 1 - 1 
l -butenvll -
Phenol, 4-[2-
Nitro-2-
phenyl-l -[4-
Triphenylelhylene tox-537 [2- 107144-84-3 1 1 (1 pyrrolidinyl) 1 1 - 1 - 1 
ethoxy)phenyl 
]elhenyl]phen 
vI. IE 1-
Phenol, 4,4'-
Triphenylethylene tox-538 (2-phenyl- l - 91221 -46-4 1 1 butenylidene) 1 1 - 1 - 1 
bis-
Pyrrolidine, 1-
[2-[4-(1 -(4-
methoxyphen 
Triphenylethylene tox-564 YI) -2-nitro-2- 77413-87-7 1 1 I 0 - - 1 1 
phenylethenyl 
]phenoxy]eth 
vll -, IE I 
Bis(p -
acetoxy)-
Triphenylethylene tox-60 1.1.2- 100808-54-6 1 1 I 0 - - 1 1 
triphenylbut-
l - ene 
Triethylamine, 
2-[p -[6-
methoxy-2-
Triphenylethylene tox-620 phenyl-3- 64-96-0 U - - - - - - -
inden-3-
yl)phenoxy) 
hydrochloride 
1.1,2-
Triphenylethylene tox-626 Triphenylbul- 63019-13-6 1 1 1 0 - - I 1 
l -ene 
p -(2-(Alloxyl)-
6-ethyl-ll ,12-
Triphenylethylene; t 
Phenol ox-IO 
dihydrodibenz 
o[a,e 85850-87-9 I 1 1 1 - 1 
- 1 
)cyclooctene--
5- vllohenol 
p -(3-(Alloxyl)-
ll -e thyl-6H -
Triphenylethylene; t 
ox-9 dibenzo[b.f 85850-88-0 1 1 1 1 - I - 1 Phenol )thlocin-12-
yl)phenol 
hemihvdrate 
Triphenylethylene; t ox-478 Nafoxidine 1845- tl-O 1 1 0 0 0 1 Stilbene 
Triphenylmethane t ox-539 Phenolphthal 77-09-8 1 1 I 0 1 0 ein 
Triphenylmethane t ox-540 Phenolphthali 81 -90-3 1 1 1 0 1 0 n 
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Chemical class 10 Substance CAS Nr. 
Activity Fl F2 F3 F4 F5 F6 Predicted 
class Ring Ar Phe He t P3P other Class 
4-Elhyl-7-
hydroxy-3-
Other tox-297 (methoxyphe 5219-17-0 1 1 1 0 1 0 nyl) 2H -1-
benzopyron-
2-one 
3-[ ( IO-Ethyl-
11 -
phenyldibenz 
o-[b.f lthiepin-
Other tox-311 3-yl)oxYl - l.2- 85850-90-4 I I I 0 - - I I 
propanediol. 
complexed 
with isopropyl 
alcohol 2:1 
3-[(lI -Ethyl-
12-phenyl-6H -
dibenzo [b.f 
Other tox-312 lthiocin-3- 85850-92-6 I I I 0 - - I I 
yl)oxy)-1.2-
propanediol. 
hydrate 14:11 
3-[( 6-Ethyl-5-
phenyl- I 1.12-
dihydrodibenz 
Other tox-313 o[a .e 85850-91 -5 I 1 1 0 - - I I 
lcycloocten-
2-yl)oxYl-I .2-
orooanediol 
7-Quinolinol. 
l -elhyl- I .2-
Other lox-566 dihydro-3-(4 107144-83-2 1 I 1 1 - I - I 
hydroxypheny 
1l-4-melhyl-
6-Quinolinol. 
l -elhyl- l .2-
Other lox-567 dihydro-3-(4 107144-82-1 I I I I - I - I 
hydroxypheny 
11-4-methyl-
Other lox-613 Triaryl-oyrazole 1 I 
I 0 - - 0 0 
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ANNEX B 
Dataset extracted from the METI database [120] and used for the models 
developed in Chapter 5. Experimental label for both receptor binding affinity 
(RBA) and reporter gene assay (RA) is given (I = Inactive; A = Active) and dataset 
assignment is provided. 
10 Structure CAS Nr. Name RBA RA Set 
1/ 
1-001 I;;: 52-68-6 Trichlorfon I 1 Test 
HO 
CI 
CI 
1/ 
o- p= s 
1-002 / I 60-51-5 Dimethoate 1 1 Train )Y' 
H 
1/ 
o-p= o 
1-003 / I 62-73-7 Dichlorvos 1 1 Train 
::lo 
lo 
1-004 
° 
121-75-5 Malathon 1 I Train 
i / (0 s= p- o I /0 
\ f--0 -
1-005 ~ 0y 40596-69-8 Methoprene 
1 I Train 
° 
1-006 ~~~,~ 927-67-3 Propylthiourea I I Train 
1-007 
",-'0 96-29-7 2-Butanone I 1 Train oxime 
157 
1-008 
O).--OH 
Bf-\ Bf 
1-011 
1-013 
s 
1-015 
1-016 
1-017 
1-018 
~ o 1-019 
1-020 
1-021 
I~ 
1-022 O-P=O fl~ 
1-023 )-SL / 
-\ 1/ \ 
s 
631-64-1 
103-23-1 
137-26-8 
1983-10-4 
Dibromoacetic 
acid 
Bis(2-
elhylhexyl)adip 
ate 
Thiram 
Stannane, 
tributylfluoro-
16752-77-5 Methomyl 
116-06-3 Aldicarb 
919-86-8 Demeton-s-methyl 
5392-40-5 Citral 
97-77-8 
94-96-2 
126-73-8 
97-74-5 
Disulfiram 
2-Ethyl-1,3-
hexanediol 
Tributyl 
phosphate 
Bis(dimethylthi 
ocarbamoyl) 
sulfide 
Annex B 
Train 
Train 
A Val 
A Train 
Val 
Test 
Test 
Train 
A Test 
Train 
Train 
A Train 
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o~ Tris(2-1-024 115-96-8 chloroethyl)ph I I Train ~/o osphate 
CI~O/\~CI 
0 /"'--, Phorate (ISO); 
O,O-diethyl 
1-025 ~~-~-) 298-02-2 ethylthiomethyl I I Val phosphorodithi oate 
1-026 HO~ 107-21-1 
Ethylene I I Train OH glycol 
1-027 I 68-12-2 Dimethylforma I I Val O~N .......... mide(OMFA) 
CIJ-
1-028 96-12-8 
Oibromochloro I I Test Br propane 
Br 
\ Dimethyl 
1-029 CI-{- 79-44-7 carbamyl I I Train chloride 
0 
1-032 C\) 2279-76-7 Tri-n-propyltin (TPrT) A I Train 
~sU 
/ 
1-033 \~~- 7786-34-7 Mevinphos = I I Val / \ f Phosdrin 1 00 
HN 
1-036 \ TI r-< 1113-02-6 Omethoate I I Val o - p- s 0 
I 
0 .......... 
o \ 
1-037 .......... ~s, ! 2540-82-1 Formothion I I Test 0) /1' 1 
j/ 
o- p= o 
1-038 / I 30560-19-1 Acephate I I Train HNy 
0 
-<-1-044 
CI Perchloroethyl I Train 127-18-4 I CI ene 
CI 
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1-045 
2-001 
2-003 
2-004 
2-005 
2-006 ~o 
2-007 
HO 
2-009 
HO 
2-010 
2-011 
I 
1461-22-9 Tributylchloros A 
tannane 
OH 
OH 
~ 
" 0 
50-28-2 beta-Estradiol 
53-16-7 Estrone 
50-27-1 Estriol 
57-63-6 
979-32-8 
50-50-0 
Ethynyl 
estradiol 
Estradiol 
valerate 
beta-Estradiol-
3-benzoate 
beta-Estradiol 
0
\ r\ 63042-18-2 3-benzoate J 17-n-butyrate 
1743-60-8 beta-Estradiol 17-acetate 
OH 
1474-53-9 Estriol 3-methyl ether 
1624-62-0 
Estrone 3-
methyl ether 
A 
A 
A 
A 
A 
A 
A 
A 
A 
Annex B 
Val 
A Test 
A Train 
A Train 
A Val 
A Train 
Train 
A Train 
A Val 
A Train 
A Train 
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o 
2-013 HO 
HO 
2-014 
o~ 
2-015 HO \_-<OH 
0 
2-016 HO 
'~' 
0 
2-017 ~o;;ob-," 
2-016 
q 
OH 
2-019 
O==< 
OH 
2-020 0>-, 
HO 
113-38-2 
Estradiol 
dipropionate 
72-33-3 Mestranol 
313-06-4 
41164-36-7 
7696-93-3 
4956-37-0 
152-43-2 
901 -93-9 
69260-14-6 
beta-Estradiol 
17 -cypionate 
beta-Estradiol 
3-
carboxymethyl 
ether 
beta-Estradiol 
17-
hemisuccinate 
beta-Estradiol 
17 -enanthate 
17alpha 
Ethynyl 
estradiol-3-
cyclopentyl 
ether 
Estrone 
acetate 
Estriol 3-
carboxymethyl 
ether 
Annex B 
A A Val 
A A Train 
A A Val 
A A Test 
A A Train 
A A Test 
A A Train 
A A Train 
A A Val 
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2-021 
2-022 
OH 
2-024 
)-
2-025 0 0 
Ao 
2-026 
OH 
2-031 OH 
3758-34-7 beta-Estradiol 17 -propionate 
18650-87-8 Estriol 3-
benzyl ether 
805-26-5 
2284-32-4 
566-76-7 
566-75-6 
Estriol 16,17-
diacetate 
Estriol 
triacetate 
16alpha-
Hydroxyestron 
e 
16-
Ketoestradiol 
2-
A 
A 
A 
A 
A 
A 
362-05-0 Hydroxyestradi A 
01 
4-
5976-61-4 Hydroxyestradi A 
362-07-2 
01 
2-Methoxy-
beta-estradiol 
2-
1232-80-0 Hydroxyestriol 
A 
A 
Annex B 
A Test 
A Train 
A Train 
A Train 
A Val 
A Train 
A Test 
A Train 
Train 
Train 
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2-032 
2-033 
2-036 
2-037 
2-038 
2-039 
2-040 
2-041 
o 
2-045 
OH 
53-45-2 3- A Deoxyestrone 
4-
3131 -23-5 Hydroxyestron A 
e 
2-
362-08-3 Methoxyestron A 
e 
6alpha-
1229-24-9 Hydroxyestradi A 
571 -92-6 
2208-12-0 
35048-47-6 
01 
6-
Ketoestradiol 
6-
Dehydroestron 
e 
Estradiol-6-
(0-
carboxymeth 
yl)oxime 
A 
A 
A 
1476-34-2 6-Ketoestrone A 
474-86-2 Equilin A 
68-23-5 Norethynodrel A 
68-22-4 Norethrindrone A 
Annex B 
A Train 
A Train 
A Test 
A Train 
A Train 
A Test 
A Test 
A Val 
A Train 
A Train 
A Train 
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OH 
2-049 ~);Z};Cr, 
2-050 
2-052 
2-053 
2-054 
2-055 
2-056 
2-058 
63-05-8 
797-63-7 
315-37-7 
53-41-8 
Androstenedio 
ne 
Levonorogestr 
el 
Testosterone 
enanthate 
Androsterone 
5alpha-
1224-92-6 androstan-
3beta-ol 
57-83-0 Progesterone 
(11beta)-
11 ,21 -
50-22-6 Dihydroxypreg 
n-4-ene-3,20-
dione 
5alpha-
571 -20-0 Androstane-3beta,17beta-
diol 
53-43-0 
Dehydroepian 
drosterone 
3604-87-3 Ecdysone 
Annex B 
Test 
A Train 
A Train 
Train 
A A Train 
Train 
Train 
A A Val 
A A Train 
Train 
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2-061 
o={ 
0""'" o 
o 
2-062 
2-063 o 
2-064 
2-067 
HO 
2-068 ~, 
o 
2-070 o 
71 -58-9 
Hydroxymethyl 
progesteronea 
cetate 
84371-85-3 RU-486 
50-23-7 Cortisol 
434-22-0 Testosterone,l 9-nor 
OH 6990-06-3 Fusidic acid 
A 
A 
Estrone 3-
58534-72-8 hemisuccinate A 
(11 beta, 16alph 
a)-9-Fluoro-
11 ,17,21-
50-02-2 trihydroxy-16-
methylpregna-
l,4-dlene-
3,20-dione 
Annex B 
Test 
Train 
Test 
A Test 
Train 
A Test 
Train 
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2-078 
2-080 
H 
0 
2-082 
2-086 
520-85-4 
Progestrone, 
medroxy 
434-07-1 Oxymetholone A 
81-23-2 Dehydrocholic acid 
1424-00-6 Mesterolone 
5alpha-
846-46-8 Androstane-
3,17-<1ione 
5alpha-
566-65-4 Pregnane-
3,20-<lione 
5alpha-
1482-70-8 Androstane-
3,11,17-trione 
Sbeta-
1553-56-0 Cholanic acid-
3-one 
5alpha-
2089-06-7 Pregnane-
3,11 ,20-trlone 
A 
Annex B 
Val 
A Train 
Train 
Train 
Train 
Test 
Val 
Train 
Train 
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53-06-5 
64-85-7 
50-03-3 
Cortisone 
Deoxycorticost 
erone 
Hydrocortison 
e acetate 
52-01-7 Spironolactone 
57-85-2 
68-96-2 
302-23-8 
630-56-8 
Testosterone 
propionate 
Hydroxyproge 
sterone 
Hydroxyproge 
sterone 
acetate 
Hydroxyproge 
sterone 
caproate 
Annex B 
Val 
Val 
Train 
Train 
A Train 
Train 
Train 
Train 
167 
0 
2-097 
0 
2-098 0 
2-099 
o 
2-100 ''' ''''0 o~ 
0 
2-101 
50-04-4 
1816-85-9 
1045-69-8 
13609-67-1 
641-77-0 
Cortisone 
acetate 
11b-
Hydroxytestost 
erone 
Testosterone 
acetate 
Hydrocortison 
e-17 -butyrate 
21 -
Deoxycortisol 
6beta-
62-99-7 Hydroxytestost 
erone 
11beta-
382-44-5 Hydroxyandro 
152-58-9 
stenedione 
11 -
Deoxycortisol 
19-
510-64-5 Hydroxyandro 
stenedione 
Annex B 
Test 
Val 
Train 
Train 
Train 
Test 
Train 
Test 
Train 
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2-109 
2-110 0 
2-111 ~ all,,, ,. 
0 
HO 
2-112 
2-113 
2-114 
2-115 
56-47-3 
127-31 -1 
57524-89-7 
514-36-3 
1524-88-5 
Deoxycorticost 
erone acetate 
Hydrocortison 
e-9a-fluoro 
Hydrocortison 
e-17 -valerate 
Fludrocortison 
eacetate 
Fludroxycortid 
e 
3093-35-4 Halcinonide 
601 -57-0 
4-Cholesten-3-
one 
Annex B 
Train 
Train 
Test 
Val 
Val 
Test 
Train 
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2-116 
2-117 
2-118 
2-120 o 
2-121 o~ 
o 0 
2-123 
2-125 
2-126 
2-127 
11alpha-
80-75-1 Hydroxyproge 
sterone 
382-45-6 Adrenosterone 
11-
516-15-4 Ketoprogester 
one 
20alpha-
145-14-2 Hydroxypregn-
4-en-3-one 
d-Aldosterone 
52910-82-4 21-
hemisuccinate 
4-Androsten-4-
61630-32-8 01-3,17-dione 
acetate 
Deoxycorticost 
10215-74-4 erone 21-
hemisuccinate 
1097-51-4 
16alpha,17alp 
ha 
Epoxyprogeste 
rone 
Deoxycorticost 
4319-56-6 erone 21 -
glucoside 
Annex B 
Train 
Train 
Test 
Train 
Val 
Val 
Test 
Train 
Train 
170 
2-128 
2-129 
HO 
2-130 
2-131 
2-132 
\\ __ OH 
-~ 
o 
o 
o~ 
"'1, 
IIOH 0 
.,,:< 
OH 0 
~o 
0 
1105.02-8 Corticosterone 
sulfate 
6678·14-4 Hydrocortison e 21-caprylate 
6beta· 
16355-28-5 Hydroxycortiso 
ne 
Hydrocortison 
2203-97-6 e 21-
hemisuccinate 
16alpha-
1239-79-8 Methylprogest 
erone 
2668-66-8 
1662-06-2 
6alpha-Methyl-
11beta 
hydroxyproges 
terone 
4-Pregnene-
17alpha,20bet 
a-diol·3-one 
Annex B 
Train 
Train 
Val 
Train 
Val 
Train 
Test 
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0 
2-135 
0 
2-146 HO 
3-001 
3-002 
3-003 
3-004 
3-005 
HO 
3-006 
3-007 
3-009 
Reichstein's 
substance 
17-alpha,21 -
640-87-9 Dihydroxypreg 
n-4-ene-3,20-
dione 21 -
acetate 
15262-86-9 Testosterone isocaproate 
Testosterone 
1180-25-2 beta-d-
glucuronide 
17230-88-5 Danazol 
108-95-2 Phenol 
123-07-9 4-Ethylphenol 
645-56-7 4-n-Propylpehnol 
1638-22-8 p-Butyl phenol 
4-n-
14938-35-3 Amylphenol 
p-n-
2446-69-7 Hexylphenol 
4-
1987-50-4 Heptylphenol 
104-43-8 4-Dodecyl-phenol 
Annex B 
Val 
Val 
Test 
A Val 
Train 
Test 
Train 
A Train 
A A Val 
A A Train 
A A Test 
A A Val 
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~ 3-n-3-010 501 -24-6 Pentadecylphe I I Train OH 
nol 
HO-0-< para-3-011 99-89-8 Isopropylphen A I Test 01 
3-012 00-0-< 99-71-8 para-sec-Butylphenol A I Train 
3-013 00-0+- 98-54-4 p-(tert-Butyl)phenol A I Val 
3-014 oo~ 80-46-6 p-(tert-Phenyl) A A Test phenol 
3-016 ,,~ 104-40-5 p-n- A A Train Nonylphenol 
3-017 yO" 140-66-9 4-tert- A A Train Octylphenol O-O-OH 4-3-018 1518-83-8 Cyclopentylph A A Train enol 
O-O-OH 4-3-019 1131-60-8 Cyclohexylphe A A Val nol 
HO-D-a 4-(1 -3-020 29799-07-3 Adamantyl)ph A A Test enol 
00-0+, p-3-021 402-45-9 Trifluoromethyl A I Train phenol 
F 
~" p-3-145 41492-05-1 Bromobutylbe I I Test nzene 
"M, 2,4-3-146 95-73-8 Dichlorotoluen I I Train e 
"--0+,, 4-3-147 5216-25-1 Chlorobenzotri I I Train chloride 
CI 
"-0+ 1-Bromo-4-3-148 3972-65-4 tert- I I Val butyl benzene 
,,-d'-< 2,4-3-149 50-84-0 Dichlorobenzoi I I Train cAcld 
- OH 
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" '( ) (" 3,4-3-150 51-44-5 Dichlorobenzoi I I Val cacid 
a ,-0-\ \ Ethyl 4-3-151 5798-75-4 bromobenzoat I I Train 
e 
0 
,~ p-3-152 29114-66-7 Fluorovaleroph I A Train enone 
r<' 2,4,6-3-153 CI N 6575-05-9 Trichlorobenzo I I Train 
nitrile 
-
CI 
* 
," peNB 3-154 CI f_' \\ 82-68-8 (pentachloronit I I Val robenzene) 
CI CI 
n ~~o ~ 3-155 N I 67747-09-5 Prochloraz I I Val L ,Ao " f" ~ N 
/o,/~ Tetrachlorvinp 3-156 P",-  CI 22248-79-9 I I Train 
_I 0 I hos = Gardona 
# 
CI CI 
"-O-\JJ 
O-(4-Bromo-2-
chlorophenyl)-
3-157 41198-08-7 
O-ethyl-S- I I Train propyl 
phosphorothio 
o~\~ ate; profenofos 
0 
3-249 ~:=b 118-60-5 2-Ethylhexyl salicylate I I Train 
3-251 < )' <~ 65405-77-8 cis-3-Hexenyl I I Test salicylate 
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) 
r' Ethyl 3-252 56424-77-2 Ocarboethoxy I I Train methylsalicylat () (~ e 
0 
"X)C 3-253 HO ~ I 93-76-5 2,4,5-T I I Train TIO CI 
0 
3-254 D;( 25013-16-5 Butylated I I Test "0 hydroxyanisole 
3-255 "U 95-76-1 3,4- I I Test 
CI I # NH2 
Dichloroaniline 
t " 
0=+ H 
3-256 
{I , 88-85-7 Dinoseb I I Train 
-
0=\ 
0 " 
3-257 ":QX CI I # N 0 
H 
330-54-1 Diuron I I Train 
3-259 -K~\ 21087-64-9 Metribuzin I I Val 
Br 
-
3-261 HO ~ I N 1689-84-5 
Bromoxynil I I Val 
Br 
I 
3-262 
" «-" 
1689-83-4 loxynil I I Test 
I 
~JJ''C\" 2,4-3-263 94-82~ Dichloropheno I I Train xybutyric acid 
175 
Annex B 
3-023 xCoo 585-34-2 3-Tert- I I Val butyl phenol 
3-024 eX- 89-72-5 ortho-sec- I I Train Butylphenol 
3-025 ( )' \ 90-00-6 2-Ethylphenol I I Train 
3-026 ~o, 620-17-7 m-Ethylphenol I I Train 
3-027 HO-o- 106-44-5 p-Cresol I I Test 
3-028 < )' I 88-18-6 2-ter- I I Test Butylphenol 
3-030 xO;( 96-76-4 2,4-di-tert- A I Train Butylphenol 
3-031 0- 499-75-2 5-lsopropyl-2- I I Train methyl-phenol 
~ Phenol, 3,5-3-035 1138-52-9 bis(1,1 - I I Test dimethylethyl)-
-HO 
3-036 !b- 89-83-8 Thymol I I Val 
3-037 ~ ;0, 732-26-3 2,4,6-Tri-t- I I Val butylphenol 
~ )' I Phenol,2-(1 ,1-3-038 1879-09-0 dlmethylethyl)- I I Train 4,6-dimethyl-
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"~ Phenol, 2,6-bis(1 ,1-
3-039 ~ 4130-42-1 dimethylethyl)- I I Train 4-ethyl-
00-0-( p-3-041 99-96-7 Hydroxybenzoi I I Train cacid 
3-043 OO-O--<~ 94-26-8 Butylparaben A A Train OOUy ~I o~ Hexyl p-3-044 1083-27-8 hydroxybenzo A A Train 
ate 
0 
p~ 
o I ~ n-Dodecyl 4-
3-045 2664-60-0 hydroxybenzo A A Train 
0 ate 
OOVy1 2-Ethylhexyl 4-3-046 ~ I 0 5153-25-3 hydroxybenzo A A Test ate 
0 
~ 
3-047 00-0-< 94-13-3 Propylparaben A A Test 
HO-D-\°~ n-Amyl-4-3-048 6521 -29-5 hydroxybenzo A A Train ate 
- 0 
"0Vy~ ~ I 0 ~ I Benzyl-4-3-049 94-18-8 hydroxybenzo A A Train 
ate 
0 
"0---0--<-< Isopropyl-4-3-050 4191 -73-5 hydroxybenzo A A Train ate 
0 OOUy 4-
3-051 ~ I 0 6521 -30-8 Hydroxybenzoi A A Val o~ c acid isoamyl ester 
3-052 HO-Q-OH 123-31-9 Hydroqulnone I I Test 
3-056 
-,-G-OH 622-62-8 4- I I Train Ethoxyphenol 
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3-057 0"" 18979-50-5 4- I I Train Propoxyphenol ~o 
"On p-3-058 ~I~ 18979-53-8 (Pentyloxy)phe A A Train nol 
0 
~~ 4-n-3-061 1# 24305-56-4 Dodecylresorci A I Train 
nol 
OH 
3-062 
-tOO" 98-29-3 4-tert-Butyl A I Train catechol 
3-063 ~O" 500-66-3 Olivetol I I Train oo~ 4-3-064 2138-20-7 Cycolhexylres A A Train orcinol 
HO r 1 Dihydroxycinn 3-065 63177-57-1 amicacld A I Train methyl ester 
L0-°" Ethyl 3,4-3-067 3943-89-3 dihydroxybenz I I Val oate 0 
3-070 ~rQ-0" 1034-01 -1 Octyl gallate A I Train 
OH 
3-071 >->-Q-0" 1138-60-9 Isopropyl A I Train gallate 
OH 
3-072 ~rO-o" 84375-71 -3 Hexyl vanillate I A Train 
f , \ Ethyl 2,4-3-073 HO 2524-37-0 dlhydroxy-6- A I Val methylbenzoat 
- 0 e 
OH 
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~ 3-074 ~ I o~ 6259-76-3 Hexyl I I Val salicylate 
0 
CI 00 - Methyl 3,5-dichloro-4-3-076 3337-59-5 hydroxybenzo I I Train ate 
hemihydrate 
CI 
oo)Q, 3-(4-3-077 10210-17-0 Hydroxyphenyl A I Train )-1 -propanol 
OH 
oo~ 4-3-079 3144-54-5 Hexanoylresor A A Train cinol 
"O~ 4-3-080 70-70-2 Hydroxyproplo I I Train phenone 
3-081 ) -L{)--o, 7400-08-0 p-Coumaric acid (PCA) I I Train 
-~ )--0-0" 4'-3-083 14392-69-9 Hydroxynonan A A Test ophenone 
-
Methyl 3-(4-
-3-084 5597-50-2 hydroxyphenyl I I Train 
HO \J 0 )proplonate 
ru 3-(4-3-085 17362-17-3 Hydroxyphenyl I I Val I I ~ OH )propionitrile 
N 
3-086 kC 59-50-7 4-Chloro-3- I I Train methylphenol HO 
0:" 4-Chloro-o-3-087 ~ I 1570-64-5 cresol I I Train 
CI 
3-088 MO' 6640-27-3 2-Chloro-4- I I Test methylphenol 
CI 
3-089 
"'-Q-" 88-04-0 4-Chloro-3,5- I I Train xylenol 
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"XX 2-Chloro-4,5-3-090 1124-04-5 dimethylpheno I I Train I 
HO 
,,~ ~' 3,4,5,6-3-092 576-55-6 Tetrabromo-o- I I Train cresol 
Br OH 
·CB ~ 5-Ethyl-5-(4-3-094 80866-89-3 hydroxyphenyl I I Train 
oAN 0 =-
OH )barbituric acid 
H 
3-095 D" 615-74-7 6-Chloro-m- I I Val cresol 
OH 1-<-0-0 • Methyl 4-3-096 14199-15-6 hydroxyphenyl A I Test acetate 
HO 
3-097 o~o. 501-97-3 Phloretic acid I I Train 
~~ 4-(4-3-098 5471 -51 -2 Hydroxyphenyl I I Test )-2-butanone 
'O~O' 4-(2-3-100 56718-71-9 Methoxyethyl)- I I Test phenol 
3-102 CI ( ) 108-90-7 
Chloro- I I Train benzene 
CI-0-C1 
para-
3-103 106-46-7 Dichlorobenze I A Val 
ne 
"D" 
m-
3-104 541 -73-1 Dichlorobenze I I Train 
ne 
" c( ) 0-3-105 95-50-1 Dichlorobenze I I Val ne 
)CC 1,2,4-3-106 120-82-1 Trichlorobenze I I Train CI I # CI ne 
cp-c, 1,3,5-3-107 108-70-3 Trichlorobenze I I Train 
ne 
CI 
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:0- 1.2.3.4-3-108 CI f_' CI 634-66-2 Tetrachlorobe A I Train nzene 
,,-Q-" 1.2.3.5-3-109 634-90-2 Tetrachlorobe I I Train nzene 
CI 
"XX" 1.2.4.5-3-110 95-94-3 Tetrachlorobe I I Val nzene 
CI CI 
'~ 3-111 f_' CI 608-93-5 Pentachlorobe I I Test nzene 
CI CI 
< }-" 1.2-3-113 583-53-9 Dibromobenze I I Train ne 
"n" 
1.3-
3-114 108-36-1 Dibromobenze I I Train 
ne 
Br-Q-Br 
1,4-
3-115 106-37.0 Dibromobenze I I Test 
ne 
)8C 1.2.4-3-116 615-54-3 Tribromobenz I I Train Br ~ I Br ene 
'p-" 1.3.5-3-117 626-39-1 Tribromobenz I A Test ene 
Br 
'XC" 1.2.4.5-3-118 636-28-2 Tetrabromobe I I Val nzene 
Br Br 
,,-6-+-, 1.2-Dichlor0-4-3-119 328-84-7 (trifluoromethyl I I Val )benzene 
F 
,,~ 2.4-3-120 94-99-5 Dichlorobenzyl I I Train chloride 
CI 
,~, 2.4-Dichloro-1 -3-121 320-60-5 (triflouromethyl I I Test )-benzene 
F 
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~ F 
- I 3-122 434-64-0 Perfluorotolu8 I I Train F ~ ;) ! F ne 
F F 
3-123 "'~ ) 95-57-8 0- I I Val Chlorophenol 
3-125 'On 120-83-2 2,4- I I Train 
CI I # CI Dichlorophenol 
3-126 D" 583-78-8 2,5- I A Train CI ~ I OH Dichlorophenol 
3-127 Qo' 87-65-0 2,6- I I Test Dichlorophenol 
CI 
CI 
3-128 ? }-o, 591 -35-5 3,5- I I Train Dichlorophenol 
CI 
~ 2,3,4-3-130 CI f_' OH 15950-66-0 Trichloropheno I I Val I 
CI 
"p-" 2,3,5-3-131 933-78-8 Trichloropheno I I Train I HO 
:0- 2,3,6-3-132 933-75-5 Trichloropheno I I Val CI ~ ;) CI I 
"xxo, 2,4,5-3-133 95-95-4 Trichloropheno I I Train 
I 
CI CI 
" < to, 2,4,6-3-134 88-06-2 Trlchloropheno I I Test I 
CI 
,,~' 2,3,4,6-3-135 58-90-2 Tetrachloroph I I Train 
enol 
CI CI 
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* 
3-136 CI f_' OH 87-86-5 Pentachloro- I I Test phenol 
CI CI 
3-137 
< >-'" 
95-56-7 2- I I Train Bromophenol 
3-138 oon" 591-20-8 3- I I Train Bromophenol 
3-139 Br-o-OH 
106-41-2 4- I I Val Bromophenol 
oon 2,4-3-140 615-58-7 Dibromopheno I I Train 
BI I # Br I 
"-Q-0 " 2,4,6-3-141 118-79-6 Tribromophen I I Train 01 
Br 
~o 4-n-3-142 15499-27-1 Butylchloroben I I Train 
zene 
~. 4-n-3-143 ~I 51554-95-1 Amylbromobe I I Val nzene 
Br 
- / 3-144 76287-49-5 1-Bromo-4-n- I I Train \-{ heptylbenzene 
\ 
3-158 < ~~ 131 -11 -3 Dimethylphthal I I Val ate 
- 0 
~ 
3-159 ( ~~ 84-66-2 Diethylphthalat I I Test e 
o L 
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~ " di-N-3-162 131-18-0 Pentylphthalat A A Train ~)=b e 
0 
di(N-
3-163 84-75-3 hexyl)Phthalat A I Test 
~>=b e 
3-164 3648-21-3 
Diheptyl A I Train phthalate 
~)=b 
0 
o¢~ Didecyl 3-167 84-77-5 I I Val ~ o phthalate 
0 
c¢~ 1,2-Benzenedicarb 3-168 ~o 2432-90-8 oxylic acid, I I Train didodecyl 
ester 
0 
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3-172 
~ o 
1,2-
Benzenedicarb 
oxylic acid 
diisooctyl ester 
Annex B 
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~174 6< 
o 
1,2-
Benzenedicarb 
oxylic acid 
diisodecyl 
ester 
Annex B 
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o 
4376-18-5 mono-Methyl 
phthalate 
131-70-4 mono-n-
Butylphthalate 
4 Phthlate 
376-20-9 monoethylhex A 
yl 
85-68-7 Butylbenzyl 
phthalate A 
85-70-1 Butylphthalyl 
butylglycolate 
3319-31 -1 
1,2,4-
Benzenetricar 
boxylic acid 
tris(2-
ethylhexyl) 
ester 
Annex B 
A Train 
Train 
Val 
Train 
A 
Test 
Test 
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r 
3-186 
i---
3-187 
3-188 
3-189 
~>=b--</ 
0 
\ ~~ ~ 0 
o 
o 
~o 
l-<- n 0-(-
o 
o 
~190Q,~ 
o I ~ 
# 
o 
\ 
3-191 )--0--\ 
\ 0 
3-192 o < 
,,---)-0--< 
o 
3-193 
\ I\!~ 
;-o~-n _~_ 0 
'-
I 
I 
152 8-49-0 
Trihexyl 
trimellitate 
53894-23-8 Triisononyl trimellitate 
2694-54-4 Triallyl 
trimellitate 
1,3-
1459-93-4 Benzenedicarb 
oxylic acid 
dimethyl e~ter 
744-45-6 
120-61-6 
636-09-9 
Diphenyl 
isophthalate 
Dimethyl 
terephthalate 
Diethyl 
terephthalate 
1026-92-2 Diallyl 
tetephthlate 
I 
T 
Annex B 
-I I l 
I I Train 
I I Train 
-
Val 
Train 
A Test 
Val 
Train 
A Train 
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T'~,1 Terephthalic 3-194 6422-86-2 acid bis(2- I I Train ethylhexyl)este r 
>-0-(-\ ) Diphenyl 3-195 
()-o - 0 
1539-04-4 terephthalate I A 
Train 
3-196 \ ( ) 100-41-4 Ethyl benzene I I Val 
3-197 Q( 104-51-8 Butyl benzene I I Train 
3-198 ~'"' 104-13-2 4-Butylaniline I I Train 
3-199 ~,~ 33228-44-3 4-Pentyl- I I Train benzenamine 
H. N ~ 3-200 33228-45-4 4-N- I I Test Hexylaniline 
3-201 ~'-o-t 769-92-8 4-Tert- I I Train butylaniline 
"O~ 4-3-202 21643-38-9 Hexylbenzoic I I Test acid 
3-203 ,,~ 3575-31 -3 4-0ctylbenzoic I I Val acid 
3-204 ('Qo 6853-57-2 Benzaldehyde, 4-pentyl- I I Val 
0Q/ 4-3-205 38350-87-7 Heptylbenzoic I I Train acid 
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3-206 -0\--0 98-95-3 Nitrobenzene I I Train 
II o -
3-207 
-D-{ 99-99-0 para- I I Train Nitrotoluene 
3-208 ).-b 88-72-2 2-Nltrotoluene I I Val 
-0 -
3-209 ",M/o 121-14-2 2,4- I I Train 
W ~- Dinitrotoluene 0 0 
3-210 H2N---O-<~C 51-05-8 Procaine I I Train hydrochloride 
- 0 
)Dy1 2-Ethylhexyl-4-3-211 I ~ 0 21245-02-3 dimethylamino I I Train benzoate 
0 
T 
3-212 y~D)2: 13311-84-7 Flutamide I I Train 
, / H 
Linuron = 
3-213 /'Y''(JC 330-55-2 Lorox I I Train 
o ~ I 
CI 
"~ 
"'" ' 0[("" 
2,4-
3-215 94-75-7 Dichloropheno I I Train 
xyacetic acid 
CI 0 
3-216 ~ I L 34256-82-1 Acetochlor I I Val N 
- (0 
CI 
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3-217 ~~ \ ;) N CI ) '-\ 15972-60-8 Alachlor I I Train 
\/OXX' 3-218 ~O/\ c::? I 2921-88-2 Chlorpyrifos A I Val 
~CI ~ CI 
3-221 ~ I 
5300-03-8 Retinoic acid I I Train 
~ OH ~ ~ 
0 
( (-\ 1,2-3-223 528-29-0 Dinitrobenzen I I Test 
e )'= 0 
·0 
3-224 ()( 119-36-8 Methyl I I Train salicylate 
"O~ 3,4,5-3-225 527-54-8 Trimethylphen I I Train 01 
~ 3,5-bis[1 ,1-Dimethylethyl)-4-3-226 67845-93-6 hydroxybenzoi I I Train C acid 
0 hexadecyl 
ester 
* 
3-228 Br f_' Br 87-82-1 Hexabromobe I I Test nzene 
Br Br 
3-229 ~*O" 608-71-9 Pentabromoph I I Train enol 
Br Br 
CIVICI 
CI 
3-232 CI 
f , ;) 29082-74-4 Octachlorostyr I I Train ene 
- CI 
CI CI 
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/ 
< 
1,2-
Benzenedicarb 
3-233 117-82-8 
oxylic acid, I I Train ~ bis(2-methoxyethyl) \ 0 - ester o~o ~ If 
~'-O-(-< 4-Aminobenzoic 3-234 1814443-9 acid 1- I I Test methylethyl 
0 ester 
F-0---<\ 
4-
3-235 451-46-7 
Fluorobenzoic 1 1 Train 
acid ethyl 
0 ester 
~ -O-{~ 4-Nitrobenzoic 3-236 
./" \-11 0 
99-77-4 acid ethyl I 1 Train 
ester NH2 
~ }J 4-3-237 16245-79-7 Octylbenzena 1 1 Train mine 
1--0-" 3,4-3-238 2033-89-8 Dimethoxyphe I 1 Train nol 
t-O 2',3' ,4'-3-239 13608-87-2 Trichloroaceto 1 1 Test ~ If CI phenone 0 
H2N-0-\°~ n-Butyl-p-3-240 94-25-7 aminobenzoat A 1 Train e 
0 
~ p-
3-241 "~--O--< 94-12-2 Aminobenzoic 1 1 Train acid , propyl ester 
+O-<H p-3-242 
F \ II 455-24-3 Trifluoromethyl 1 1 Train benzoic acid 
F 0 
F~ alpha,alpha ,al 3-243 455-19-6 ph a-Trifluoro-p 1 1 Train tolualdehyde 
F 0 
F 
F 
I 
F 3,5-
-3-244 349-58-6 bls(Trifluorome 1 I Train 
F 
1 \ II 
thyl)phenol 
OH 
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3-245 }-o---(~ 120-48-9 Butyl 4- I I Train nitrobenzoate 
0"/( 4-3-246 828-27-3 (Trifluorometh A I Train ~ I F oxy)phenol 
HO 
>-d' Dimethyl 5-3-247 13036-02-7 hydroxyisopht I I Train halate 
\ OH 
~ Isoamyl 4-3-248 \-0--< NA (dimethylamin I I Train o)benzoate 
/ - 0 
0--< S.J Stannane, 3-264 4342-36-3 (benzoyloxy)tri A I Test f' ~ butyl-
- 0 
HO~ I 3-265 :x 537-98-4 Ferulic acid I I Train ~I (FA) OH 
I 
~ 
I ~/ 3-268 23950-58-5 Pronamide I I Train ~ CI 
0 
U' 3-270 /0,,/ I 55-38-9 Fenthion I I Val P, ~ / ° 
- 0 
3-272 H0-Q-NH2 123-30-8 
4- A I Train Aminophenol 
"XX"/ 3-274 I \/0,,- 299-84-3 Ronnel A I Train 
CI ~ 0/\ 
5 
3-275 x'C\" 120-36-5 Dichloroprop I I Train 
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3-276 "'"~cc, 95-80-7 Toluene-2,4- I I Train diamine 
3-277 < ) l 10~-7 Benzyl chloride I I Train 
Q Propoxur(ISO) ; 2-isopropyloxyph enyl N 
3-278 )-0 0--( 114-26-1 methylcarbam I I Test ate: 2-
- NH isopropoxyphe 
nyl 
methylcarbam 
ate 
I Monolinuron 
"'Q'X (ISO) : 3-(4-3-279 1746-81 -2 chlorophenyl)- I I Train 1-methoxy-1-
~ ° 
methylurea 
3-281 iJo0" 93-65-2 MCPP I I Train 
CI 
3-282 iJo~" 94-74-6 Mcpa I I Test 
CI 
3-283 ( )"' 95-53-4 ortho-Toluidine I I Test 
0 '" 3-284 '0,- I # /0' 97-02-9 2,4- I I Val 
W W 
Dinitroaniline 
° ° ( )(\ N, N-Diethyl-3-3-285 134-62-3 methylbenzam I I Train Ide 
3-286 
\-( 
I HN-Q-CI 150-68-5 Monuron I I Test 
I Crufomat 0 (ISO) : 4-tert-~/o ~ butyl-2-
3-287 " N/ \ I 299-86-5 chlorophenyl I I Train 
H ! ~ methyl methylphosph 
oramldate 
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HO 
3-288 "O~ ) 87-66-1 Pyrogallol A I Train 
HO 
3-289 ,,~o 
CI -,,--t 93-72-1 Silvex I I Val 
0 
3-290 ""~ ) 95-55-6 2- I I Train Aminophenol 
3-291 ~~ ) 120-80-9 Pyrocatechol I I Test 
3-292 ~D,", 591-27-5 3- I I Train Aminophenol 
"XX"/ Bromophos (ISO) ; 0-4-I '\ /0,,- bromo-2,5-
3-293 ~ /\ 2104-96-3 dichlorophenyl A I Test 
CI ° O,O-dimethyl s phosphorothlo 
ate 
I~~~'" Thiophanate-methyl; 1 ,2-d i-(3-
3-294 23564-05-8 methoxycarbo I I Val &~y~yo" nyl-2-thloureido)ben 
I ~ s ° zene 
~1~ S-Benzyl 3-295 26087-47-8 diisopropyl I I Train 
- s-~-)-
phosphorothio 
ate; iprobenfos 
,r-Q-{ p-3-297 100-00-5 Nitrochloroben I I Train zene 
3-298 H2\-Q 100-63-0 Phenyl I I Test HN hydrazine 
... D, .. meta-3-300 108-45-2 Phenylenedia I I Val mine 
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~ 
3-301 U' 122-14-5 Fenitrothion /0,,/ I 0· I I Test /'---0 ~ 
-0 
~ 
3-303 \-o-l-~-OH 140-56-7 Fenaminosulf I I Train I \ ;j N ° 
3-306 h"~L, 6164-98-3 Chlordimeform I I Val ~I CI 
r-): HO ° 
3-307 
"o-<_y-{ 21435-27-8 SER-TYR I I Val 
~o" Ethyl 4-3-308 17138-28-2 hydroxyphenyl I I Train 
/'---.0 
acetate 
,,~o" p-3-309 370-14-9 Hydroxymetha I I Train 
mphetamlne 
~ 
ooct 1,1 -bis{4-3-314 1844-00-4 Hydroxyphenyl A A Train I )-isobutane OH 
4-001 ( > ( > 92-52-4 Biphenyl I I Val 
4-002 (>()-CI 2051 -62-9 4-Chloro-1 ,1 '- A I Val biphenyl CI ( ) < ) 2-4-003 2051-60-7 Chlorobiphenyl I I Train (PCB 1) 
'0-0 3-4-004 2051-61 -8 Chlorobiphenyl I I Train 
- ~ j (PCB 2) 
Br---\ ) < )-Br p,p'-4-005 92-86-4 Dibromobiphe I I Train nyl 
4-006 F---\ ) < )-F 398-23-2 1,1 '-Biphenyl, I I Train 4,4'--difluoro-
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4-007 1-0-0-1 3001 -15-8 4,4'- A I Train Dilodobiphenyl 
4-008 < ) < r OH 92-69-3 p- A A Train Phenylphenol 
4-009 ( > ( )" 580-51-8 m- I A Val Phenylphenol 
4-010 ( )" ( ) 90-43-7 ortho- I I Test Phenylphenol 
~ OH 
I ~ 4,4-4-011 ~ 92-88-6 Dihydroxydiph A A Test 
I 
enyl 
#' 
HO 
6D 2,2'-4-012 1806-29-7 Dihydroxyblph I I Train enyl = 2,2'-\ j \ j Biphenol 
4-013 
~" 
HO \j \j 491-45-2 Phloroglucide I I Train 
OH OH 
4-014 CI ( ) ( /-OH 28034-99-3 
4-Hydroxy-4'- A A Train 
chlorobiphenyl 
HO-\ ) ( /-BI 4-(4-4-015 29558-77-8 Bromophenyl) A A Train phenol 
4-016 \-0-0- 16881-71·3 4'·Methoxy- A A Test o \ j \ j OH biphenyl-4·ol 
)(>(r" 4'-Hydroxy-4-4-017 58574-03·1 blphenylcarbo A I Train xylic acid 
N () ( r OH 4'·Hydroxy-4-4-018 19812·93-2 biphenylcarbo A A Val nitrile 
- -
3,3',5,5'· 
4-019 HO OH 2417-04·1 
Tetramethyl- A I Val )-i ~ (1,1 '-biphenyl)-4,4'-<liol 
\-\ ) ( ) 4-4-020 613-37·6 Methoxybiphe I I Val nyl 
H~>-O--O 1,1 '·Biphenyl· 4-021 \ j \ j 92-92-2 4-carboxylic I A Test acid 
0 
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4-022 QD 101-81-5 Diphenylmetha I I Train ne ~ # 
ov 4-4-023 101-53-1 (Phenylmethyl) A A Train HO ~ # -phenol 
~ 4,4'-4-024 620-92-8 Dihydroxydiph A A Train ~ # enylmethane HO OH 
~dr 4,4'-4-025 I 2081-08-5 Ethylidenebis A A Train pieno OH 
4-026 ~ I 599-84-4 4-alpha- A A Train Cumylphenol OH 
4-027 8 80-05-7 BisphenolA A A Val 
-
V OH 
8 2,2-bis-(4-4-028 77-40-7 Hydroxyphenyl A A Train 
-
)-butane 
\ J OH 
./' 
C 2,2-bis(4-4-029 6807-17-6 Hydroxyphenyl A A Test 
- )-4-methyl-n-
\ J OH pentane 
"( 
:) 
4,4'-(1-
4-030 f '\ 1571-75-1 Phenylethyllde A A Test OH ne)blsphenol 
-C 
198 
4-031 
HO OH 
HO 
4-032 
HO OH 
4-033 F--f--+----< OH 
F 
F F 
4-034 HO 
OH 
4-035 
4-036 
27955-94-8 
81 -92-5 
1478-61 -1 
tris(Hydroxyph 
enyl)ethane 
2-[bis(4-
Hydroxyphenyl 
)methyl)benzyl 
alkohol = 
Phenolphthalol 
4,4'-
(Hexafluoroiso 
propylidene)di 
phenol 
4,4'-
843-55-0 Cyclohexylide 
1943-97-1 
3236-71-3 
nebisphenol 
4,4'-
(Octahydro-
4,7-methano-
5H-lnden-5-
ylidene) 
blsphenol 
4,4'-(9-
Fluorenylidene 
)diphenol 
Annex B 
A A Val 
A A Train 
A A Train 
A A Val 
A Train 
A Val 
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4-038 OH 
4-039 
4-040 
4-041 
4-042 OH 
4-043 
CI 
603-45-2 Rosolic acid 
143-74-8 Phenol red 
126-00-1 
13595-25-0 
2167-51 -3 
4,4-bis(4-
Hydroxyphenyl 
) valerie aeid 
4,4'-(1 ,3-
Phenylenediis 
opropylidene) 
bisphenol 
4,4'-(1,4-
Phenylenediis 
opropyllidene) 
bisphenol 
37693-01 -9 Clofoetol 
Annex B 
A Train 
Train 
A Train 
A Train 
A Test 
A Test 
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4-044 ~TI~ HO~~~ OH 
o 
HO 
4-045 
4-047 
4-048 
4-049 
4-050 
4-051 
Br 
80-09-1 
4,4'-
Sulfonyldiphen 
01 
5-phenyl-5-(p-
2784-27-2 hydroxy)pheny 
I-hydantoin 
2303-01 -7 m-Cresol 
purple 
4,4'-
A 
A 
1844-01 -5 Dihydroytetrap A 
henylmethane 
4,4'-
Methylenebls 
5384-21-4 (2,6- A 
5613-46-7 
dimethylpheno 
I) 
2,2-bis-(3,5-
Dimethyl-4-
hydroxyphenyl 
)-propane 
Tetrabromobls 
79-94-7 phenol A 
(TBBP-A) 
A 
Annex B 
A Train 
Train 
A Train 
Train 
Train 
A Test 
Tr In 
20 1 
H 
4-052 
4-053 
4-054 
HO 
CI CI 
4-060 
""--0 0/ 
4-063 
CI 
4-064 
CI CI 
4-065 
CI 
4-066 
CI 
79-97-0 
2,2-bis(4-
Hydroxy-3-
methylphenyl) 
propane 
2,2'-
1745-89-7 Diallylbisphen 
olA 
1,1,3-tris(2-
Methyl-4-
1843-03-4 hydroxy-5-
tertbutylphenyl 
)butane 
72-43-5 Methoxychlor 
Dichlarodiphen 
72-54-8 yldichlaroetha 
ne 
72-55-9 p,p'-DDE 
53-19-0 a,p'-DDD 
3424-82-6 a,p'-DDE 
Annex B 
A A Train 
A Test 
A Train 
A Val 
Train 
Test 
A A Train 
A Train 
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4-067 C 115-32-2 Dicofol = A I Train 
-
Kelthane 
HO \ J CI 
CI- -CI 
CI 
4-068 C p? 80-06-8 Chlorfenethol I I Train 
-
\ J CI 
OH 
HO 
2,2-Bis(p-
"J; 
4-069 ~ 2642-82-2 chlorophenyl)e I A Test 
I thanol # 
CI 
CI ~ ~ 
CI 
I I 4,4'-4-070 ~ ~ 90-97-1 Dichlorobenzh I I Train ydrol 
OH 
!u 
HO f 
" 
3,3,3-tris (4-
4-071 CI 2168-06-1 Chlorophenyl) I I Val propionic acid 
-
I 
~ 
# 
CI 
N~ C ~ 
f 
" 
3,3,3-tris (4-
4-072 CI 2172-51 -2 Chlorophenyl) I I Train 
propionitrlle 
-
I 
~ 
# 
CI 
203 
4-076 
NH, 
4-0BO 
OH 
4-0B1 
4-082 
4-0B3 
- 0 0 -
4,4',4"-
3010-BO-B Trlchlorotrityl 
alcohol 
2990-17-2 
27064-94-4 
119-56-2 
22B56-62-B 
p,p'-
Dibromodiphe 
nyl 
trichloroethane 
Chloro bis-(4-
fluorophenyl)m 
ethane 
4-chloro-a-
phenyl-
benzenemetha 
nol 
4,4'-
Ethylenedi-m-
toluidine 
103-29-7 Bibenzyl 
84-16-2 Hexestrol 
84-17-3 
Dehydrostilbes 
trol 
1226-42-2 p-Anlsll 
Annex B 
Test 
Train 
A Train 
Test 
A A Train 
Test 
A A Train 
A A Train 
Test 
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/ 
o 
4-084 
I 
4-085 Sr 
4-086 
4-087 
4-088 
HO 
4-089 
o 
4-090 
HO 
4-091 
120-44-5 Desoxyanisoin 
4,4'-
35578-47-3 Dibromobenzil 
3,3'-
40101 -17-5 Dimethoxyben 
zil 
8enzyI2,4-
3669-41 -8 dihydroxyphen 
yl ketone 
Benzyl 4-
2491 -32-9 hydroxyphenyl 
ketone 
4825-53-0 Hexestrol 
dipropionate 
103-30-0 trans-Stilbene 
56-53-1 
dlethylstilbestr 
01 
Annex B 
Train 
Train 
Train 
A A Train 
A A Test 
A A Train 
Test 
A A Train 
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4-092 
4-093 I j "" 
HO 0 
HO 
4-094 
NH2 
H 
HO 
OH 
4-095 
4-096 
N~ 
HO 
4-097 
OH 
HO 
4-099 
\ 
10540-29-1 Tamoxifen 
68047-06-3 
836-44-2 
10083-24-6 
54760-75-7 
501 -36-0 
569-57-3 
4-
Hydroxytamoxi 
fen 
4-Amino-4'-
hydroxystilben 
e 
Piceatannol 
4,4'-
Diaminostilnen 
e 
dihydrochlorid 
e 
Resveratrol 
Chlorotrianlse 
ne 
Annex B 
A Train 
A Val 
A A Train 
A A Test 
Train 
A A Train 
A Test 
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130-80-3 
58-72-0 
119-61 -9 
1137-42-4 
117-99-7 
4-105 13020-57-0 
611 -99-4 
OH 
131 -56-6 
4-108 1470-79-7 
4-109 835-11 -0 
Diethylstilbestr 
01 dipropionale 
Triphenylethyl 
ene 
Benzophenon 
e 
4-
Hydroxybenzo 
phenone 
2-
Hydroxybenzo 
phenone 
3-
Hydroxybenzo 
phenone 
4,4'-
Dihydroxybenz 
ophenone 
2,4-
Dlhydroxybenz 
ophenone 
2,4 ,4'-
Trlhydroxyben 
zophenone 
2,2'-
Dihydroxybenz 
ophenone 
Annex B 
A A Val 
A A Train 
Train 
A A Test 
Val 
A A Train 
A A Train 
A A Val 
A A Val 
Train 
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,doc 2,3,4,4'-4-110 31127-54-5 Tetrahydroxyb A I Train I #' ~ I enzophenon HO OH 
,ffQ, 4,4'-4-111 90-96-0 Dimethoxyben I I Val zophenone 
" #' ~ ,/ o 0 
~~ 2,2',4,4'-4-112 131-55-5 Tetrahydroxyb A A Test enzophenone OH 
oodu" 4-Chloro-4'-4-113 42019-78-3 hydroxybenzo A A Train phenone 
,du" 4-Fluoro-4'-4-114 25913-05-7 hydroxybenzo A A Train phenone 
d'C OH 2,3,4-4-115 1143-72-2 Trihydroxyben A I Test zophenone OH 
CI ~ ~ CI 
I I 4,4'-4-116 ~ ~ 90-98-2 Dichlorobenzo I I Val phenone 
0 
"J: ~. 
4,4'-
4-117 3988-03-2 Dibromobenzo A A Train 
phenone 
f)°D 4-4-118 I #' I #, 831 -82-3 Phenoxypheno A A Train I 
HO 
00-0-1 ( ) Hydroquinone 4-119 103-16-2 monobenzylet A A Test her 
4-120 JY'Q 1965-09-9 4,4'- A A Val Oxydlphenol HO OH Qf)" 1-Chloro-4-4-121 ~ I I #, 7005-72-3 phenoxybenze I I Train ne 
0 
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4-122 ~:xv~h~' 51-48-9 L-Thyroxine I I Val 
I 
D°'Q p,p'-4-123 2050-47-7 Dibromodiphe I I Train nyl ether 
~ ~ 
4-124 26002-80-2 Fenothrin I I Train o \ j 
\ j 
_ ~o 
4-125 0-0 0 52645-53-1 Permethrin I I Test 
\ j 
9 
0 
4-127 f , 52315-07-8 Cypermethrin I I Val 
::~ -CI ~ 
0 N 
~ -::::r 0 ~ 4-128 0",.,0 I &" " 1836-75-5 Nitrofen I I Train 
I 
o· 
% 119446-68- Dlfenoconazol 4-129 (". ° "" I ~" I I Val 3 e NJ ~ # 0 
209 
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4-130 l~f°'C-D 79127-80-3 Fenoxycarb I I Train 
° N 0 H 
~ ~ OH 
I I 4-4-132 # ~ ~ 20426-12-4 Hydroxychalco A A Val ne 
0 
4-134 
( <"~Oo 
17355-11 -2 TYR-PHE I A Train y' f' NH2 HO\_ 
4-135 J-.!-h 579-56-6 Isoxsuprine I I Train 
o \ j hydrochloride o 0" 
-o-rO 4-4-137 Hof_' / - 1689-82-3 Hydroxyazobe A A Train nzene 
"oA 
4,4'-(1,3-
4-139 37677-93-3 Adamantanedi A A Train 
yl)diphenol 
OH 
H 
I 
~ 
# 
1,3,5-Trls(4-
4-140 15797-52-1 hyrdroxypheny A I Train 
~ I)benzene 
"O~ 
I 
~o. ~ 
HO OH 
-
\ j 
4-141 500-38-9 
Nordihydrogua A I Train iaretic acid 
-
HO \ j 
HO 
210 
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,pH 
'" .~~ 
4-142 HO--Q-FNH 
-
Ritodrine 
23239-51 -2 hydrochloride I I Train 
\ j 
OH 
HO ~ OH ~ OH 
I I 4-143 ~ ~ 60-82-2 Phloretin A A Train 
OH 0 
H 
HO ~ 
I 3,3,3',3'-HO #' Tetramethyl-
4-144 ~~ 
77-08-7 1,1'- A A Train 
spirobisindane 
-5,5' ,6,6'-tetrol 
HO ~ OH ~ OH 
I I 4-145 #' ~ ~ 961 -29-5 Isoliquirtigenin A A Val 
0 
HO 
f , 
- ~NH2 
l 
4-146 1050-28-8 TYR-TYR I I Train 
0 
~-< ) ") (" 
4-147 O''Q 2664-63-3 4,4'-Thiobls- A A Train phenol 
HO OH Q 4-1 48 
- HN-Q 102-06-7 
Diphenylguani I I Train dine 
HN--{ -
NH 
4-1 49 78-30-8 
Tris( o-cresyl) A I Train phosphate 
O~\ f , 
0 
21 1 
Annex B 
H ClO"l) Diphenyl-p-4-150 ~ I I # 1# 74-31-7 phenylenedia A I Train mine 
N 
H 
CI 
~ CI I ~N 
~ /-NV 
4-152 q ,,,\ -0-/\-< 65277-42-1 Ketoconazol I I Train 
H 0 f '\ N N 
- "----I 0 
~ - ,yO S-{1 -methyl-1-4-153 61432-55-1 phenylelhyl)pi I I Train peridine-1-carbothioate 
0 
~'---o-~-o-'"' 4,4'-4-154 80-08-0 Sulfonylbisben I I Val zenamine 0 
4-156 Clf) 122-39-4 Diphenyl I I Test amine 
N 
H 
1 O-Ethyl 0-4-0,;) nitrophenyl-
4-157 >-o-''l) 2104-64-5 phenylphosph I I Train onothioate ; EPN 
ClI /'yl Bensultap; N" 1 ,3-
4-158 17606-31-4 
bis{phenylsulfo A I Val 
nylthlo)-2-
i {N,Ndimethyla mino)propane 
'0' 
\ Leptophos 
-Q~! (ISO) ; 0-4-bromo-2,5-4-159 - ! ~ 21609-90-5 dichlorophenyl A I Train 
"\#'U 
0 -
melhylphenylp 
hosphorothioat 
e 
CI 
212 
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I 
4-160 M'V'il 33089-61 -1 Amitraz I I Train ~ n ~ I 
4-161 ~x 34123-59-6 Isoproturon I A Val N 0 
H 
HO-C>-O--OH 
142172-97- 2-(4-
4-162 2 Hydroxyphenyl 
I I Train 
)-5-pyrimidinol 
N 
4-163 Q-,b-o• 2051-85-6 Sudan orange A A Train G f "/I -
X 
2,2'-Thiobis[4-
4-164 OH 3294-03-9 
(1,1,3,3- A I Train ~ ~ Tetramethylbut I I yl)phenol # # 
s 
OH 
< ) ( ) N-Benzoyl-L-0 4-165 3483-82-7 tyrosine I I Test 
-
NH ethylester 
HO U 
H 
'0 .-? 4-166 oo~. - 49745-95-1 Dobutamine A I Train hydrochloride 
4-167 ,o--cS-~ --0- ! 74-39-5 Azo violet I I Test 
- N f " N' ~ 
- 0 
J70 ~oo 3,3'5-4-169 HO I # I 51-24-1 Trilodothyroac A I Test ellc acid 
I 
213 
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'XY~t HO 0 3,5,3'-Triiodo-4-170 ~ I I ~ 6893-02-3 L-thyronine I I Train HO I NH2 
I 
-
~ \ j H L-3,3',5'-4-171 5817-39-0 Triiodothyronin I I Test e H~ 0 
HO I 
~ I ~ CI 1 I Clomiphene 4-172 50-41-9 citrate (cis and A I Train 
~ ~ f'~ trans mixture) I I ~ ~ 0 
~ I H H 4-174  0 'y''Q 35367-38-5 Diflubenzuron I I Train 
CI 
9 Fentin 
4-177 Ho - sn-< ) 76-87-9 hydroxide A I Test 
6 
~ F ~ F 
- -
2,3,5,6-
4-179 2894-87-3 
Tetrafluoro-4- A I Val F \ j \ j OH (pentafluoroph enyl)phenol 
F F F F 
n 4,4'-4-182 728-87-0 Dimethoxyben I I Train zhydrol 
"0 ~ ~ 0/ 
~ 4,4'-4-189 101-77-9 Methylenebisb I I Train H2N ~ ~ NH2 enzeneamine 
~,f)0'Q,", 4,4'-4-190 101-80-4 oxybisbenzena I I Val mine 
214 
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4-191 
, ~O" 
,-0-0-0 " 22494-42-4 Diflunisal I I Train 
4-192 Br-< ) < ) 92-66-0 4- I I Test Bromobiphenyl 
{I' }-O--P 4-4-193 1144-74-7 Nitrobenzophe I I Train none 
6-<-0 Phenyl 4-195 {I '\ - 118-55-8 salicylate I I Train 
- 0 
CI 
{I '\ 
-
4-197 (I '\ 1620-21-9 Chlorcyclizine I I Train hydrochloride 
-r-N I~ 
""-N/ 
4-198 980-71-2 
Brompheniram I I Train ine 
N 
::l" 
-::Y 
I ~ 
~ F ~ F 
-
-
4-199 F F 434-90-2 
Decafluorobip I I Train 
\ j) \ j) henyl 
F F F F 
\ < ) < ) (1 ,1'-4-200 3218-36-8 Blphenyl)-4- I I Test carboxaldehyd e 
,~ m-4-201 CI # # 1016-78-0 Chlorobenzop I I Val henone 
0 
d'c p-4-202 134-85-0 Chlorobenzop I I Train henone CI 
215 
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* 
p-
4-203 90-90-4 Bromobenzop I I Test 
henone 
~ # Br 
4-204 < ) < ) < 92-91 -1 p- I I Train Acetylbiphenyl 
I 
0 ~ HO ~ 2,2'-Dihydroxy-
4-205 I I 131 -53-3 4- I I Train ~ ~ methoxybenzo phenone 
OH 0 
QoDy" 3-4-206 3739-38.Q Phenoxybenzo I I Train icacid 
0 
~ CI ~ CI Methanone, 
I I (2-4-207 # ~ 85-29-0 chlorophenyl) I I Train (4-
chlorophenyl)-
0 
~) 4-
4-210 }-o-\ 611 -95-0 Benzoylbenzoi I I Test c acid 
CI 
f 
" - 1-(4-4-211 - 303-26-4 Chlorobenzhy I I Train 
~ j dryl)piperazine Q 
4-212 
:) 
2051-90-3 
Dichlorodiphen I I Val 
f 
" 
ylmethane 
CI 
-CI 
~-) 4-
4-213 530-44-9 
(Dimethylamin I I Test \--0--\ o)benzopheno I - 0 ne 
216 
4·214 
4·215 
4·216 
4·217 
HO 
4-218 
4·219 1\ 0\......JN 
f 
4·220 
4·221 
4-222 
3457-48·5 
345·83·5 
324·74·3 
6554·98-9 
611 ·94·9 
24758-49-4 
632·51 ·9 
342·25-6 
4,4'· 
Dimethylbenzil 
4· 
Fluorobenzoph 
enone 
4· 
Fluorobiphenyl 
trans-4· 
Hydroxystilben 
e 
4· 
Methoxybenzo 
phenone 
4· 
Morpholinoben 
zophenone 
Tetraphenyleth 
ylene 
2,4'· 
Difluorobenzo 
phenone 
A 
A 
1607.57-4 Bromotrlpheny A 
lethylene 
Annex B 
Train 
Val 
Val 
A Train 
Val 
Train 
Train 
Train 
A Train 
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Q 
4-223 6 '-0 892-20-6 Triphenyltin A I Val hydride 
\ j 
~. 4-4-224 5731 -13-5 Ethylbiphenyl- I I Train 4'-carboxylic OH acid 
~ 4,4'-4-225 457-68-1 Difluorodlphen I I Train # ~ ylmethane F F 
'-..../ N 
I 
~ 
I 4,4'-
4-226 / N ~ ~ 
17078-27-2 Bis(dimethyla I I Train 
I 
mino)benzi! 
# 
0 
0 
0-< 
r-\ Stilbene, 
4-227 833-81-8 alpha-methyl-, I I Train 
- (E)-
0-<--0-" 4-4-229 2005-08-5 Chlorophenyl I I Val \ j benzoate 
0 )=O--O-{ 4,4'-4-230 787-70-2 Biphenyldicarb I I Test oxylic acid 
Ch - 150253-59- 4-4-231 1 Chloromethylst I A Train U ilbene CI 
Ch - trans-4-4-232 40200-69-9 Stilbenecarbox I I Train \ j , aldehyde 
0 
- I F 
\ j ! F 
3,3'-
4-233 F 1868-00-4 
Bis(lrifluorome I I Test 
-
thyl)benzophe 
none 
~ 0 
J-O-' 3,4-4-234 85118-07-6 Difluorobenzo I I Test 
(_) F 
phenone 
218 
4-235 
4-236 
CI 
F 
4-237 
4-238 
/ \ 
4-239 
F-+--+---<' 
4-240 
F-.j----jf--< 
F 
F 
3,3'-
345-70-0 Difluorobenzo 
109936-21 -
2 
phenone 
2-(4-
Chlorophenyl)-
1,1-
dlphenylethan 
01 
3,4'-
21084-22-0 Bis(trifluorome 
thyl)benzophe 
none 
4,41.4"-
A 
49757-42-8 Trlmethoxytrity A 
1171-47-7 
1095-77-8 
I chloride 
4,4'-
(Hexafluoroiso 
propylidene)bi 
s(benzoic 
acid) 
4 ,4'-
(Hexafluoroiso 
propylidene)dit 
oluene 
A 
A 
Annex B 
Train 
Val 
Val 
Train 
Train 
Test 
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4-241 
NH, 
F 
4-242 
H,N NH, 
4-243 
H, N 
4-244 F 
4-245 ,p°'QO" 
F 
4-247 
H, N 
4-249 
4-250 
1095-78-9 
611 -98-3 
19471-12-6 
579-39-5 
39634-42-9 
106246-33-
7 
4,4'-
(Hexafluoroiso 
propylidene )di 
aniline 
4,4'-
Diaminobenzo 
phenone 
3,3'-
Methylenedian 
iline 
4,4'-
Difluorobenzil 
4-(4-
(Trifluorometh 
yl)phenoxy)ph 
enol 
4,4'-
Methylenebis( 
3-chloro-2,6-
diethylanillne) 
1,3-615(4-
108464-88- fluorobenzoyl) 
6 benzene 
1,4-
3016-97-5 Dlbenzoylbenz 
ene 
Annex B 
A A Val 
Train 
Train 
Train 
A Train 
A Train 
Train 
Train 
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4-251 
NH, 
p 
4-252 o 
osY () 
4-253 ~~ 0 
4-256 
CI 
4-257 
Br 
4-258 ( ) / o 
4-259 
o 
F 
4-260 \ N' 
/ 
'0 
4,4'-(1 ,3-
2687-27-6 Phenylenediis 
?propylidene)b 
Isaniline 
5447-02-9 
3,4-
Dibenzyloxybe 
nzaldehyde 
49562-28-9 Fenofibrate 
Benzyl 4-
1889-71 -0 chlorophenyl 
ketone 
Benzyl 4-
2001 -29-8 bromophenyl 
ketone 
4-
54589-41-2 Benzyloxyben 
25650-13-9 
zophenone 
trans-1,2-
Bis(4-
f1uorobenzoyl) 
ethylene 
3,4-Dlmethyl-
42187-33-7 3'-
nitrobenzophe 
none 
Annex B 
A Train 
A Val 
Test 
Train 
Val 
Train 
A A Train 
Train 
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4-261 
/ 
o 
OH 
4-264 
j)Q 4-265 
"- # ~ ./' N N 
I I )=0 
4-270 HO~O 
4-271 
yo 
4-273 o~O 
4-276 
OH 
HO 
143130-82- Dimethyl cis-
9 stilbene-4,4'-
dicarboxylate 
cis-Stilbene-
133005-88- 4,4'-
6 dicarboxylic 
acid 
4,4'-Methylene 
101-61-1 bis(N,N'-dimethylaniline 
) 
Bisphenol A 
3539-42-2 O,O-Diacetic 
acid 
2,4-
bis(alpha,alph 
2772-45-4 a A 
dimethylbenzyl 
)Phenol 
2,2'-bis(4-(2,3-
1675-54-3 epoxypropoxy) phenyl)Propan 
e 
0-
596-27-0 Cresolphthalei A 
n 
Annex B 
Train 
Val 
Train 
Train 
Val 
Train 
Train 
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4-277 
4-279 
CI-+--<' \ 
4-281 
4-282 
4-284 
4-285 
519-73-3 
Triphenylmeth 
ane 
4,4'-
40615-36-9 Dimethoxytrityl 
chloride 
595-91 -5 Triphenylaceti C acid 
2,2,2-
A 
466-37-5 Triphenylaceto A 
phenone 
Tris-(4-amino-
467-62-9 phenyl)- A 
methanol 
3,3,3-
900-91-4 Triphenylpropi 
onicacid 
Annex B 
Test 
Train 
Val 
Train 
Val 
Test 
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q 4-288 HO I .;::7 I OH 
4-292 OOu 
0 
OH 
ft 
4-293 ~'  (j''-o 
o OH o~ 
/N~ 
-0 0 
4-295 
5-001 OH 
HO 
5-002 
5-003 / OH 
0 
5-004 
\ 
5-005 HO 
3,3',5-
51 -26-3 Triiodothyropr A 
opionic acid 
1596-67-4 L-Thyronine 
O-Mono-2,4-
10567-73-4 DNP-L-
tyrosine 
1,1 ,4,4-
1450-63-1 Tetraphenyl-
1,3-butadiene 
491 -80-5 Biochanin A 
486-66-8 Daidzein 
2-Carbelhoxy-
5,7-dihydroxy-
15485-76-4 4'-
methoxyisoflav 
one 
4',7-
1157-39-7 Dimethoxyisofl 
avone 
3',4',7-
465-63-2 Trihydroxyisofl 
avone 
A 
A 
A 
A 
A 
Annex B 
Train 
Train 
Test 
Val 
A Val 
A Train 
A Train 
Train 
A Train 
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5-006 
5-007 
5-008 
5-009 
HO 
5-011 
OH 
Annex B 
520-18-3 Kaempferol A A Train 
480-41 -1 Naringenin A A Train 
491-70-3 Luteolin A A Test 
7-Hydroxy-2-
6665-86-7 phenyl-4H-1- A Val benzopyran-4-
one 
480-16-0 Morin A A Val 
520-36-5 Apigenin A A Train 
6-
4250-77-5 Hydroxyflavon A A Train 
56-55-3 
50-32-8 
e 
Benz(a)anthra 
cene 
Benzo[a)pyren 
e 
A A Train 
Test 
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I 
~ 
~ Benzo[ e )pyren 
5-019 192-97-2 I A Train e 
# 
I # # 
0 
N 
-:P' 
5-020 ~ ~ I 57-24-9 Strychnine I I Train ~ ~ H 
4 
" 
< 
H .f N 
~ 
H 
5-021 m 135-19-3 2-Naphthol A I Test ~ ~HO 
M)" 6-Bromo-2-5-022 1## 15231-91-1 naphthol A A Train 
Br 
5-023 ~I 83-79-4 Rotenone I I Val \ j H 
o 0 -
5-024 ".~oJO 63-25-2 Carbaryl I I Train I # 
5-025 ~ I ## 0" 90-15-3 1-Naphthol I I Train 
m 5,6,7,8-5-026 1125-78-6 Tetrahydro-2- A I Train naphthol = 6-HO ~ Hydroxytetralin 
5-027 ~ 530-91-6 Tetrahydronap I I Train hthol-2 OH 
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H 
'( ~ I 
p-
5-028 145-50-6 Naphtholbenz A A Test 
~ ~ ein I # 
I 0 
# 
5-029 5:b-~ 6949-73-1 2-Hydroxy-9- A A Train fluorenone 
.!/ 
OH HO 
~ I r ~ 1,1'-
5-030 1096-84-0 Methylenedi-2- A I Test 
I C naphthol # 
5-031 
'-CO-P 52222-87-4 6-Benzoyl-2- A A Train HO _ , naphthol - 0 ~ 2-5-032 2443-58-5 Hydroxyfluore A A Val  ~ j OH ne 
5-034 m 1470-94-6 5- I I Val Hydroxyindan HO 
H 
~ OH 
5-035 I 490-46-0 L-Epicatechin A I Train ~ ~ OH HO 0 I ~ OH 
00 ~I 8-5-036 41175-50-2 Hydroxyjulolidi I I Train ne N 
5-038 (:((" 533-31 -3 Sesamol I I Train 
ill 6-5-039 580-16-5 Hydroxyquinoli I I Val HO # # ne 
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5-040 
5-042 
5-044 
fX)" ~.,.I#' #' 
1## 
HO 
2:t 0 
f 
- 0 
, 
O~ 
o 
OH 
OH 
6-Hydroxy-2-
6088-51 -3 naphthyl 
disulfide 
2-Hydroxy-4-
607-66-9 methylquinolin 
e 
1847-63-8 Nafoxidlne 
77-73-6 Dicyclopentadi ene 
303-45-7 Gossypol 
5,7-
480-40-0 Hydroxyflavon 
e 
517-28-2 Hematoxylin 
3-
577-85-5 Hydroxyflavon 
e 
Annex B 
A A Train 
Train 
A Test 
Train 
Train 
A Train 
A Train 
Train 
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5-050 
5-051 OH 
OH 
5-052 
5-054 
5-055 
5-056 
HO 
5-057 
5-058 
525-82-6 Flavone 
475-25-2 Hematein 
alpha-
604-59-1 Naphthoflavon 
e 
641-38-3 Alternariol 
487-26-3 Flavanone 
5-
491-78-1 Hydroxyflavon 
e 
529-44-2 Myricetin 
6051-87-2 5,6-Benzoflavone 
Annex B 
Val 
A Train 
Train 
A A Train 
Train 
Train 
A Val 
Train 
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HO 
OH 
528-48-3 Fisetin 
480-44-4 Acacetin 
38183-03-8 
7,8-Dihydroxy-
2-phenyl-4h-1 -
benzopyran-4-
one 
2.4,7-
7061-81-6 Trichlorofluore 
ne 
6297-11-6 2,7-Dichloro-9-
fluorenone 
7 -Hydroxy-4-
Annex B 
A Train 
A Test 
A Train 
Train 
Train 
575-03-1 (trifluoromethyl A Train 
)coumarin 
6-
6665-83-4 Hydroxyflavon A A Train 
e 
1 0420-73-2 ~-hloroflavone Train 
29976-75-8 ~ethYlflaVOne A Train 
230 
5-070 
\ 
5-071 
5-075 
-0 
5-077 
/ 
-0 
HO 
5-078 
/ 
o 
5-079 
5-081 HO 
6-
26964-24-9 Methoxyflavon 
e 
7-
22395-22-8 Methoxyflavon 
e 
491-67-8 Baicalein A 
3',4',7,8-
3440-24-2 Tetrahydroxyfl A 
22395-24-0 
29550-13-8 
avone 
3',4',7-
Tromethoxyfla 
vone 
5,6-Dihydroxy-
7-
methoxyflavon 
e 
6,7-
Dimethoxy-
A 
34334-69-5 3',4',5- A 
trihydroxyflavo 
ne 
3',4'· 
4143-62-8 Dimethoxyflav 
one 
3',4'-
4143-64-0 Dihydroxyflavo A 
ne 
Annex B 
Test 
Train 
Train 
Test 
Train 
Val 
Train 
Train 
Test 
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5-082 
HO 
5-083 
HO 
0/ 
I 
° 
()o OH 5-084 
I 
° 
0,,-
5-085 
"-0 
/ 0 ° 0,,-
-0 
\ H 
0 
5-086 
\ 
5-087 
/ 
-0 
\ 
0 
5-088 
5-089 
5-090 
437-64-9 
491-54-3 
62507-01-1 
73694-15-2 
855-96-9 
855-97-0 
973-67-1 
218-01 -9 
238-84-6 
4' ,5-Dihydroxy-
7-
methoxyflavon 
e 
4'-Methoxy-
3,5,7-
trihydroxyflavo 
ne 
3'-Benzyloxy-
5,7-dihydroxy-
3,4'-
dimethoxyflavo 
ne 
2'-Hydroxy-
2,4,4',5',6'-
pentamethoxy 
chalcone 
3',5-Dihydroxy-
4',6,7-
trimethoxyflav 
one 
3',4',5,7-
Tetramethoxyfl 
avone 
5,6,7-
Trimethoxyflav 
one 
Chrysene 
Benzo[aJf1uore 
ne 
Annex B 
A Train 
A Val 
A Train 
Train 
Test 
Train 
Val 
Train 
Train 
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OH 
66-76-2 Dicoumarin 
alpha-
6948-88-5 Naphtholbenz 
ein 
4-Methyl-7 -
90-33-5 hydroxycouma 
rin 
485-72-3 Formononetin 
4709-68-6 Benzhydrylide 
nefluorene 
1801-42-9 2,3-Diphenyl-
1-indenone 
alpha-
A 
A 
A 
596-01-0 Naphtholphtha A 
lein 
Annex B 
Train 
A Val 
Train 
A Train 
Val 
A Val 
A Train 
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NH2 
5-101 
NH 2 
6-001 
o 
HO 
6-002 
OH 
HO 
H 
6-004 
OH 
HO 
H 
6-005 
o 
HO 
6-006 
HO 
OH 
6-007 HO 
OH 
4,4'-(9-
15499-84-0 Fluorenylidene 
)dianiline 
17924-92-4 Zearalenone 
beta-
42422-68-4 Zearalanol 
beta-
71030-11-0 Zearalenol 
5975-78-0 Zearalanone 
479-13-0 Coumestrol 
446-72-0 Genistein 
A 
A 
A 
A 
A 
A 
Annex B 
Train 
A Train 
A Train 
A Val 
A Test 
A Val 
A Test 
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-(I 
6-008 
"'---< ~ 1912-24-9 Atrazine I I Train -< N- HN\ 
1-
m 6-010 59-31-4 2-(1 H)- I I Test Quinolinone o N H 
'I X 
3-(2-
(Diethylamino) 
6-011 (N 15776-59-7 ethyl)-7- I I Train hydroxy-4-
methylcoumari 
0 OH nhydrochloride HO ~ 0 0 7-
I Hydroxycouma 6-012 # # 01 
6093-71-6 rin-3- I A Train 
carboxylic acid 
ethyl ester 
0 
-~ 3-
6-013 6468-96-8 Phenylumbelllf A A Train 
- ~_)-OH erone 
6-014 
,,-q' 
0* 32809-16-8 
Procymldon I I Train 
~ ~ 6-015 o I # 36734-19-7 Iprodione I I Test >-?_Q c, 
0 
6-016 
CI >--~ )--')-h 50471-44-8 Vinclozolin I A Train 
CI 0 1-
CI CI 
6-017 C""""~"""C' 58-89-9 Lindane I I Train 
CI CI 
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6-018 
6-019 
6-022 
6-023 
6-024 
" Ji:" CI", CI CI 
'CI 
CI""'CI CI 
CI 
" "\ '}--" 
CI-"N I CI 
~;n.CI 
o hr CI 
=~" " ~
6-025 CI 
Cl 
6-026 
6-027 
2385-85-5 Mlrex 
143-50-0 Kepone 
52-86-8 Haloperidol 
60207-90-1 Proplconazole 
50-55-5 Reserpine 
60168-88-9 Fenarimol 
61 -82-5 
50-06-6 
Amitrol = 
Aminotriazol 
Phenobarbital 
Annex B 
Train 
A A Train 
Train 
Train 
Train 
A Train 
Train 
Train "Lin OANJ0=) 
r-__ -r ____ ~H------------------------~--------r_--------,------- I----~ 
:¢= 6-028 CI ~ C II ; =0 115-29-7 Endosulfan A Train 
CI 0 
CI 
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P 6-029 5: ~,,- ~ 122931-48- Rlmsulfuron I I Train ~ /h {'\ /"-- 0 
-0 
,N N,) 
N 
- 114369-43- Fenbuconazol 
6-030 I I Test 6 e \ j f '\ 
II 
CI 
-N /oyo 
6-032 
NyNH 
< S-=y~~ 17804-35-2 Benomyl I I Train 
° /o~ 
6-033 c( b 16069-36-6 Dicyclohexyl- I I Train 18-crown-6 
o~/o 
° 
6-035 0-(\ 2212-67-1 Mollnate I I Train 
N~N 
6-036 !Yl 1214-39-7 N-6-Benzyl I I Val 'u adenine LNH H ~ I 
H 
6-037 (N)=S 96-45-7 Ethylene I I Test thiourea N 
H 
=c \ N - 2-6-038 -)--0 612-96-4 Phenylqulnolin I I Train e 
Yc 4-(4-6-039 14548-48-2 Chlorobenzoyl I I Test )pyrldlne N~ # CI 
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,-__ ,_------------~--------------,-------.---------r-~--~I----() <=b 6·040 
0y~~ 
~ OH 6·041 
o 
6·043 
~s ~! L(LOH 
6·045 HO 
6·046 -)~o 
r N o \ 
2·Phenyl-4h· 
3,1· 
1022-46-4 benzoxazin-4. 
one 
19315·93..0 ~~nOlinediOI 
3-(2· 
58851·99·3 Benzothiazolyl 
)umbelliferone 
3-(5-Chloro-2· 
benzoxazolyl)· 
97477-81·1 4· 
cyanoumbellife 
rone 
56·06·2 Caffeine 
1563.66-2 Carbofuran 
10605-21·7 Carbendazim 
431 21-43·3 Triadlmefon 
66246-88-0 Penconazole 
Train 
Train 
A A Train 
A Train 
Train 
Train 
Train 
Val 
Train 
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107534-96-
6-054 f , 3 Tebuconazole I I Train r \ OH CI -NV N 
CI 
6-056 «C)() 74115-24-5 Clofentezine I I Train 
CI 
\ 
6-060 0-0 54-11 -5 Nicoline I I Tra in \ ;) 
-
"'" 
- 0 
6-061 / 0 ~ # 64-86-8 Colchicine I I Test 
,::?' 
h 
H Ny ~ '" I ..... ~ H 0 
~',/" Caplan (ISO) ; 1,2,3,6-6-062 133-06-2 letrahydro-N- A I Tra in (Irichloromethy CI Ithio)phthalimi 
\ 0 de 
~ N-
6-063 N- X' 133-07-3 
(Trichlorometh A I Tesl ylthlo)phthaliml 
~ de 
CI 
0 CI 
0 0 
0 
6-065 \ f , 81 -81 -2 Warfarin I I Train 
U HO -
6-066 0' 105-60-2 Caprolaclam I I Train 
cq,~~" Captafol (ISO); 1,2,3,6-tetrahydro-N-6-067 2425-06-1 (1 ,1,2,2- A I VI I trachloroethy Ithlo)phthallml de 
0 CI Q Trldemorph (ISO); 2,6-6-068 24602-86-6 dimethyl-4- I I Train 
trldecylmorpho 
line 
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0-.:-(1) N-Cyclohexyl-6-071 95-33..Q 2- A I Test benzothlazoles 
ulfenamide 
CX)-/-\1) 2,2'-6-072 120-78-5 Dithiobis[benz A I Train othiazole) 
,,-<1) 2-6-074 149-30-4 Benzothiazolet A I Train N # hiol 
\ 
-<s 
Ametryn (ISO); 
2-ethylamino-
6-075 HN-( \ 834-12-8 4- I I Train isopropylamln 
-< ==< o-6-methylthlo-N HN\ 1,3,5-trlazine 
6-076 
-Q-< 16807-48-0 Dehydroacetic I I Train acid 
0 
6-077 -<D-~ 51 -55-8 Atropine I I Train o OH 
\ H N ~ 
6-078 "- I O~NH 57-47-6 Physostl9mlne I I Test N # 
I 
6..Q79 HO-o 108-93-0 Cyclohexanol I I Val 
2: Isatoic 6-080 # NH 118-48-9 anhydride I I Test o oAo 
/ 
s 
>-N Simetryn (ISO); 2,4-
6-081 N }-NH 1014-70-6 bis(ethyl mlno I I T st )=N L- )-6-methylthlo-1,3,5-trlazlne 
iNH 
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I~ Dlalifos (ISO) ; 
2-chloro-1-
6-082 oq,--cr ' 10311-84-9 phthalimldoeth A I Train ~ CI ) yIO,O-diethyl phosphorodithl 
oate 
0 
CI)= 
-N 
6-083 '% }-5(*' 2172~6-2 Cyanazine I I Train 
>-N 
jNH 
'?O Bentazone (ISO); 3-o=j I Isopropyl-6-084 25057-89-0 2,1,3- I I Train iN # benzothiadiazl n84-one-2,2-
0 dioxide 
I ./ &:lH~~~i,/ Methyl alpha-«4,6-6-085 83055-99-6 dimethoxypyri I I Train midin-2-yl)ureidosulph onyl)-o-toluate 
3=5=" 3,7-6-086 CI 84087-01-4 Dlchloroquinoli I I Train ne-S-N OH carboxylic acid 
0 
~ 6-087 f CI 77-47-4 Hexachlorocyc A I Train CI ~ lopentadlene CI 
CI 
6-088 ~) 94-59-7 Safrole I I Val 
,p 1,2-6-089 1120-71-4 Oxathlolane I I Val 
2,2-dloxlde 
0 
6-090 'Q-( 
\;) 0 
1702-17-6 Clopyralid I I Train 
CI 
~ 2-Chlor0-6-6-091 CI N# 1929-82-4 (trichloromethy I I Tr In I)pyridlne CI 
CI 
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\-{---<--o 3-Cyclohexyl-6-dimethylamino -1-methyl-
6-093 ; ;-{ 51235-04-2 1,2,3,4- I I Test tetrahydro-0 1,3,5-triazine-
2,4-dlone; 
hexazlnone 
Q 2-(Benzothlazol-6-094 ex' 73250-08-7 2-yloxy)-N- I I Train I r o N- methyl-N-~ s "---\ phenylacetaml de; mefenacet 
0 p--9 4-(3-(2-f \ N Chlorophenoth iazln-10-
6-095 
CI- ~,/\.~ 58-39-9 yl)propyl)-1- I I Train piperazineetha 
"---I OH nol 
":~ F 6-096 I 70458-96-7 Norfloxacln I I Train Nl N ) ~NH 
q 3-(4-
6-098 95333-64-5 
Hydroxybenzyl I I Train HO-(Y SH )-imldazole-2-thlone 
-)==N 
6-099 N~ j-NH 7287-19-6 Prometryn I I Val 
r.t-' r-
( 
6-100 O)"'Q'X 76578-14-8 Qulzalofop- I I Train ethyl CI N 0 
'~Q 6-101 o ~ j 69806-5Q-4 Fluazlfop-butyl I I Vol J ,-0+. 
F 
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iii 
~ 
I 6-102 88671 -89-0 Myclobutanil I I Test ~ 
CI () 
N 
6-103 -K~L 64529-56-2 Ethiozin I I Test 
;='i~ CI 6-105 N~ \ # 94361-06-5 Cyproconazole I I Train ~N 
NJ C'W 6-106 I N 35554-44-0 Imazalil I I Train # 
CI O~ 
6-108 - 78473-71-9 Enterolactone A I Train 
\ ;) C OH OH 
L ~ NH r\ 6-110 ):: 0 26644-46-2 Triforine I I Train 
CI CI~ HN\ 
CI 0 
.,.;:;'~C' 3-Amino-1 -6-113 27241 -31 -2 (2,4,6- A I Train trichlorophenyl )-5-pyrazolone 
CI 
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